# Dossier zur Nutzenbewertung gemäß § 35a SGB V

*Concizumab (Alhemo®)*

Novo Nordisk Pharma GmbH

## Anhang 4-H

*Routineprophylaxe von Blutungen bei Patienten ab einem Alter von 12 Jahren mit schwerer Hämophilie A (Faktor VII < 1%) ohne Faktor-VIII-Hemmkörper*

Analysen für das Nutzendossier

Stand: 01.10.2025

# Inhaltsverzeichnis

## Studie Explorer8



* Die Gesamtmortalität wurde in der Studie Explorer8 über den Studienzeitraum im Rahmen der Sicherheitsanalysen erfasst.

# Studie Explorer8

## Analysesets

| Analyseset[a] | Beschreibung |
|---|---|
| On-treatment without data before restart (OTexBR) | Das Analyseset umfasst die jeweils relevante Teilpopulation. Aufgrund der fehlenden Abbildung der zweckmäßigen Vergleichstherapie kann dieses Analyseset jedoch nicht zur Ableitung eines Zusatznutzens herangezogen werden.<br><br>Umfasst den Beobachtungszeitraum nach dem Neustart, in dem die Patienten eine Bedarfsbehandlung (Studien-Arm 1) oder Routineprophylaxe mit Concizumab entsprechend der Fachinformation (Studien-Arm 2) erhalten haben (Zeitraum nach dem Neustart).<br><br>Der Beobachtungszeitraum vor dem Neustart wird ausgeschlossen (Zeitraum vor dem Neustart). |
| On-treatment without ancillary therapy[b] excluding data before restart (OTwoATexBR) | Wird im Rahmen der vorliegenden Nutzenbewertung zusätzlich für alle Blutungsendpunkte als Sensitivitätsanalyse in Anhang 4-H dargestellt.<br><br>Umfasst den Beobachtungszeitraum nach dem Neustart, in dem die Patienten eine Bedarfsbehandlung (Studien-Arm 1) oder Routineprophylaxe mit Concizumab entsprechend der Fachinformation (Studien-Arm 2) erhalten haben (Zeitraum nach dem Neustart).<br>**Zusätzlich** wurden Zeiträume, in denen Patienten Faktorpräparate nicht im Zusammenhang mit der Behandlung einer Blutungsepisode erhalten haben, ausgeschlossen.<br><br>Der Beobachtungszeitraum vor dem Neustart wird ausgeschlossen (Zeitraum vor dem Neustart). |

a. Es wurden nur Analysesets dargestellt, die die in Anhang 4-H enthaltenen Outputs umfassen.

b. Der Begriff „ancillary therapy“ (Zusatztherapie) bezieht sich auf die Anwendung von Faktorpräparaten, die nicht im Zusammenhang mit der Behandlung einer Blutungsepisode eingesetzt wurden, außer bei diagnostischen Verfahren, intramuskulären Injektionen und kleineren chirurgischen Eingriffen.

# Table of contents

**Page**

# Statistical documentation

## 1.1.1 Demographics and baseline characteristics - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) N (%) | Concizumab PPX (arm 2) N (%) | Total N (%) |
|---|---|---|---|
| Number of patients | 9 | 18 | 27 |
| Age group (years) | | | |
| Adolescents (12-17 years) | 4 (44.4) | 4 (22.2) | 8 (29.6) |
| Adults (18-64 years) | 4 (44.4) | 14 (77.8) | 18 (66.7) |
| Elderly/very elderly (65-84 years) | 1 (11.1) | 0 | 1 ( 3.7) |
| Ethnicity | | | |
| Hispanic or Latino | 1 (11.1) | 0 | 1 ( 3.7) |
| Not Hispanic or Latino | 8 (88.9) | 18 ( 100) | 26 (96.3) |
| Not Reported | 0 | 0 | 0 |
| Race | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 (11.1) | 8 (44.4) | 9 (33.3) |
| Black or African American | 1 (11.1) | 1 ( 5.6) | 2 ( 7.4) |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 7 (77.8) | 9 (50.0) | 16 (59.3) |
| Not Reported | 0 | 0 | 0 |
| Country | | | |
| Estonia | 0 | 1 ( 5.6) | 1 ( 3.7) |
| India | 0 | 3 (16.7) | 3 (11.1) |
| Italy | 1 (11.1) | 0 | 1 ( 3.7) |
| Malaysia | 0 | 1 ( 5.6) | 1 ( 3.7) |
| Poland | 3 (33.3) | 3 (16.7) | 6 (22.2) |
| Russian Federation | 0 | 1 ( 5.6) | 1 ( 3.7) |
| Serbia | 0 | 3 (16.7) | 3 (11.1) |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients.
Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1.
Note: information on age, ethnicity and race are according to local regulations.
Cut off date for data is 12th July 2022.

Demographics and baseline characteristics - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) N (%) | Concizumab PPX (arm 2) N (%) | Total N (%) |
|---|---|---|---|
| South Africa | 1 (11.1) | 1 ( 5.6) | 2 ( 7.4) |
| Republic of Korea | 1 (11.1) | 4 (22.2) | 5 (18.5) |
| Turkey | 0 | 1 ( 5.6) | 1 ( 3.7) |
| Ukraine | 3 (33.3) | 0 | 3 (11.1) |
| OECD membership | | | |
| Non-OECD country | 4 (44.4) | 9 (50.0) | 13 (48.1) |
| OECD country | 5 (55.6) | 9 (50.0) | 14 (51.9) |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients.
Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1.
Note: information on age, ethnicity and race are according to local regulations.
Cut off date for data is 12th July 2022.

## 1.1.2 Demographics and baseline characteristics - descriptive statistics - HA - OTexBR - full analysis set

| | No PPX | Concizumab PPX | Total |
|---|---|---|---|
| | Arm 1 | Arm 2 | |
| Number of patients | 9 | 18 | 27 |
| Age(years) | | | |
| N | 9 | 18 | 27 |
| Median | 36.0 | 32.0 | 33.0 |
| P25 ; P75 | 15.0 ; 52.0 | 26.0 ; 37.0 | 17.0 ; 40.0 |
| Mean (SD) | 34.7 (21.3) | 30.7 (9.6) | 32.0 (14.3) |
| Min ; Max | 12.0 ; 66.0 | 15.0 ; 49.0 | 12.0 ; 66.0 |
| Height (m) | | | |
| N | 9 | 18 | 27 |
| Median | 1.7 | 1.7 | 1.7 |
| P25 ; P75 | 1.7 ; 1.8 | 1.7 ; 1.8 | 1.7 ; 1.8 |
| Mean (SD) | 1.7 (0.1) | 1.8 (0.1) | 1.7 (0.1) |
| Min ; Max | 1.6 ; 1.9 | 1.6 ; 2.0 | 1.6 ; 2.0 |
| Body weight (kg) | | | |
| N | 9 | 18 | 27 |
| Median | 66.0 | 81.4 | 79.6 |
| P25 ; P75 | 50.8 ; 87.5 | 60.3 ; 99.4 | 52.0 ; 94.0 |
| Mean (SD) | 68.2 (19.2) | 78.8 (22.4) | 75.2 (21.6) |
| Min ; Max | 46.5 ; 94.3 | 38.0 ; 107.2 | 38.0 ; 107.2 |
| BMI, (kg/m^2) | | | |
| N | 9 | 18 | 27 |
| Median | 24.0 | 26.6 | 25.3 |
| P25 ; P75 | 18.2 ; 25.7 | 20.0 ; 29.7 | 19.8 ; 28.1 |
| Mean (SD) | 22.5 (4.7) | 25.4 (6.1) | 24.4 (5.8) |
| Min ; Max | 16.5 ; 28.2 | 14.5 ; 36.4 | 14.5 ; 36.4 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, SD: standard deviation, P25/P75 is the 25th/75th percentile, Min: minimum, Max: maximum, BMI: body mass index.
Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1.
Cut off date for data is 12th July 2022.

## 1.1.3 Electrocardiography (ECG) at baseline - overall interpretation - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) N (%) | Concizumab PPX (arm 2) N (%) | Total N (%) |
|---|---|---|---|
| Number of Patients | 9 | 18 | 27 |
| ECG | | | |
| N | 9 | 18 | 27 |
| Normal | 8 (88.9) | 16 (88.9) | 24 (88.9) |
| Abnormal, NCS | 1 (11.1) | 2 (11.1) | 3 (11.1) |
| Abnormal, CS | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, ECG: electrocardiography, NCS: not clinically significant, CS: clinically significant.
Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1.
Cut off date for data is 12th July 2022.

## 1.1.4 Haemophilia details - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) N (%) | Concizumab PPX (arm 2) N (%) | Total N (%) |
|---|---|---|---|
| Number of patients | 9 | 18 | 27 |
| Classification of haemophilia type | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Haemophilia A | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Factor VIII level at diagnosis | | | |
| N | 7 (100.0) | 12 (100.0) | 19 (100.0) |
| < 1% | 7 (100.0) | 11 ( 91.7) | 18 ( 94.7) |
| > 1% | 0 | 1 ( 8.3) | 1 ( 5.3) |
| Family history of haemophilia | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Yes | 6 ( 66.7) | 12 ( 66.7) | 18 ( 66.7) |
| No | 2 ( 22.2) | 5 ( 27.8) | 7 ( 25.9) |
| Unknown | 1 ( 11.1) | 1 ( 5.6) | 2 ( 7.4) |
| Family history of prothrombotic disorders | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Yes | 0 ( 0.0) | 0 ( 0.0) | 0 ( 0.0) |
| No | 7 ( 77.8) | 13 ( 72.2) | 20 ( 74.1) |
| Unknown | 2 ( 22.2) | 5 ( 27.8) | 7 ( 25.9) |
| Family history of thromboembolism | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Yes | 0 ( 0.0) | 0 ( 0.0) | 0 ( 0.0) |
| No | 7 ( 77.8) | 13 ( 72.2) | 20 ( 74.1) |
| Unknown | 2 ( 22.2) | 5 ( 27.8) | 7 ( 25.9) |
| Family history of inhibitors | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Yes | 0 ( 0.0) | 1 ( 5.6) | 1 ( 3.7) |
| No | 8 ( 88.9) | 15 ( 83.3) | 23 ( 85.2) |
| Unknown | 1 ( 11.1) | 2 ( 11.1) | 3 ( 11.1) |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients.
Cut off date for data is 12th July 2022.

## 1.1.5 Haemophilia treatment and bleed history - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) | Concizumab PPX (arm 2) | Total |
|---|---|---|---|
| Number of patients | 9 | 18 | 27 |
| Type of previous treatment, N (%) | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| On demand | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| Prophylaxis | 3 ( 33.3) | 1 ( 5.6) | 4 ( 14.8) |
| Time on prophylaxis, (months) | | | |
| N | 3 | 1 | 4 |
| Median | 6.2 | 34.7 | 7.9 |
| P25 ; P75 | 3.8 ; 9.6 | 34.7 ; 34.7 | 5.0 ; 22.1 |
| Mean (SD) | 6.5 (2.9) | 34.7 | 13.6 (14.3) |
| Min ; Max | 3.8 ; 9.6 | 34.7 ; 34.7 | 3.8 ; 34.7 |
| Time on on demand, (months) | | | |
| N | 8 | 12 | 20 |
| Median | 11.0 | 12.0 | 12.0 |
| P25 ; P75 | 7.3 ; 12.6 | 11.5 ; 16.2 | 10.5 ; 12.6 |
| Mean (SD) | 11.1 (6.2) | 13.8 (5.1) | 12.7 (5.6) |
| Min ; Max | 3.3 ; 24.1 | 6.3 ; 24.0 | 3.3 ; 24.1 |
| Number of bleeding episodes during the prophylaxis treatment period | | | |
| N | 2 | 1 | 3 |
| Median | 14.0 | 3.0 | 3.0 |
| P25 ; P75 | 1.0 ; 27.0 | 3.0 ; 3.0 | 1.0 ; 27.0 |
| Mean (SD) | 14.0 (18.4) | 3.0 | 10.3 (14.5) |
| Min ; Max | 1 ; 27 | 3 ; 3 | 1 ; 27 |
| ABR during the prophylaxis treatment period | | | |
| N | 2 | 1 | 3 |
| Median | 18.5 | 1.0 | 3.1 |
| P25 ; P75 | 3.1 ; 33.9 | 1.0 ; 1.0 | 1.0 ; 33.9 |
| Mean (SD) | 18.5 (21.7) | 1.0 | 12.7 (18.4) |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, P25/P75 is the 25th/75th percentile, PPX: Prophylaxis, Min: minimum, Max: maximum, ABR: annualised bleeding rate
Patients can report both on-demand and prophylaxis prior to screening so therefore the Ns do not necessarily add up.
Cut off date for data is 12th July 2022.

Haemophilia treatment and bleed history - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) | Concizumab PPX (arm 2) | Total |
|---|---|---|---|
| Min ; Max | 3.1 ; 33.9 | 1.0 ; 1.0 | 1.0 ; 33.9 |
| Number of spontaneous bleeding episodes during the prophylaxis treatment period | | | |
| N | 2 | 1 | 3 |
| Median | 8.0 | 3.0 | 3.0 |
| P25 ; P75 | 1.0 ; 15.0 | 3.0 ; 3.0 | 1.0 ; 15.0 |
| Mean (SD) | 8.0 (9.9) | 3.0 | 6.3 (7.6) |
| Min ; Max | 1 ; 15 | 3 ; 3 | 1 ; 15 |
| Type of factor product during the prophylaxis treatment period, N (%) | | | |
| N | 3 (100.0) | 1 (100.0) | 4 (100.0) |
| HAEMOSOLVATE | 1 ( 33.3) | 0 | 1 ( 25.0) |
| PLASMA DERIVED | 1 ( 33.3) | 0 | 1 ( 25.0) |
| RECOMBINANT FACTOR CONCENTRATE | 0 | 1 (100.0) | 1 ( 25.0) |
| XYNTHA | 1 ( 33.3) | 0 | 1 ( 25.0) |
| Approximate number of doses to treat a bleed, during the prophylaxis treatment period | | | |
| N | 3 | 1 | 4 |
| Median | 1.0 | 1.0 | 1.0 |
| P25 ; P75 | 1.0 ; 4.0 | 1.0 ; 1.0 | 1.0 ; 2.5 |
| Mean (SD) | 2.0 (1.7) | 1.0 | 1.8 (1.5) |
| Min ; Max | 1 ; 4 | 1 ; 1 | 1 ; 4 |
| Number of bleeding episodes during the on demand treatment period | | | |
| N | 9 | 18 | 27 |
| Median | 24.0 | 17.5 | 20.0 |
| P25 ; P75 | 13.0 ; 25.0 | 11.0 ; 37.0 | 11.0 ; 34.0 |
| Mean (SD) | 20.4 (11.6) | 32.4 (34.7) | 28.4 (29.3) |
| Min ; Max | 4 ; 38 | 6 ; 137 | 4 ; 137 |
| ABR during the on demand treatment period | | | |
| N | 8 | 12 | 20 |
| Median | 19.3 | 14.3 | 14.6 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, P25/P75 is the 25th/75th percentile, PPX: Prophylaxis, Min: minimum, Max: maximum, ABR: annualised bleeding rate
Patients can report both on-demand and prophylaxis prior to screening so therefore the Ns do not necessarily add up.
Cut off date for data is 12th July 2022.

Haemophilia treatment and bleed history - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) | Concizumab PPX (arm 2) | Total |
|---|---|---|---|
| P25 ; P75 | 12.5 ; 37.9 | 10.5 ; 16.6 | 11.2 ; 24.4 |
| Mean (SD) | 23.3 (13.4) | 16.4 (11.3) | 19.2 (12.3) |
| Min ; Max | 7.5 ; 39.8 | 5.3 ; 48.6 | 5.3 ; 48.6 |
| Number of spontaneous bleeding episodes during the on demand treatment period | | | |
| N | 9 | 18 | 27 |
| Median | 21.0 | 14.5 | 15.0 |
| P25 ; P75 | 8.0 ; 24.0 | 8.0 ; 33.0 | 8.0 ; 30.0 |
| Mean (SD) | 17.8 (11.2) | 29.1 (33.8) | 25.3 (28.5) |
| Min ; Max | 4 ; 37 | 2 ; 128 | 2 ; 128 |
| Type of factor product during the on demand treatment period, N (%) | | | |
| N | 9 (100.0) | 18 (100.0) | 27 (100.0) |
| ADVATE | 0 | 1 ( 5.6) | 1 ( 3.7) |
| ADVATE 1500 IU | 0 | 1 ( 5.6) | 1 ( 3.7) |
| ADVATE, NOVOEIGHT, IMMUNATE | 0 | 1 ( 5.6) | 1 ( 3.7) |
| ADYNOVATE | 0 | 1 ( 5.6) | 1 ( 3.7) |
| ADYNOVI | 0 | 1 ( 5.6) | 1 ( 3.7) |
| BERIATE | 0 | 1 ( 5.6) | 1 ( 3.7) |
| BERIATE, FANHDI | 0 | 1 ( 5.6) | 1 ( 3.7) |
| ELOCTATE, KOGENATE, XYNTHA | 0 | 1 ( 5.6) | 1 ( 3.7) |
| EMOCLOT | 1 ( 11.1) | 0 | 1 ( 3.7) |
| FACTOR VIII | 0 | 1 ( 5.6) | 1 ( 3.7) |
| FANHDI | 0 | 1 ( 5.6) | 1 ( 3.7) |
| HAEMOSOLVATE | 1 ( 11.1) | 1 ( 5.6) | 2 ( 7.4) |
| IMMUNATE | 0 | 1 ( 5.6) | 1 ( 3.7) |
| KOVALTRY | 1 ( 11.1) | 0 | 1 ( 3.7) |
| NOVOEIGHT | 1 ( 11.1) | 0 | 1 ( 3.7) |
| OCTANATE | 1 ( 11.1) | 1 ( 5.6) | 2 ( 7.4) |
| PLASMA DERIVED | 3 ( 33.3) | 0 | 3 ( 11.1) |
| RECOMBINANT FACTOR CONCENTRATE | 0 | 3 ( 16.7) | 3 ( 11.1) |
| XYNTHA | 1 ( 11.1) | 2 ( 11.1) | 3 ( 11.1) |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, P25/P75 is the 25th/75th percentile, PPX: Prophylaxis, Min: minimum, Max: maximum, ABR: annualised bleeding rate
Patients can report both on-demand and prophylaxis prior to screening so therefore the Ns do not necessarily add up.
Cut off date for data is 12th July 2022.

Haemophilia treatment and bleed history - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) | Concizumab PPX (arm 2) | Total |
|---|---|---|---|
| Approximate number of doses to treat a bleed, during the on demand treatment period | | | |
| N | 9 | 18 | 27 |
| Median | 1.0 | 1.0 | 1.0 |
| P25 ; P75 | 1.0 ; 2.0 | 1.0 ; 1.0 | 1.0 ; 1.0 |
| Mean (SD) | 2.0 (1.9) | 1.1 (0.3) | 1.4 (1.2) |
| Min ; Max | 1 ; 7 | 1 ; 2 | 1 ; 7 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, P25/P75 is the 25th/75th percentile, PPX: Prophylaxis, Min: minimum, Max: maximum, ABR: annualised bleeding rate
Patients can report both on-demand and prophylaxis prior to screening so therefore the Ns do not necessarily add up.
Cut off date for data is 12th July 2022.

## 1.1.6 Target joints at baseline - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) | | Concizumab PPX (arm 2) | | Total | |
|---|---|---|---|---|---|---|
| Number of patients | 9 | | 18 | | 27 | |
| Number of patients having at least one target joint, N (%) | 7 ( 77.8) | | 16 ( 88.9) | | 23 ( 85.2) | |
| Target joint location, N (%) E | | | | | | |
| Ankle | 1 ( 11.1) | 2 | 9 ( 50.0) | 10 | 10 ( 37.0) | 12 |
| Elbow | 6 ( 66.7) | 8 | 7 ( 38.9) | 9 | 13 ( 48.1) | 17 |
| Knee | 2 ( 22.2) | 2 | 7 ( 38.9) | 9 | 9 ( 33.3) | 11 |
| Shoulder | 0 | | 2 ( 11.1) | 2 | 2 ( 7.4) | 2 |
| Body position of joint, N (%) E | | | | | | |
| Left | 5 ( 55.6) | 6 | 12 ( 66.7) | 16 | 17 ( 63.0) | 22 |
| Right | 5 ( 55.6) | 6 | 11 ( 61.1) | 14 | 16 ( 59.3) | 20 |
| Number of bleeds in specified joint within 12 months | | | | | | |
| E | 12 | | 30 | | 42 | |
| Median | 6.0 | | 8.0 | | 6.5 | |
| P25 ; P75 | 4.5 ; 7.0 | | 5.0 ; 10.0 | | 5.0 ; 10.0 | |
| Mean (SD) | 6.9 (4.1) | | 10.5 (13.7) | | 9.5 (11.8) | |
| Min ; Max | 3.0 ; 16.0 | | 3.0 ; 79.0 | | 3.0 ; 79.0 | |
| Number of bleeds in specified joint within 12 months, categorised, N (%) E | | | | | | |
| 3 | 2 ( 22.2) | 2 | 2 ( 11.1) | 2 | 4 ( 14.8) | 4 |
| 4 | 1 ( 11.1) | 1 | 3 ( 16.7) | 3 | 4 ( 14.8) | 4 |
| 5 | 1 ( 11.1) | 1 | 3 ( 16.7) | 4 | 4 ( 14.8) | 5 |
| 6 | 2 ( 22.2) | 5 | 3 ( 16.7) | 3 | 5 ( 18.5) | 8 |
| 7 | 0 | | 1 ( 5.6) | 2 | 1 ( 3.7) | 2 |
| 8 | 1 ( 11.1) | 1 | 4 ( 22.2) | 4 | 5 ( 18.5) | 5 |
| 9 | 0 | | 2 ( 11.1) | 2 | 2 ( 7.4) | 2 |
| 10 | 0 | | 2 ( 11.1) | 4 | 2 ( 7.4) | 4 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, E: number of target joints, P25/P75 is the 25th/75th percentile, SD: standard deviation, Min: minimum, Max: maximum.
Target joint is defined as having three or more spontaneous bleeds into a single joint within a consecutive 6-month period. Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1. Patients can have more than one target joint, thus the percentage do not add up to 100.
Cut off date for data is 12th July 2022.

Target joints at baseline - summary - HA - OTexBR - full analysis set

| | No PPX (arm 1) | | Concizumab PPX (arm 2) | | Total | |
|---|---|---|---|---|---|---|
| 11 | 0 | | 1 ( 5.6) | 1 | 1 ( 3.7) | 1 |
| 12 | 0 | | 1 ( 5.6) | 1 | 1 ( 3.7) | 1 |
| 13 | 0 | | 1 ( 5.6) | 1 | 1 ( 3.7) | 1 |
| 14 | 1 ( 11.1) | 1 | 0 | | 1 ( 3.7) | 1 |
| 16 | 1 ( 11.1) | 1 | 1 ( 5.6) | 1 | 2 ( 7.4) | 2 |
| 25 | 0 | | 1 ( 5.6) | 1 | 1 ( 3.7) | 1 |
| 79 | 0 | | 1 ( 5.6) | 1 | 1 ( 3.7) | 1 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients, E: number of target joints, P25/P75 is the 25th/75th percentile, SD: standard deviation, Min: minimum, Max: maximum.
Target joint is defined as having three or more spontaneous bleeds into a single joint within a consecutive 6-month period. Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1. Patients can have more than one target joint, thus the percentage do not add up to 100.
Cut off date for data is 12th July 2022.

## 1.1.7 Target joints at baseline and bleeding in the last 24 weeks before study entry - HA - OTexBR - full analysis set

| | No PPX (arm 1) N (%) | Concizumab PPX (arm 2) N (%) | Totals N (%) |
|---|---|---|---|
| Number of patients | 9 | 18 | 27 |
| Target joints at baseline | | | |
| Patients with zero target joints, N (%) | 2 (22.2) | 2 (11.1) | 4 (14.8) |
| Patients with one target joint, N (%) | 4 (44.4) | 8 (44.4) | 12 (44.4) |
| Patients with > 1 target joints, N (%) | 3 (33.3) | 8 (44.4) | 11 (40.7) |
| Bleeding episodes in the last 24 weeks before study entry | | | |
| < 9 bleeding episodes, N (%) | 3 (33.3) | 6 (33.3) | 9 (33.3) |
| >= 9 bleeding episodes, N (%) | 6 (66.7) | 12 (66.7) | 18 (66.7) |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients.
Target joint is defined as having three or more spontaneous bleeds into a single joint within a consecutive 6-month period.
Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1.
Cut off date for data is 12th July 2022.

## 1.1.8 Haemophilia patient preference questionnaire (H-PPQ) - week 24 - descriptive statistics - HA - OTexBR - full analysis set

| | No PPX | Concizumab PPX |
|---|---|---|
| | Arm 1<br>N (%) | Arm 2<br>N (%) |
| Number of patients | 9 | 18 |
| 1. Overall, which treatment do you prefer? | | |
| Current treatment | 2 (22.2) | 13 (72.2) |
| Previous treatment | 0 | 0 |
| No preference | 3 (33.3) | 2 (11.1) |
| Missing | 4 (44.4) | 3 (16.7) |
| For patients preferring current treatment: | | |
| N preferring current treatment | 2 ( 100) | 13 ( 100) |
| 2. How strong is this treatment preference (indicated in question 1)? | | |
| Very strong | 0 | 10 (76.9) |
| Fairly strong | 2 ( 100) | 3 (23.1) |
| Not very strong | 0 | 0 |
| 3. What are the TWO main reasons for this treatment preference? | | |
| Easier to remember to inject | 0 | 1 ( 7.7) |
| Feels less emotionally distressing | 1 (50.0) | 4 (30.8) |
| Less painful to inject | 0 | 3 (23.1) |
| How often do you have to inject | 0 | 0 |
| Fewer bleeds | 1 (50.0) | 5 (38.5) |
| Require less time | 0 | 6 (46.2) |
| Other reason | 0 | 1 ( 7.7) |
| For patients preferring previous treatment: | | |
| N preferring previous treatment | 0 | 0 |
| 2. How strong is this treatment preference (indicated in question 1)? | | |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients.
Patients in arm 1 also responded to the questionnaire at week 24 even though they had not received any trial drug at that point in time.
These arm 1 data should therefore be interpreted with caution.
Cut off date for data is 12th July 2022.

Haemophilia patient preference questionnaire (H-PPQ) - week 24 - descriptive statistics - HA - OTexBR - full analysis set

| | No PPX | Concizumab PPX |
|---|---|---|
| | Arm 1<br>N (%) | Arm 2<br>N (%) |
| Very strong | 0 | 0 |
| Fairly strong | 0 | 0 |
| Not very strong | 0 | 0 |
| 3. What are the TWO main reasons for this treatment preference? | | |
| Easier to remember to inject | 0 | 0 |
| Feels less emotionally distressing | 0 | 0 |
| Less painful to inject | 0 | 0 |
| How often do you have to inject | 0 | 0 |
| Fewer bleeds | 0 | 0 |
| Require less time | 0 | 0 |
| Other reason | 0 | 0 |

HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis, N: number of patients, %: percentage of patients.
Patients in arm 1 also responded to the questionnaire at week 24 even though they had not received any trial drug at that point in time.
These arm 1 data should therefore be interpreted with caution.
Cut off date for data is 12th July 2022.

## 1.1.9 Observation time in weeks - descriptive statistics - HA - safety analysis set

| | Arm 1 - No PPX | Arm 2 - Concizumab PPX |
|---|---|---|
| Patient weeks of observation / exposure | | |
| ADS: On-treatment excluding data before restart (OTexBR) | | |
| For safety endpoints/assessments relating to events [a][b] | | |
| N | 9 | 18 |
| Median | 24.1 | 33.0 |
| P25 ; P75 | 24.0 ; 28.0 | 32.1 ; 56.4 |
| Mean (SD) | 26.7 (4.5) | 45.0 (19.2) |
| Min ; Max | 24.0 ; 36.3 | 28.3 ; 80.4 |
| For all other endpoint/assessments [c] | | |
| N | 9 | 18 |
| Median | 24.1 | 33.0 |
| P25 ; P75 | 24.0 ; 28.0 | 32.1 ; 56.4 |
| Mean (SD) | 26.7 (4.5) | 44.4 (19.7) |
| Min ; Max | 24.0 ; 36.3 | 21.4 ; 80.4 |

HA: haemophilia A.
N: number of subjects, SD: standard deviation, P25/P75 is the 25th/75th percentile, Min: minimum, Max: maximum. ADS: Analysis data set.
Arm 1 represents the patients in arm 1, showing observation time in main phase (no PPX).
[a]: Covering number of thromboembolic events, number of hypersensitivity type reactions, number of injection site reactions, number of patients with antibodies to concizumab, number of adverse events.
[b]: End of period is defined as the first of 1) death, 2) withdrawal date, 3) last contact for LTFU patients, 4) date of discontinuation of concizumab + 7 weeks , 5) primary analysis cut-off.
[c]: End of period is defined as the first of 1) death, 2) withdrawal date, 3) last contact for LTFU patients, 4) date of discontinuation of concizumab + 1 day, 5) primary analysis cut-off.

Cut off date for data is 12th July 2022.

# Table of contents

**Page**

# Statistical documentation

## 1.2.1 Treated spontaneous and traumatic bleeding episodes - Explorer 8 - HA - OTwoATexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 2.73 [ 1.63 , 4.59] | 9 | 9 | 19.28 [11.25 , 33.03] | 0.14 [0.07 , 0.29]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 3.42 [ 1.26 , 9.28] | 4 | 4 | 19.12 [ 8.62 , 42.42] | 0.18 [0.05 , 0.64]<br>NA [ NA , Inf] | 0.0083 | 0.8729 |
| >= 18 years | 14 | 14 | 2.55 [ 1.42 , 4.59] | 5 | 5 | 19.33 [ 9.22 , 40.50] | 0.13 [0.06 , 0.32]<br>NA [ NA , Inf] | < 0.0001 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 2.30 [ 1.15 , 4.61] | 4 | 4 | 19.12 [ 8.88 , 41.17] | 0.12 [0.04 , 0.34]<br>NA [ NA , Inf] | 0.0001 | 0.7816 |
| OECD country | 9 | 9 | 3.18 [ 1.64 , 6.15] | 5 | 5 | 19.36 [ 9.48 , 39.54] | 0.16 [0.07 , 0.41]<br>NA [ NA , Inf] | 0.0001 | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTwoATexBR = On-treatment without ancillary therapy excluding data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.2 Treated spontaneous bleeding episodes - Explorer 8 - HA - OTwoATexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 1.87 [ 1.04 , 3.35] | 9 | 9 | 13.32 [ 7.44 , 23.81] | 0.14 [0.06 , 0.30] | < 0.0001 | |
| | | | | | | | NA [ NA , Inf] | | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 2.34 [ 0.84 , 6.51] | 4 | 4 | 8.07 [ 3.44 , 18.96] | 0.29 [0.08 , 1.10] | 0.0691 | 0.3842 |
| | | | | | | | NA [ NA , Inf] | | |
| >= 18 years | 14 | 14 | 1.88 [ 1.02 , 3.47] | 5 | 5 | 17.95 [ 8.72 , 36.94] | 0.10 [0.04 , 0.25] | < 0.0001 | |
| | | | | | | | NA [ NA , Inf] | | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 1.84 [ 0.89 , 3.82] | 4 | 4 | 8.07 [ 3.44 , 18.91] | 0.23 [0.07 , 0.70] | 0.0099 | 0.3976 |
| | | | | | | | NA [ NA , Inf] | | |
| OECD country | 9 | 9 | 2.11 [ 1.03 , 4.36] | 5 | 5 | 17.88 [ 8.71 , 36.70] | 0.12 [0.05 , 0.31] | < 0.0001 | |
| | | | | | | | NA [ NA , Inf] | | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTwoATexBR = On-treatment without ancillary therapy excluding data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.3 Treated spontaneous and traumatic joint bleeds - Explorer 8 - HA - OTwoATexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 2.22 [ 1.28 , 3.83] | 9 | 9 | 13.94 [ 7.96 , 24.40] | 0.16 [0.08 , 0.33]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 3.36 [ 1.24 , 9.12] | 4 | 4 | 11.35 [ 4.91 , 26.21] | 0.30 [0.08 , 1.09]<br>NA [ NA , Inf] | 0.0680 | 0.5318 |
| >= 18 years | 14 | 14 | 1.98 [ 1.06 , 3.68] | 5 | 5 | 16.07 [ 7.59 , 34.05] | 0.12 [0.05 , 0.30]<br>NA [ NA , Inf] | < 0.0001 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 2.36 [ 1.16 , 4.80] | 4 | 4 | 11.33 [ 4.92 , 26.07] | 0.21 [0.07 , 0.63]<br>NA [ NA , Inf] | 0.0053 | 0.8139 |
| OECD country | 9 | 9 | 2.17 [ 1.05 , 4.51] | 5 | 5 | 16.24 [ 7.68 , 34.32] | 0.13 [0.05 , 0.36]<br>NA [ NA , Inf] | 0.0001 | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTwoATexBR = On-treatment without ancillary therapy excluding data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.4 Treated spontaneous and traumatic target joint bleeds - Explorer 8 - HA - OTwoATexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 1.12 [ 0.54 , 2.33] | 9 | 9 | 4.36 [ 2.04 , 9.34] | 0.26 [0.11 , 0.60] | 0.0019 | |
| | | | | | | | NA [ NA , Inf] | | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 1.26 [ 0.36 , 4.38] | 4 | 4 | 2.49 [ 0.80 , 7.73] | 0.50 [0.10 , 2.49] | 0.3997 | 0.4624 |
| | | | | | | | NA [ NA , Inf] | | |
| >= 18 years | 14 | 14 | 1.15 [ 0.54 , 2.48] | 5 | 5 | 5.99 [ 2.41 , 14.91] | 0.19 [0.07 , 0.52] | 0.0012 | |
| | | | | | | | NA [ NA , Inf] | | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 1.11 [ 0.46 , 2.68] | 4 | 4 | 2.49 [ 0.81 , 7.68] | 0.45 [0.12 , 1.66] | 0.2278 | 0.4564 |
| | | | | | | | NA [ NA , Inf] | | |
| OECD country | 9 | 9 | 1.24 [ 0.51 , 3.00] | 5 | 5 | 5.97 [ 2.41 , 14.79] | 0.21 [0.07 , 0.63] | 0.0053 | |
| | | | | | | | NA [ NA , Inf] | | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTwoATexBR = On-treatment without ancillary therapy excluding data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.5 Treated spontaneous and traumatic bleeding episodes - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 2.73 [ 1.63 , 4.59] | 9 | 9 | 19.28 [11.25 , 33.03] | 0.14 [0.07 , 0.29]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 3.42 [ 1.26 , 9.27] | 4 | 4 | 19.12 [ 8.62 , 42.42] | 0.18 [0.05 , 0.64]<br>NA [ NA , Inf] | 0.0083 | 0.8728 |
| >= 18 years | 14 | 14 | 2.55 [ 1.42 , 4.59] | 5 | 5 | 19.33 [ 9.22 , 40.50] | 0.13 [0.06 , 0.32]<br>NA [ NA , Inf] | < 0.0001 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 2.30 [ 1.15 , 4.61] | 4 | 4 | 19.12 [ 8.88 , 41.17] | 0.12 [0.04 , 0.34]<br>NA [ NA , Inf] | 0.0001 | 0.7819 |
| OECD country | 9 | 9 | 3.18 [ 1.64 , 6.15] | 5 | 5 | 19.36 [ 9.48 , 39.53] | 0.16 [0.07 , 0.41]<br>NA [ NA , Inf] | 0.0001 | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTexBR = On-treatment without data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.6 Treated spontaneous bleeding episodes - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 1.87 [ 1.04 , 3.35] | 9 | 9 | 13.31 [ 7.44 , 23.81] | 0.14 [0.06 , 0.30]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 2.34 [ 0.84 , 6.51] | 4 | 4 | 8.07 [ 3.44 , 18.96] | 0.29 [0.08 , 1.10]<br>NA [ NA , Inf] | 0.0690 | 0.3842 |
| >= 18 years | 14 | 14 | 1.88 [ 1.02 , 3.46] | 5 | 5 | 17.95 [ 8.72 , 36.94] | 0.10 [0.04 , 0.25]<br>NA [ NA , Inf] | < 0.0001 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 1.84 [ 0.89 , 3.82] | 4 | 4 | 8.07 [ 3.44 , 18.91] | 0.23 [0.07 , 0.70]<br>NA [ NA , Inf] | 0.0099 | 0.3977 |
| OECD country | 9 | 9 | 2.11 [ 1.03 , 4.35] | 5 | 5 | 17.88 [ 8.71 , 36.70] | 0.12 [0.05 , 0.31]<br>NA [ NA , Inf] | < 0.0001 | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTexBR = On-treatment without data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.7 Treated spontaneous and traumatic joint bleeds - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 2.21 [ 1.28 , 3.83] | 9 | 9 | 13.94 [ 7.96 , 24.40] | 0.16 [0.08 , 0.33]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 3.36 [ 1.24 , 9.12] | 4 | 4 | 11.35 [ 4.91 , 26.21] | 0.30 [0.08 , 1.09]<br>NA [ NA , Inf] | 0.0680 | 0.5317 |
| >= 18 years | 14 | 14 | 1.98 [ 1.06 , 3.68] | 5 | 5 | 16.07 [ 7.59 , 34.04] | 0.12 [0.05 , 0.30]<br>NA [ NA , Inf] | < 0.0001 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 2.36 [ 1.16 , 4.80] | 4 | 4 | 11.33 [ 4.92 , 26.08] | 0.21 [0.07 , 0.63]<br>NA [ NA , Inf] | 0.0053 | 0.8139 |
| OECD country | 9 | 9 | 2.17 [ 1.05 , 4.51] | 5 | 5 | 16.24 [ 7.68 , 34.32] | 0.13 [0.05 , 0.36]<br>NA [ NA , Inf] | 0.0001 | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTexBR = On-treatment without data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.8 Treated spontaneous and traumatic target joint bleeds - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 1.12 [ 0.54 , 2.33] | 9 | 9 | 4.36 [ 2.04 , 9.34] | 0.26 [0.11 , 0.60] | 0.0019 | |
| | | | | | | | NA [ NA , Inf] | | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 1.25 [ 0.36 , 4.38] | 4 | 4 | 2.49 [ 0.80 , 7.73] | 0.50 [0.10 , 2.49] | 0.3997 | 0.4624 |
| | | | | | | | NA [ NA , Inf] | | |
| >= 18 years | 14 | 14 | 1.15 [ 0.54 , 2.48] | 5 | 5 | 5.99 [ 2.41 , 14.91] | 0.19 [0.07 , 0.52] | 0.0012 | |
| | | | | | | | NA [ NA , Inf] | | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 1.11 [ 0.46 , 2.68] | 4 | 4 | 2.49 [ 0.81 , 7.68] | 0.45 [0.12 , 1.66] | 0.2278 | 0.4565 |
| | | | | | | | NA [ NA , Inf] | | |
| OECD country | 9 | 9 | 1.24 [ 0.51 , 3.00] | 5 | 5 | 5.97 [ 2.41 , 14.78] | 0.21 [0.07 , 0.63] | 0.0053 | |
| | | | | | | | NA [ NA , Inf] | | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTexBR = On-treatment without data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. Cut off date for data is 12th July 2022.

## 1.2.9 All treated and untreated spontaneous and traumatic bleeding episodes - Explorer 8 - HA - OTwoATexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 5.49 [ 3.52 , 8.56] | 9 | 9 | 23.79 [13.26 , 42.68] | 0.23 [0.11 , 0.47]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 6.12 [ 2.45 , 15.29] | 4 | 4 | 20.05 [ 8.73 , 46.05] | 0.31 [0.09 , 1.03]<br>NA [ NA , Inf] | 0.0567 | 0.8403 |
| >= 18 years | 14 | 14 | 5.36 [ 3.27 , 8.77] | 5 | 5 | 27.27 [12.58 , 59.15] | 0.20 [0.08 , 0.48]<br>NA [ NA , Inf] | 0.0003 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 4.01 [ 2.09 , 7.69] | 4 | 4 | 19.74 [ 8.84 , 44.06] | 0.20 [0.07 , 0.56]<br>NA [ NA , Inf] | 0.0021 | 0.4163 |
| OECD country | 9 | 9 | 6.90 [ 3.88 , 12.26] | 5 | 5 | 25.99 [12.29 , 54.98] | 0.27 [0.10 , 0.68]<br>NA [ NA , Inf] | 0.0057 | |

ABR: Annualized bleeding rate, HB: Haemophilia B, OTwoATexBR = On-treatment without ancillary therapy excluding data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment.

## 1.2.10 All treated and untreated spontaneous and traumatic bleeding episodes - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX (arm 2) | | | No PPX (arm 1) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N | n | ABR [95% CI] | N | n | ABR [95% CI] | ABR ratio [95% CI] | p-value | p-value int. |
| All subjects | 18 | 18 | 5.49 [ 3.52 , 8.56] | 9 | 9 | 23.79 [13.26 , 42.68] | 0.23 [0.11 , 0.47]<br>NA [ NA , Inf] | < 0.0001 | |
| Age | | | | | | | | | |
| < 18 years | 4 | 4 | 6.12 [ 2.45 , 15.29] | 4 | 4 | 20.05 [ 8.73 , 46.05] | 0.31 [0.09 , 1.03]<br>NA [ NA , Inf] | 0.0567 | 0.8403 |
| >= 18 years | 14 | 14 | 5.36 [ 3.27 , 8.76] | 5 | 5 | 27.27 [12.57 , 59.15] | 0.20 [0.08 , 0.48]<br>NA [ NA , Inf] | 0.0003 | |
| Region | | | | | | | | | |
| Non-OECD country | 9 | 9 | 4.01 [ 2.09 , 7.69] | 4 | 4 | 19.74 [ 8.84 , 44.07] | 0.20 [0.07 , 0.56]<br>NA [ NA , Inf] | 0.0021 | 0.4166 |
| OECD country | 9 | 9 | 6.90 [ 3.88 , 12.25] | 5 | 5 | 25.99 [12.29 , 54.98] | 0.27 [0.10 , 0.68]<br>NA [ NA , Inf] | 0.0057 | |

ABR: Annualized bleeding rate, HA: Haemophilia A, OTexBR = On-treatment without data before restart, PPX: Prophylaxis, N: number of subjects in the analysis set, n: number of subjects with an observation, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). Bleeding endpoints are analysed using a negative binomial regression model with the logarithm of the length of the observation period included (in years) as offset with treatment and bleeding frequency prior to screening as factors. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment.

## 1.2.11 Zero treated spontaneous and traumatic bleeding episodes - Explorer 8 - HA - OTwoATexBR - Full analysis set

| | Concizumab PPX (arm 2) | | No PPX (arm 1) | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | |
|---|---|---|---|---|---|---|
| | N | n | N | n | Odds ratio [95% CI] | p-value int. |
| All subjects | 18 | 6 | 9 | 0 | NA [ NA , NA] | NA |
| Age | | | | | | |
| < 18 years | 4 | 1 | 4 | 0 | NA [ NA , NA] | NA |
| >= 18 years | 14 | 5 | 5 | 0 | NA [ NA , NA] | NA |
| Region | | | | | | |
| Non-OECD country | 9 | 3 | 4 | 0 | NA [ NA , NA] | NA |
| OECD country | 9 | 3 | 5 | 0 | NA [ NA , NA] | NA |

HA: Haemophilia A, PPX: Prophylaxis,, N: number of subjects in the analysis set, n: number of subjects with zero bleeding episodes, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). The number of subjects with zero bleeding episodes is analysed using a logistic regression model with treatment and bleeding frequency prior to screening as fixed effects. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. In case there are no subjects having zero treated spontaneous or traumatic bleeding episodes in a group the analysis comparing the number of subjects with zero bleeding episodes is not performed (indicated by "NA" in the table). Cut off date for data is 12th July 2022.

## 1.2.12 Zero treated spontaneous and traumatic bleeding episodes - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX (arm 2) | | No PPX (arm 1) | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | |
|---|---|---|---|---|---|---|
| | N | n | N | n | Odds ratio [95% CI] | p-value int. |
| All subjects | 18 | 6 | 9 | 0 | NA [ NA , NA] | NA |
| Age | | | | | | |
| < 18 years | 4 | 1 | 4 | 0 | NA [ NA , NA] | NA |
| >= 18 years | 14 | 5 | 5 | 0 | NA [ NA , NA] | NA |
| Region | | | | | | |
| Non-OECD country | 9 | 3 | 4 | 0 | NA [ NA , NA] | NA |
| OECD country | 9 | 3 | 5 | 0 | NA [ NA , NA] | NA |

HA: Haemophilia A, PPX: Prophylaxis,, N: number of subjects in the analysis set, n: number of subjects with zero bleeding episodes, SD: Standard deviation, SE: Standard error, CI: confidence interval, p-value: unadjusted two-sided p-value for test of no difference from arm 1 (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test). The number of subjects with zero bleeding episodes is analysed using a logistic regression model with treatment and bleeding frequency prior to screening as fixed effects. For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. In case there are no subjects having zero treated spontaneous or traumatic bleeding episodes in a group the analysis comparing the number of subjects with zero bleeding episodes is not performed (indicated by "NA" in the table). Cut off date for data is 12th July 2022.

# Table of contents

**Page**

## Statistical documentation

## 1.3.2.1 Haem-A-QoL dealing with haemophilia domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 22.22 (19.48) | 18 | 14 | 27.38 (20.00) |
| Week 4 | 9 | 5 | 18.33 (16.03) | 18 | 14 | 19.64 (11.14) |
| Week 8 | 9 | 6 | 22.22 (14.59) | 18 | 14 | 19.64 (14.10) |
| Week 16 | 9 | 5 | 25.00 (14.43) | 18 | 11 | 13.64 (10.72) |
| Week 24 | 9 | 5 | 20.00 (18.26) | 17 | 10 | 17.50 (22.72) |
| Week 32 | | | | 16 | 9 | 12.04 (15.65) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 8.33 ( NA) | 4 | 2 | 4.17 ( 5.89) |
| Week 4 | 4 | 1 | 41.67 ( NA) | 4 | 2 | 16.67 (11.79) |
| Week 8 | 4 | 1 | 16.67 ( NA) | 4 | 2 | 37.50 (17.68) |
| Week 16 | 4 | 1 | 33.33 ( NA) | 4 | 2 | 20.83 ( 5.89) |
| Week 24 | | | | 3 | 1 | 25.00 ( NA) |
| Week 32 | | | | 3 | 1 | 8.33 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 25.00 (20.41) | 14 | 12 | 31.25 (18.84) |
| Week 4 | 5 | 4 | 12.50 (10.76) | 14 | 12 | 20.14 (11.49) |
| Week 8 | 5 | 5 | 23.33 (16.03) | 14 | 12 | 16.67 (11.79) |
| Week 16 | 5 | 4 | 22.92 (15.77) | 14 | 9 | 12.04 (11.11) |
| Week 24 | 5 | 5 | 20.00 (18.26) | 14 | 9 | 16.67 (23.94) |
| Week 32 | | | | 13 | 8 | 12.50 (16.67) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL dealing with haemophilia domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 8.33 ( NA) | 9 | 7 | 26.19 (27.40) |
| Week 4 | 4 | 1 | 41.67 ( NA) | 9 | 7 | 17.86 (12.20) |
| Week 8 | 4 | 1 | 16.67 ( NA) | 9 | 7 | 21.43 (15.11) |
| Week 16 | 4 | 1 | 33.33 ( NA) | 9 | 7 | 13.10 (10.60) |
| Week 24 | | | | 8 | 6 | 19.44 (29.19) |
| Week 32 | | | | 8 | 6 | 11.11 (12.55) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 25.00 (20.41) | 9 | 7 | 28.57 (10.60) |
| Week 4 | 5 | 4 | 12.50 (10.76) | 9 | 7 | 21.43 (10.60) |
| Week 8 | 5 | 5 | 23.33 (16.03) | 9 | 7 | 17.86 (13.97) |
| Week 16 | 5 | 4 | 22.92 (15.77) | 9 | 4 | 14.58 (12.50) |
| Week 24 | 5 | 5 | 20.00 (18.26) | 9 | 4 | 14.58 (10.49) |
| Week 32 | | | | 8 | 3 | 13.89 (24.06) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.2 Haem-A-QoL feeling domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 48.96 (39.21) | 18 | 14 | 44.64 (22.45) |
| Week 4 | 9 | 5 | 27.50 (41.83) | 18 | 14 | 29.46 (21.71) |
| Week 8 | 9 | 6 | 35.42 (29.49) | 18 | 14 | 28.57 (22.70) |
| Week 16 | 9 | 5 | 30.00 (20.44) | 18 | 11 | 31.25 (25.46) |
| Week 24 | 9 | 5 | 53.75 (32.66) | 17 | 10 | 26.25 (24.62) |
| Week 32 | | | | 16 | 9 | 18.06 (20.12) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 12.50 ( NA) | 4 | 2 | 31.25 (26.52) |
| Week 4 | 4 | 1 | 0.00 ( NA) | 4 | 2 | 18.75 (26.52) |
| Week 8 | 4 | 1 | 0.00 ( NA) | 4 | 2 | 9.38 (13.26) |
| Week 16 | 4 | 1 | 6.25 ( NA) | 4 | 2 | 15.62 (22.10) |
| Week 24 | | | | 3 | 1 | 0.00 ( NA) |
| Week 32 | | | | 3 | 1 | 0.00 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 56.25 (39.03) | 14 | 12 | 46.88 (22.22) |
| Week 4 | 5 | 4 | 34.38 (44.92) | 14 | 12 | 31.25 (21.65) |
| Week 8 | 5 | 5 | 42.50 (26.66) | 14 | 12 | 31.77 (22.69) |
| Week 16 | 5 | 4 | 35.94 (17.95) | 14 | 9 | 34.72 (25.98) |
| Week 24 | 5 | 5 | 53.75 (32.66) | 14 | 9 | 29.17 (24.21) |
| Week 32 | | | | 13 | 8 | 20.31 (20.25) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL feeling domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 12.50 ( NA) | 9 | 7 | 49.11 (23.23) |
| Week 4 | 4 | 1 | 0.00 ( NA) | 9 | 7 | 32.14 (24.59) |
| Week 8 | 4 | 1 | 0.00 ( NA) | 9 | 7 | 21.43 (23.62) |
| Week 16 | 4 | 1 | 6.25 ( NA) | 9 | 7 | 20.54 (21.56) |
| Week 24 | | | | 8 | 6 | 20.83 (21.53) |
| Week 32 | | | | 8 | 6 | 12.50 (19.76) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 56.25 (39.03) | 9 | 7 | 40.18 (22.49) |
| Week 4 | 5 | 4 | 34.38 (44.92) | 9 | 7 | 26.79 (20.00) |
| Week 8 | 5 | 5 | 42.50 (26.66) | 9 | 7 | 35.71 (20.95) |
| Week 16 | 5 | 4 | 35.94 (17.95) | 9 | 4 | 50.00 (22.24) |
| Week 24 | 5 | 5 | 53.75 (32.66) | 9 | 4 | 34.38 (29.97) |
| Week 32 | | | | 8 | 3 | 29.17 (19.09) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.3 Haem-A-QoL future domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 46.67 (35.87) | 18 | 14 | 42.86 (16.72) |
| Week 4 | 9 | 5 | 43.00 (33.28) | 18 | 14 | 35.36 (18.96) |
| Week 8 | 9 | 6 | 41.67 (30.93) | 18 | 14 | 37.50 (16.61) |
| Week 16 | 9 | 5 | 39.00 (17.82) | 18 | 11 | 37.73 (19.02) |
| Week 24 | 9 | 5 | 52.00 (29.71) | 17 | 10 | 32.00 (18.44) |
| Week 32 | | | | 16 | 9 | 30.00 (17.68) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 15.00 ( NA) | 4 | 2 | 30.00 (14.14) |
| Week 4 | 4 | 1 | 25.00 ( NA) | 4 | 2 | 27.50 ( 3.54) |
| Week 8 | 4 | 1 | 15.00 ( NA) | 4 | 2 | 22.50 ( 3.54) |
| Week 16 | 4 | 1 | 15.00 ( NA) | 4 | 2 | 32.50 ( 3.54) |
| Week 24 | | | | 3 | 1 | 25.00 ( NA) |
| Week 32 | | | | 3 | 1 | 30.00 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 53.00 (36.16) | 14 | 12 | 45.00 (16.65) |
| Week 4 | 5 | 4 | 47.50 (36.63) | 14 | 12 | 36.67 (20.26) |
| Week 8 | 5 | 5 | 47.00 (31.34) | 14 | 12 | 40.00 (16.65) |
| Week 16 | 5 | 4 | 45.00 (13.54) | 14 | 9 | 38.89 (21.03) |
| Week 24 | 5 | 5 | 52.00 (29.71) | 14 | 9 | 32.78 (19.38) |
| Week 32 | | | | 13 | 8 | 30.00 (18.90) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL future domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 15.00 ( NA) | 9 | 7 | 31.43 ( 9.45) |
| Week 4 | 4 | 1 | 25.00 ( NA) | 9 | 7 | 25.00 (10.00) |
| Week 8 | 4 | 1 | 15.00 ( NA) | 9 | 7 | 27.14 (11.50) |
| Week 16 | 4 | 1 | 15.00 ( NA) | 9 | 7 | 28.57 ( 8.52) |
| Week 24 | | | | 8 | 6 | 22.50 (12.94) |
| Week 32 | | | | 8 | 6 | 20.00 (10.00) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 53.00 (36.16) | 9 | 7 | 54.29 (14.56) |
| Week 4 | 5 | 4 | 47.50 (36.63) | 9 | 7 | 45.71 (20.70) |
| Week 8 | 5 | 5 | 47.00 (31.34) | 9 | 7 | 47.86 (14.68) |
| Week 16 | 5 | 4 | 45.00 (13.54) | 9 | 4 | 53.75 (22.87) |
| Week 24 | 5 | 5 | 52.00 (29.71) | 9 | 4 | 46.25 (17.02) |
| Week 32 | | | | 8 | 3 | 50.00 (10.00) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.4 Haem-A-QoL partnership and sexuality domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 47.22 (44.93) | 18 | 14 | 39.88 (32.88) |
| Week 4 | 9 | 5 | 46.67 (50.55) | 18 | 12 | 29.86 (38.18) |
| Week 8 | 9 | 6 | 29.17 (39.35) | 18 | 14 | 25.60 (36.47) |
| Week 16 | 9 | 5 | 16.67 (22.82) | 18 | 11 | 27.27 (39.81) |
| Week 24 | 9 | 4 | 50.00 (41.39) | 17 | 9 | 22.22 (37.27) |
| Week 32 | | | | 16 | 8 | 12.50 (35.36) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 100.00 ( NA) | 4 | 2 | 58.33 (11.79) |
| Week 4 | 4 | 1 | 100.00 ( NA) | 4 | 2 | 12.50 ( 5.89) |
| Week 8 | 4 | 1 | 0.00 ( NA) | 4 | 2 | 4.17 ( 5.89) |
| Week 16 | 4 | 1 | 0.00 ( NA) | 4 | 2 | 8.33 (11.79) |
| Week 24 | | | | 3 | 1 | 0.00 ( NA) |
| Week 32 | | | | 3 | 1 | 0.00 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 36.67 (41.08) | 14 | 12 | 36.81 (34.53) |
| Week 4 | 5 | 4 | 33.33 (47.14) | 14 | 10 | 33.33 (41.20) |
| Week 8 | 5 | 5 | 35.00 (40.99) | 14 | 12 | 29.17 (38.35) |
| Week 16 | 5 | 4 | 20.83 (24.06) | 14 | 9 | 31.48 (43.06) |
| Week 24 | 5 | 4 | 50.00 (41.39) | 14 | 8 | 25.00 (38.83) |
| Week 32 | | | | 13 | 7 | 14.29 (37.80) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL partnership and sexuality domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 100.00 ( NA) | 9 | 7 | 48.81 (40.38) |
| Week 4 | 4 | 1 | 100.00 ( NA) | 9 | 7 | 38.10 (44.58) |
| Week 8 | 4 | 1 | 0.00 ( NA) | 9 | 7 | 30.95 (47.32) |
| Week 16 | 4 | 1 | 0.00 ( NA) | 9 | 7 | 32.14 (46.75) |
| Week 24 | | | | 8 | 5 | 26.67 (43.46) |
| Week 32 | | | | 8 | 5 | 20.00 (44.72) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 36.67 (41.08) | 9 | 7 | 30.95 (22.93) |
| Week 4 | 5 | 4 | 33.33 (47.14) | 9 | 5 | 18.33 (27.26) |
| Week 8 | 5 | 5 | 35.00 (40.99) | 9 | 7 | 20.24 (23.99) |
| Week 16 | 5 | 4 | 20.83 (24.06) | 9 | 4 | 18.75 (27.53) |
| Week 24 | 5 | 4 | 50.00 (41.39) | 9 | 4 | 16.67 (33.33) |
| Week 32 | | | | 8 | 3 | 0.00 ( 0.00) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.5 Haem-A-QoL physical health domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 60.00 (18.71) | 18 | 14 | 47.86 (18.99) |
| Week 4 | 9 | 4 | 43.75 (28.69) | 18 | 14 | 29.64 (19.95) |
| Week 8 | 9 | 6 | 52.50 (21.15) | 18 | 14 | 30.71 (23.11) |
| Week 16 | 9 | 5 | 51.25 ( 6.73) | 18 | 11 | 37.73 (18.08) |
| Week 24 | 9 | 5 | 62.00 (21.68) | 17 | 10 | 34.50 (18.92) |
| Week 32 | | | | 16 | 9 | 25.56 (15.09) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | 4 | 2 | 62.50 ( 3.54) |
| Week 4 | 4 | 1 | 20.00 ( NA) | 4 | 2 | 17.50 ( 3.54) |
| Week 8 | 4 | 1 | 35.00 ( NA) | 4 | 2 | 15.00 (21.21) |
| Week 16 | 4 | 1 | 40.00 ( NA) | 4 | 2 | 45.00 ( 7.07) |
| Week 24 | | | | 3 | 1 | 25.00 ( NA) |
| Week 32 | | | | 3 | 1 | 25.00 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 65.00 (15.81) | 14 | 12 | 45.42 (19.48) |
| Week 4 | 5 | 3 | 51.67 (29.30) | 14 | 12 | 31.67 (20.93) |
| Week 8 | 5 | 5 | 56.00 (21.62) | 14 | 12 | 33.33 (23.19) |
| Week 16 | 5 | 4 | 54.06 ( 2.77) | 14 | 9 | 36.11 (19.65) |
| Week 24 | 5 | 5 | 62.00 (21.68) | 14 | 9 | 35.56 (19.76) |
| Week 32 | | | | 13 | 8 | 25.62 (16.13) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL physical health domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | 9 | 7 | 57.86 (10.75) |
| Week 4 | 4 | 1 | 20.00 ( NA) | 9 | 7 | 28.57 (19.94) |
| Week 8 | 4 | 1 | 35.00 ( NA) | 9 | 7 | 27.86 (20.59) |
| Week 16 | 4 | 1 | 40.00 ( NA) | 9 | 7 | 38.57 (16.00) |
| Week 24 | | | | 8 | 6 | 35.00 (19.49) |
| Week 32 | | | | 8 | 6 | 24.17 (17.72) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 65.00 (15.81) | 9 | 7 | 37.86 (20.79) |
| Week 4 | 5 | 3 | 51.67 (29.30) | 9 | 7 | 30.71 (21.49) |
| Week 8 | 5 | 5 | 56.00 (21.62) | 9 | 7 | 33.57 (26.73) |
| Week 16 | 5 | 4 | 54.06 ( 2.77) | 9 | 4 | 36.25 (23.94) |
| Week 24 | 5 | 5 | 62.00 (21.68) | 9 | 4 | 33.75 (20.97) |
| Week 32 | | | | 8 | 3 | 28.33 (10.41) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.6 Haem-A-QoL sport and leisure domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 5 | 81.50 (13.39) | 18 | 14 | 71.85 (25.51) |
| Week 4 | 9 | 5 | 78.50 (28.15) | 18 | 13 | 59.49 (28.03) |
| Week 8 | 9 | 5 | 73.00 (13.51) | 18 | 10 | 61.75 (25.46) |
| Week 16 | 9 | 5 | 77.00 (13.51) | 18 | 7 | 62.32 (33.48) |
| Week 24 | 9 | 5 | 83.00 (17.18) | 17 | 7 | 45.54 (26.85) |
| Week 32 | | | | 16 | 5 | 45.00 (27.84) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 70.00 ( NA) | 4 | 2 | 71.25 (22.98) |
| Week 4 | 4 | 1 | 30.00 ( NA) | 4 | 2 | 63.75 ( 1.77) |
| Week 8 | 4 | 1 | 55.00 ( NA) | 4 | 1 | 43.75 ( NA) |
| Week 16 | 4 | 1 | 60.00 ( NA) | 4 | 1 | 56.25 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 4 | 84.38 (13.56) | 14 | 12 | 71.94 (26.85) |
| Week 4 | 5 | 4 | 90.62 ( 8.75) | 14 | 11 | 58.71 (30.64) |
| Week 8 | 5 | 4 | 77.50 (10.41) | 14 | 9 | 63.75 (26.16) |
| Week 16 | 5 | 4 | 81.25 (11.09) | 14 | 6 | 63.33 (36.56) |
| Week 24 | 5 | 5 | 83.00 (17.18) | 14 | 7 | 45.54 (26.85) |
| Week 32 | | | | 13 | 5 | 45.00 (27.84) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL sport and leisure domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 70.00 ( NA) | 9 | 7 | 83.93 (16.82) |
| Week 4 | 4 | 1 | 30.00 ( NA) | 9 | 7 | 73.81 (18.43) |
| Week 8 | 4 | 1 | 55.00 ( NA) | 9 | 4 | 73.44 (20.35) |
| Week 16 | 4 | 1 | 60.00 ( NA) | 9 | 3 | 82.08 (22.92) |
| Week 24 | | | | 8 | 3 | 52.92 (10.92) |
| Week 32 | | | | 8 | 2 | 67.50 ( 3.54) |
| OECD country | | | | | | |
| Baseline | 5 | 4 | 84.38 (13.56) | 9 | 7 | 59.76 (28.04) |
| Week 4 | 5 | 4 | 90.62 ( 8.75) | 9 | 6 | 42.78 (29.26) |
| Week 8 | 5 | 4 | 77.50 (10.41) | 9 | 6 | 53.96 (27.14) |
| Week 16 | 5 | 4 | 81.25 (11.09) | 9 | 4 | 47.50 (34.76) |
| Week 24 | 5 | 5 | 83.00 (17.18) | 9 | 4 | 40.00 (35.59) |
| Week 32 | | | | 8 | 3 | 30.00 (26.46) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.7 Haem-A-QoL total score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 51.84 (21.12) | 18 | 14 | 45.18 (14.39) |
| Week 4 | 9 | 5 | 46.33 (24.43) | 18 | 14 | 33.31 (13.90) |
| Week 8 | 9 | 6 | 49.96 (20.79) | 18 | 14 | 31.87 (13.87) |
| Week 16 | 9 | 5 | 47.12 (10.35) | 18 | 11 | 32.93 (15.28) |
| Week 24 | 9 | 5 | 57.41 (21.73) | 17 | 10 | 28.80 (15.38) |
| Week 32 | | | | 16 | 9 | 22.55 ( 9.17) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 36.31 ( NA) | 4 | 2 | 41.79 ( 2.99) |
| Week 4 | 4 | 1 | 29.76 ( NA) | 4 | 2 | 26.43 ( 6.44) |
| Week 8 | 4 | 1 | 27.38 ( NA) | 4 | 2 | 22.38 ( 1.79) |
| Week 16 | 4 | 1 | 35.71 ( NA) | 4 | 2 | 30.00 ( 7.07) |
| Week 24 | | | | 3 | 1 | 16.67 ( NA) |
| Week 32 | | | | 3 | 1 | 18.92 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 54.95 (22.03) | 14 | 12 | 45.75 (15.54) |
| Week 4 | 5 | 4 | 50.48 (26.10) | 14 | 12 | 34.46 (14.64) |
| Week 8 | 5 | 5 | 54.47 (19.68) | 14 | 12 | 33.46 (14.42) |
| Week 16 | 5 | 4 | 49.98 ( 9.40) | 14 | 9 | 33.59 (16.82) |
| Week 24 | 5 | 5 | 57.41 (21.73) | 14 | 9 | 30.15 (15.68) |
| Week 32 | | | | 13 | 8 | 23.00 ( 9.70) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL total score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 36.31 ( NA) | 9 | 7 | 46.31 (13.52) |
| Week 4 | 4 | 1 | 29.76 ( NA) | 9 | 7 | 31.99 (11.48) |
| Week 8 | 4 | 1 | 27.38 ( NA) | 9 | 7 | 27.28 ( 7.49) |
| Week 16 | 4 | 1 | 35.71 ( NA) | 9 | 7 | 28.70 (11.35) |
| Week 24 | | | | 8 | 6 | 24.00 ( 8.76) |
| Week 32 | | | | 8 | 6 | 19.42 ( 5.43) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 54.95 (22.03) | 9 | 7 | 44.05 (16.21) |
| Week 4 | 5 | 4 | 50.48 (26.10) | 9 | 7 | 34.64 (16.81) |
| Week 8 | 5 | 5 | 54.47 (19.68) | 9 | 7 | 36.47 (17.65) |
| Week 16 | 5 | 4 | 49.98 ( 9.40) | 9 | 4 | 40.35 (20.14) |
| Week 24 | 5 | 5 | 57.41 (21.73) | 9 | 4 | 36.01 (21.61) |
| Week 32 | | | | 8 | 3 | 28.80 (13.22) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.8 Haem-A-QoL treatment domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 53.12 (22.10) | 18 | 14 | 45.54 (21.15) |
| Week 4 | 9 | 5 | 51.88 (23.45) | 18 | 14 | 29.11 (26.99) |
| Week 8 | 9 | 6 | 62.50 (12.96) | 18 | 14 | 25.03 (24.62) |
| Week 16 | 9 | 5 | 56.25 ( 7.65) | 18 | 11 | 27.64 (27.67) |
| Week 24 | 9 | 5 | 64.38 (16.03) | 17 | 10 | 24.42 (24.38) |
| Week 32 | | | | 16 | 9 | 19.84 (23.91) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 34.38 ( NA) | 4 | 2 | 46.88 ( 8.84) |
| Week 4 | 4 | 1 | 43.75 ( NA) | 4 | 2 | 20.98 (14.52) |
| Week 8 | 4 | 1 | 53.12 ( NA) | 4 | 2 | 16.29 ( 7.89) |
| Week 16 | 4 | 1 | 59.38 ( NA) | 4 | 2 | 23.88 (23.68) |
| Week 24 | | | | 3 | 1 | 3.57 ( NA) |
| Week 32 | | | | 3 | 1 | 3.57 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 56.88 (22.47) | 14 | 12 | 45.31 (22.83) |
| Week 4 | 5 | 4 | 53.91 (26.56) | 14 | 12 | 30.47 (28.77) |
| Week 8 | 5 | 5 | 64.38 (13.55) | 14 | 12 | 26.49 (26.36) |
| Week 16 | 5 | 4 | 55.47 ( 8.61) | 14 | 9 | 28.47 (29.71) |
| Week 24 | 5 | 5 | 64.38 (16.03) | 14 | 9 | 26.74 (24.66) |
| Week 32 | | | | 13 | 8 | 21.88 (24.72) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL treatment domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 34.38 ( NA) | 9 | 7 | 41.96 (16.02) |
| Week 4 | 4 | 1 | 43.75 ( NA) | 9 | 7 | 22.07 (27.38) |
| Week 8 | 4 | 1 | 53.12 ( NA) | 9 | 7 | 17.16 (21.03) |
| Week 16 | 4 | 1 | 59.38 ( NA) | 9 | 7 | 20.22 (27.70) |
| Week 24 | | | | 8 | 6 | 11.53 (13.00) |
| Week 32 | | | | 8 | 6 | 12.57 (19.02) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 56.88 (22.47) | 9 | 7 | 49.11 (26.13) |
| Week 4 | 5 | 4 | 53.91 (26.56) | 9 | 7 | 36.16 (26.69) |
| Week 8 | 5 | 5 | 64.38 (13.55) | 9 | 7 | 32.91 (26.95) |
| Week 16 | 5 | 4 | 55.47 ( 8.61) | 9 | 4 | 40.62 (25.77) |
| Week 24 | 5 | 5 | 64.38 (16.03) | 9 | 4 | 43.75 (25.90) |
| Week 32 | | | | 8 | 3 | 34.38 (30.14) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.9 Haem-A-QoL view of yourself domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 60.00 (25.88) | 18 | 14 | 50.71 (18.80) |
| Week 4 | 9 | 5 | 47.00 (31.74) | 18 | 14 | 45.36 (18.55) |
| Week 8 | 9 | 6 | 51.67 (27.33) | 18 | 14 | 47.50 (19.19) |
| Week 16 | 9 | 5 | 53.00 (24.65) | 18 | 11 | 49.09 (22.89) |
| Week 24 | 9 | 5 | 63.00 (27.29) | 17 | 10 | 41.00 (17.92) |
| Week 32 | | | | 16 | 9 | 37.78 (18.05) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | 4 | 2 | 40.00 (21.21) |
| Week 4 | 4 | 1 | 15.00 ( NA) | 4 | 2 | 30.00 (14.14) |
| Week 8 | 4 | 1 | 20.00 ( NA) | 4 | 2 | 50.00 ( 7.07) |
| Week 16 | 4 | 1 | 20.00 ( NA) | 4 | 2 | 42.50 (10.61) |
| Week 24 | | | | 3 | 1 | 30.00 ( NA) |
| Week 32 | | | | 3 | 1 | 50.00 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 5 | 65.00 (25.50) | 14 | 12 | 52.50 (18.77) |
| Week 4 | 5 | 4 | 55.00 (30.28) | 14 | 12 | 47.92 (18.40) |
| Week 8 | 5 | 5 | 58.00 (25.15) | 14 | 12 | 47.08 (20.72) |
| Week 16 | 5 | 4 | 61.25 (18.87) | 14 | 9 | 50.56 (25.06) |
| Week 24 | 5 | 5 | 63.00 (27.29) | 14 | 9 | 42.22 (18.56) |
| Week 32 | | | | 13 | 8 | 36.25 (18.66) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL view of yourself domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | 9 | 7 | 48.57 (20.76) |
| Week 4 | 4 | 1 | 15.00 ( NA) | 9 | 7 | 40.71 (22.25) |
| Week 8 | 4 | 1 | 20.00 ( NA) | 9 | 7 | 41.43 (19.52) |
| Week 16 | 4 | 1 | 20.00 ( NA) | 9 | 7 | 40.00 (20.00) |
| Week 24 | | | | 8 | 6 | 32.50 (15.08) |
| Week 32 | | | | 8 | 6 | 30.00 (16.73) |
| OECD country | | | | | | |
| Baseline | 5 | 5 | 65.00 (25.50) | 9 | 7 | 52.86 (17.99) |
| Week 4 | 5 | 4 | 55.00 (30.28) | 9 | 7 | 50.00 (14.14) |
| Week 8 | 5 | 5 | 58.00 (25.15) | 9 | 7 | 53.57 (18.19) |
| Week 16 | 5 | 4 | 61.25 (18.87) | 9 | 4 | 65.00 (20.41) |
| Week 24 | 5 | 5 | 63.00 (27.29) | 9 | 4 | 53.75 (14.93) |
| Week 32 | | | | 8 | 3 | 53.33 ( 7.64) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.10 Haem-A-QoL work and studies domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 4 | 40.62 (16.54) | 18 | 13 | 35.10 (24.41) |
| Week 4 | 9 | 4 | 50.52 (37.51) | 18 | 12 | 23.26 (16.01) |
| Week 8 | 9 | 5 | 52.50 (33.25) | 18 | 12 | 14.06 (17.90) |
| Week 16 | 9 | 3 | 61.11 ( 6.70) | 18 | 11 | 20.45 (20.17) |
| Week 24 | 9 | 3 | 52.08 (23.66) | 17 | 10 | 22.50 (18.45) |
| Week 32 | | | | 16 | 9 | 10.42 (17.12) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 1 | 25.00 ( NA) | 4 | 2 | 25.00 ( 0.00) |
| Week 4 | 4 | 1 | 6.25 ( NA) | 4 | 2 | 34.38 ( 4.42) |
| Week 8 | 4 | 1 | 12.50 ( NA) | 4 | 2 | 15.62 (22.10) |
| Week 16 | 4 | 1 | 56.25 ( NA) | 4 | 2 | 37.50 (17.68) |
| Week 24 | | | | 3 | 1 | 25.00 ( NA) |
| Week 32 | | | | 3 | 1 | 25.00 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 45.83 (15.73) | 14 | 11 | 36.93 (26.29) |
| Week 4 | 5 | 3 | 65.28 (28.36) | 14 | 10 | 21.04 (16.68) |
| Week 8 | 5 | 4 | 62.50 (28.41) | 14 | 10 | 13.75 (18.35) |
| Week 16 | 5 | 2 | 63.54 ( 7.37) | 14 | 9 | 16.67 (19.52) |
| Week 24 | 5 | 3 | 52.08 (23.66) | 14 | 9 | 22.22 (19.54) |
| Week 32 | | | | 13 | 8 | 8.59 (17.34) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL work and studies domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 1 | 25.00 ( NA) | 9 | 7 | 35.71 (27.41) |
| Week 4 | 4 | 1 | 6.25 ( NA) | 9 | 7 | 22.02 (17.59) |
| Week 8 | 4 | 1 | 12.50 ( NA) | 9 | 7 | 11.61 (13.22) |
| Week 16 | 4 | 1 | 56.25 ( NA) | 9 | 7 | 18.75 (21.35) |
| Week 24 | | | | 8 | 6 | 19.79 (17.86) |
| Week 32 | | | | 8 | 6 | 7.29 (10.01) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 45.83 (15.73) | 9 | 6 | 34.38 (22.96) |
| Week 4 | 5 | 3 | 65.28 (28.36) | 9 | 5 | 25.00 (15.31) |
| Week 8 | 5 | 4 | 62.50 (28.41) | 9 | 5 | 17.50 (24.37) |
| Week 16 | 5 | 2 | 63.54 ( 7.37) | 9 | 4 | 23.44 (20.65) |
| Week 24 | 5 | 3 | 52.08 (23.66) | 9 | 4 | 26.56 (21.27) |
| Week 32 | | | | 8 | 3 | 16.67 (28.87) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.11 Haem-A-QoL family planning domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 3 | 12.50 (21.65) | 18 | 10 | 24.38 (22.91) |
| Week 4 | 9 | 1 | 0.00 ( NA) | 18 | 8 | 16.67 (26.26) |
| Week 8 | 9 | 1 | 43.75 ( NA) | 18 | 7 | 19.05 (27.65) |
| Week 16 | 9 | 2 | 16.67 (23.57) | 18 | 7 | 16.67 (29.24) |
| Week 24 | 9 | 3 | 8.33 (14.43) | 17 | 7 | 17.56 (29.19) |
| Week 32 | | | | 16 | 6 | 5.90 ( 7.27) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | | | | 4 | 1 | 25.00 ( NA) |
| Week 4 | | | | 4 | 1 | 12.50 ( NA) |
| Week 8 | | | | 4 | 1 | 6.25 ( NA) |
| Week 16 | | | | 4 | 1 | 6.25 ( NA) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 12.50 (21.65) | 14 | 9 | 24.31 (24.30) |
| Week 4 | 5 | 1 | 0.00 ( NA) | 14 | 7 | 17.26 (28.30) |
| Week 8 | 5 | 1 | 43.75 ( NA) | 14 | 6 | 21.18 (29.65) |
| Week 16 | 5 | 2 | 16.67 (23.57) | 14 | 6 | 18.40 (31.63) |
| Week 24 | 5 | 3 | 8.33 (14.43) | 14 | 7 | 17.56 (29.19) |
| Week 32 | | | | 13 | 6 | 5.90 ( 7.27) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 1 patient below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Haem-A-QoL family planning domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | | | | 9 | 5 | 20.00 (20.92) |
| Week 4 | | | | 9 | 4 | 11.46 (15.73) |
| Week 8 | | | | 9 | 4 | 9.90 (15.90) |
| Week 16 | | | | 9 | 4 | 5.73 ( 7.86) |
| Week 24 | | | | 8 | 3 | 7.64 ( 8.42) |
| Week 32 | | | | 8 | 3 | 7.64 ( 8.42) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 12.50 (21.65) | 9 | 5 | 28.75 (26.37) |
| Week 4 | 5 | 1 | 0.00 ( NA) | 9 | 4 | 21.88 (35.90) |
| Week 8 | 5 | 1 | 43.75 ( NA) | 9 | 3 | 31.25 (39.03) |
| Week 16 | 5 | 2 | 16.67 (23.57) | 9 | 3 | 31.25 (43.75) |
| Week 24 | 5 | 3 | 8.33 (14.43) | 9 | 4 | 25.00 (38.53) |
| Week 32 | | | | 8 | 3 | 4.17 ( 7.22) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 1 patient below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.2.12 Hemo-TEM Total Score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 28.63 (27.67) | 18 | 14 | 27.82 (15.59) |
| Week 24 | 9 | 5 | 41.12 (27.69) | 17 | 15 | 13.43 (13.32) |
| Week 32 | | | | 16 | 12 | 15.09 (14.80) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 17.72 (17.07) | 4 | 2 | 22.02 ( 1.00) |
| Week 24 | 4 | 1 | 20.06 ( NA) | 3 | 3 | 12.00 (13.25) |
| Week 32 | | | | 3 | 2 | 9.29 (11.37) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 39.54 (35.57) | 14 | 12 | 28.79 (16.73) |
| Week 24 | 5 | 4 | 46.38 (28.94) | 14 | 12 | 13.79 (13.90) |
| Week 32 | | | | 13 | 10 | 16.25 (15.63) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 17.72 (17.07) | 9 | 7 | 28.62 (14.66) |
| Week 24 | 4 | 1 | 20.06 ( NA) | 8 | 7 | 7.41 ( 9.36) |
| Week 32 | | | | 8 | 6 | 10.55 (14.10) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 39.54 (35.57) | 9 | 7 | 27.02 (17.61) |
| Week 24 | 5 | 4 | 46.38 (28.94) | 9 | 8 | 18.71 (14.56) |
| Week 32 | | | | 8 | 6 | 19.63 (15.27) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.13 Hemo-TEM ease of use by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 25.00 (22.97) | 18 | 14 | 28.57 (20.34) |
| Week 24 | 9 | 5 | 35.00 (34.05) | 17 | 15 | 10.56 (12.39) |
| Week 32 | | | | 16 | 12 | 13.89 (18.58) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 16.67 (16.67) | 4 | 2 | 16.67 ( 0.00) |
| Week 24 | 4 | 1 | 25.00 ( NA) | 3 | 3 | 19.44 (20.97) |
| Week 32 | | | | 3 | 2 | 12.50 (17.68) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 33.33 (28.87) | 14 | 12 | 30.56 (21.42) |
| Week 24 | 5 | 4 | 37.50 (38.79) | 14 | 12 | 8.33 ( 9.40) |
| Week 32 | | | | 13 | 10 | 14.17 (19.66) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 16.67 (16.67) | 9 | 7 | 30.95 (20.81) |
| Week 24 | 4 | 1 | 25.00 ( NA) | 8 | 7 | 10.71 (15.75) |
| Week 32 | | | | 8 | 6 | 13.89 (23.96) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 33.33 (28.87) | 9 | 7 | 26.19 (21.21) |
| Week 24 | 5 | 4 | 37.50 (38.79) | 9 | 8 | 10.42 ( 9.71) |
| Week 32 | | | | 8 | 6 | 13.89 (13.61) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.14 Hemo-TEM emotional impact by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 37.50 (34.86) | 18 | 14 | 30.12 (20.55) |
| Week 24 | 9 | 5 | 42.50 (37.55) | 17 | 15 | 16.94 (22.07) |
| Week 32 | | | | 16 | 12 | 15.21 (17.42) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 30.56 (31.27) | 4 | 2 | 21.25 (12.37) |
| Week 24 | 4 | 1 | 20.83 ( NA) | 3 | 3 | 8.33 (14.43) |
| Week 32 | | | | 3 | 2 | 10.00 (14.14) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 44.44 (43.77) | 14 | 12 | 31.60 (21.65) |
| Week 24 | 5 | 4 | 47.92 (41.04) | 14 | 12 | 19.10 (23.60) |
| Week 32 | | | | 13 | 10 | 16.25 (18.47) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 30.56 (31.27) | 9 | 7 | 31.07 (21.35) |
| Week 24 | 4 | 1 | 20.83 ( NA) | 8 | 7 | 5.95 (10.45) |
| Week 32 | | | | 8 | 6 | 7.50 (11.73) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 44.44 (43.77) | 9 | 7 | 29.17 (21.38) |
| Week 24 | 5 | 4 | 47.92 (41.04) | 9 | 8 | 26.56 (25.58) |
| Week 32 | | | | 8 | 6 | 22.92 (19.68) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.15 Hemo-TEM interference by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 29.17 (30.53) | 18 | 14 | 28.72 (23.29) |
| Week 24 | 9 | 5 | 46.67 (32.23) | 17 | 15 | 7.08 (12.24) |
| Week 32 | | | | 16 | 12 | 9.20 (11.32) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 14.58 (13.01) | 4 | 2 | 21.88 (13.26) |
| Week 24 | 4 | 1 | 6.25 ( NA) | 3 | 3 | 10.42 (13.01) |
| Week 32 | | | | 3 | 2 | 11.46 ( 7.37) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 43.75 (39.03) | 14 | 12 | 29.86 (24.80) |
| Week 24 | 5 | 4 | 56.77 (26.54) | 14 | 12 | 6.25 (12.50) |
| Week 32 | | | | 13 | 10 | 8.75 (12.22) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 14.58 (13.01) | 9 | 7 | 34.82 (24.70) |
| Week 24 | 4 | 1 | 6.25 ( NA) | 8 | 7 | 4.46 ( 9.35) |
| Week 32 | | | | 8 | 6 | 9.03 (12.68) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 43.75 (39.03) | 9 | 7 | 22.62 (21.86) |
| Week 24 | 5 | 4 | 56.77 (26.54) | 9 | 8 | 9.38 (14.56) |
| Week 32 | | | | 8 | 6 | 9.38 (11.00) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.16 Hemo-TEM physical impact by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 18.75 (18.59) | 18 | 14 | 22.62 (17.12) |
| Week 24 | 9 | 5 | 35.00 (22.36) | 17 | 15 | 16.39 (13.50) |
| Week 32 | | | | 16 | 12 | 18.40 (14.26) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 12.50 (11.02) | 4 | 2 | 27.08 ( 2.95) |
| Week 24 | 4 | 1 | 37.50 ( NA) | 3 | 3 | 11.11 (15.77) |
| Week 32 | | | | 3 | 2 | 12.50 (17.68) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 25.00 (25.00) | 14 | 12 | 21.88 (18.47) |
| Week 24 | 5 | 4 | 34.38 (25.77) | 14 | 12 | 17.71 (13.31) |
| Week 32 | | | | 13 | 10 | 19.58 (14.31) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 12.50 (11.02) | 9 | 7 | 23.81 (14.77) |
| Week 24 | 4 | 1 | 37.50 ( NA) | 8 | 7 | 11.31 (10.12) |
| Week 32 | | | | 8 | 6 | 14.58 (12.00) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 25.00 (25.00) | 9 | 7 | 21.43 (20.33) |
| Week 24 | 5 | 4 | 34.38 (25.77) | 9 | 8 | 20.83 (15.11) |
| Week 32 | | | | 8 | 6 | 22.22 (16.39) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.17 Hemo-TEM treatment burden by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 32.74 (35.89) | 18 | 14 | 29.08 (23.39) |
| Week 24 | 9 | 5 | 46.43 (29.12) | 17 | 15 | 16.19 (21.38) |
| Week 32 | | | | 16 | 12 | 18.75 (25.89) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 14.29 (14.29) | 4 | 2 | 23.21 (17.68) |
| Week 24 | 4 | 1 | 10.71 ( NA) | 3 | 3 | 10.71 ( 6.19) |
| Week 32 | | | | 3 | 2 | 0.00 ( 0.00) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 51.19 (44.65) | 14 | 12 | 30.06 (24.72) |
| Week 24 | 5 | 4 | 55.36 (24.48) | 14 | 12 | 17.56 (23.76) |
| Week 32 | | | | 13 | 10 | 22.50 (26.94) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 14.29 (14.29) | 9 | 7 | 22.45 (18.64) |
| Week 24 | 4 | 1 | 10.71 ( NA) | 8 | 7 | 4.59 ( 6.75) |
| Week 32 | | | | 8 | 6 | 7.74 (18.95) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 51.19 (44.65) | 9 | 7 | 35.71 (27.12) |
| Week 24 | 5 | 4 | 55.36 (24.48) | 9 | 8 | 26.34 (24.96) |
| Week 32 | | | | 8 | 6 | 29.76 (28.72) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.18 PROMIS Numeric Rating Scale v.1.0 Pain Intensity 1a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 6 | 2.50 ( 1.05) | 18 | 14 | 4.71 ( 2.27) |
| Week 4 | 9 | 5 | 2.00 ( 1.00) | 18 | 14 | 3.14 ( 2.63) |
| Week 8 | 9 | 6 | 2.50 ( 1.22) | 18 | 15 | 2.87 ( 2.23) |
| Week 16 | 9 | 6 | 2.67 ( 2.16) | 18 | 16 | 2.94 ( 2.32) |
| Week 24 | 9 | 5 | 2.80 ( 1.48) | 17 | 15 | 2.80 ( 2.04) |
| Week 32 | | | | 16 | 13 | 2.46 ( 2.37) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 3.00 ( 1.00) | 4 | 2 | 5.00 ( 2.83) |
| Week 4 | 4 | 2 | 1.50 ( 0.71) | 4 | 1 | 6.00 ( NA) |
| Week 8 | 4 | 3 | 2.33 ( 1.15) | 4 | 3 | 3.00 ( 1.00) |
| Week 16 | 4 | 3 | 3.33 ( 3.06) | 4 | 4 | 2.25 ( 1.50) |
| Week 24 | 4 | 1 | 5.00 ( NA) | 3 | 3 | 1.67 ( 1.53) |
| Week 32 | | | | 3 | 2 | 1.50 ( 2.12) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 2.00 ( 1.00) | 14 | 12 | 4.67 ( 2.31) |
| Week 4 | 5 | 3 | 2.33 ( 1.15) | 14 | 13 | 2.92 ( 2.60) |
| Week 8 | 5 | 3 | 2.67 ( 1.53) | 14 | 12 | 2.83 ( 2.48) |
| Week 16 | 5 | 3 | 2.00 ( 1.00) | 14 | 12 | 3.17 ( 2.55) |
| Week 24 | 5 | 4 | 2.25 ( 0.96) | 14 | 12 | 3.08 ( 2.11) |
| Week 32 | | | | 13 | 11 | 2.64 ( 2.46) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

PROMIS Numeric Rating Scale v.1.0 Pain Intensity 1a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 3.00 ( 1.00) | 9 | 7 | 4.71 ( 2.69) |
| Week 4 | 4 | 2 | 1.50 ( 0.71) | 9 | 5 | 4.20 ( 3.49) |
| Week 8 | 4 | 3 | 2.33 ( 1.15) | 9 | 6 | 2.50 ( 1.52) |
| Week 16 | 4 | 3 | 3.33 ( 3.06) | 9 | 9 | 2.00 ( 1.41) |
| Week 24 | 4 | 1 | 5.00 ( NA) | 8 | 7 | 2.00 ( 1.53) |
| Week 32 | | | | 8 | 6 | 1.83 ( 1.72) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 2.00 ( 1.00) | 9 | 7 | 4.71 ( 1.98) |
| Week 4 | 5 | 3 | 2.33 ( 1.15) | 9 | 9 | 2.56 ( 2.01) |
| Week 8 | 5 | 3 | 2.67 ( 1.53) | 9 | 9 | 3.11 ( 2.67) |
| Week 16 | 5 | 3 | 2.00 ( 1.00) | 9 | 7 | 4.14 ( 2.79) |
| Week 24 | 5 | 4 | 2.25 ( 0.96) | 9 | 8 | 3.50 ( 2.27) |
| Week 32 | | | | 8 | 7 | 3.00 ( 2.83) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.19 PROMIS Short Form v2.0 Upper Extremity 7a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 3 | 54.55 ( 6.31) | 18 | 8 | 44.41 (10.87) |
| Week 4 | 9 | 2 | 48.67 ( 1.99) | 18 | 6 | 44.47 (10.81) |
| Week 8 | 9 | 3 | 46.97 ( 2.89) | 18 | 7 | 43.73 ( 7.67) |
| Week 16 | 9 | 4 | 50.11 ( 6.02) | 18 | 9 | 42.92 ( 7.65) |
| Week 24 | 9 | 2 | 46.53 ( 0.09) | 17 | 7 | 47.00 ( 8.90) |
| Week 32 | | | | 16 | 5 | 46.58 ( 7.91) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 3 | 54.55 ( 6.31) | 4 | 2 | 44.19 ( 2.62) |
| Week 4 | 4 | 2 | 48.67 ( 1.99) | 4 | 1 | 38.18 ( NA) |
| Week 8 | 4 | 3 | 46.97 ( 2.89) | 4 | 3 | 40.54 ( 3.02) |
| Week 16 | 4 | 3 | 49.79 ( 7.33) | 4 | 3 | 39.49 ( 5.63) |
| Week 24 | 4 | 1 | 46.47 ( NA) | 3 | 2 | 42.85 ( 2.54) |
| Week 32 | | | | 3 | 1 | 41.79 ( NA) |
| >= 18 years | | | | | | |
| Baseline | | | | 14 | 6 | 44.48 (12.81) |
| Week 4 | | | | 14 | 5 | 45.73 (11.59) |
| Week 8 | | | | 14 | 4 | 46.12 ( 9.68) |
| Week 16 | 5 | 1 | 51.07 ( NA) | 14 | 6 | 44.63 ( 8.38) |
| Week 24 | 5 | 1 | 46.60 ( NA) | 14 | 5 | 48.66 (10.26) |
| Week 32 | | | | 13 | 4 | 47.78 ( 8.59) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

PROMIS Short Form v2.0 Upper Extremity 7a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 3 | 54.55 ( 6.31) | 9 | 7 | 42.44 (10.09) |
| Week 4 | 4 | 2 | 48.67 ( 1.99) | 9 | 5 | 41.73 ( 9.47) |
| Week 8 | 4 | 3 | 46.97 ( 2.89) | 9 | 6 | 42.73 ( 7.89) |
| Week 16 | 4 | 3 | 49.79 ( 7.33) | 9 | 8 | 43.01 ( 8.17) |
| Week 24 | 4 | 1 | 46.47 ( NA) | 8 | 6 | 45.13 ( 8.12) |
| Week 32 | | | | 8 | 5 | 46.58 ( 7.91) |
| OECD country | | | | | | |
| Baseline | | | | 9 | 1 | 58.19 ( NA) |
| Week 4 | | | | 9 | 1 | 58.19 ( NA) |
| Week 8 | | | | 9 | 1 | 49.70 ( NA) |
| Week 16 | 5 | 1 | 51.07 ( NA) | 9 | 1 | 42.17 ( NA) |
| Week 24 | 5 | 1 | 46.60 ( NA) | 9 | 1 | 58.19 ( NA) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.20 SF-36v2 general health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 45.31 (12.20) | 18 | 14 | 42.18 ( 9.43) |
| Week 4 | 9 | 5 | 39.97 (11.02) | 18 | 15 | 40.89 ( 7.95) |
| Week 8 | 9 | 6 | 39.79 (10.99) | 18 | 16 | 43.74 ( 9.08) |
| Week 16 | 9 | 7 | 41.71 (13.03) | 18 | 17 | 44.74 ( 9.78) |
| Week 24 | 9 | 5 | 38.73 (11.92) | 17 | 15 | 45.48 ( 9.44) |
| Week 32 | | | | 16 | 14 | 46.87 ( 9.45) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 52.35 ( 7.90) | 4 | 2 | 38.44 ( 0.67) |
| Week 4 | 4 | 2 | 47.95 ( 2.69) | 4 | 1 | 41.30 ( NA) |
| Week 8 | 4 | 3 | 46.85 ( 6.86) | 4 | 3 | 46.85 ( 5.49) |
| Week 16 | 4 | 3 | 50.81 (12.58) | 4 | 4 | 53.90 ( 5.62) |
| Week 24 | 4 | 1 | 46.05 ( NA) | 3 | 3 | 48.43 ( 4.12) |
| Week 32 | | | | 3 | 3 | 53.66 (11.18) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 35.91 (11.01) | 14 | 12 | 42.80 (10.10) |
| Week 4 | 5 | 3 | 34.64 (11.53) | 14 | 14 | 40.86 ( 8.25) |
| Week 8 | 5 | 3 | 32.74 (10.29) | 14 | 13 | 43.02 ( 9.75) |
| Week 16 | 5 | 4 | 34.88 ( 9.43) | 14 | 13 | 41.92 ( 9.11) |
| Week 24 | 5 | 4 | 36.90 (12.93) | 14 | 12 | 44.75 (10.36) |
| Week 32 | | | | 13 | 11 | 45.01 ( 8.57) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 general health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 52.35 ( 7.90) | 9 | 7 | 45.31 ( 8.98) |
| Week 4 | 4 | 2 | 47.95 ( 2.69) | 9 | 6 | 45.10 ( 8.64) |
| Week 8 | 4 | 3 | 46.85 ( 6.86) | 9 | 7 | 48.30 ( 9.27) |
| Week 16 | 4 | 3 | 50.81 (12.58) | 9 | 9 | 50.22 ( 9.37) |
| Week 24 | 4 | 1 | 46.05 ( NA) | 8 | 7 | 49.65 ( 9.74) |
| Week 32 | | | | 8 | 7 | 52.23 ( 9.57) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 35.91 (11.01) | 9 | 7 | 39.06 ( 9.44) |
| Week 4 | 5 | 3 | 34.64 (11.53) | 9 | 9 | 38.08 ( 6.47) |
| Week 8 | 5 | 3 | 32.74 (10.29) | 9 | 9 | 40.19 ( 7.61) |
| Week 16 | 5 | 4 | 34.88 ( 9.43) | 9 | 8 | 38.57 ( 6.01) |
| Week 24 | 5 | 4 | 36.90 (12.93) | 9 | 8 | 41.83 ( 8.01) |
| Week 32 | | | | 8 | 7 | 41.50 ( 5.88) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.21 SF-36v2 mental health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 50.12 (14.06) | 18 | 14 | 48.07 ( 9.32) |
| Week 4 | 9 | 5 | 46.68 (15.98) | 18 | 15 | 48.43 (11.64) |
| Week 8 | 9 | 6 | 50.43 (13.59) | 18 | 16 | 48.74 (11.11) |
| Week 16 | 9 | 7 | 42.65 (14.28) | 18 | 17 | 48.71 (10.87) |
| Week 24 | 9 | 5 | 44.59 (15.21) | 17 | 15 | 48.25 (11.27) |
| Week 32 | | | | 16 | 14 | 51.06 (11.54) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 52.18 (11.00) | 4 | 2 | 53.48 ( 3.70) |
| Week 4 | 4 | 2 | 50.87 ( 7.40) | 4 | 1 | 37.79 ( NA) |
| Week 8 | 4 | 3 | 52.61 (10.58) | 4 | 3 | 52.61 (10.57) |
| Week 16 | 4 | 3 | 48.25 ( 5.23) | 4 | 4 | 52.17 ( 6.92) |
| Week 24 | 4 | 1 | 48.25 ( NA) | 3 | 3 | 51.74 ( 9.19) |
| Week 32 | | | | 3 | 3 | 53.49 ( 9.43) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 47.38 (19.81) | 14 | 12 | 47.16 ( 9.75) |
| Week 4 | 5 | 3 | 43.89 (21.30) | 14 | 14 | 49.19 (11.68) |
| Week 8 | 5 | 3 | 48.25 (18.31) | 14 | 13 | 47.85 (11.44) |
| Week 16 | 5 | 4 | 38.44 (18.30) | 14 | 13 | 47.65 (11.85) |
| Week 24 | 5 | 4 | 43.67 (17.40) | 14 | 12 | 47.38 (11.93) |
| Week 32 | | | | 13 | 11 | 50.39 (12.37) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 mental health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 52.18 (11.00) | 9 | 7 | 50.50 ( 9.12) |
| Week 4 | 4 | 2 | 50.87 ( 7.40) | 9 | 6 | 53.92 ( 9.56) |
| Week 8 | 4 | 3 | 52.61 (10.58) | 9 | 7 | 56.10 ( 7.40) |
| Week 16 | 4 | 3 | 48.25 ( 5.23) | 9 | 9 | 54.07 ( 7.26) |
| Week 24 | 4 | 1 | 48.25 ( NA) | 8 | 7 | 53.86 ( 7.46) |
| Week 32 | | | | 8 | 7 | 57.97 ( 7.04) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 47.38 (19.81) | 9 | 7 | 45.64 ( 9.55) |
| Week 4 | 5 | 3 | 43.89 (21.30) | 9 | 9 | 44.76 (11.92) |
| Week 8 | 5 | 3 | 48.25 (18.31) | 9 | 9 | 43.02 (10.30) |
| Week 16 | 5 | 4 | 38.44 (18.30) | 9 | 8 | 42.69 (11.48) |
| Week 24 | 5 | 4 | 43.67 (17.40) | 9 | 8 | 43.35 (12.14) |
| Week 32 | | | | 8 | 7 | 44.14 (11.29) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.22 SF-36v2 role emotional by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 49.21 (11.37) | 18 | 14 | 44.48 ( 8.70) |
| Week 4 | 9 | 5 | 47.12 (18.36) | 18 | 15 | 47.35 ( 8.62) |
| Week 8 | 9 | 6 | 46.89 (15.83) | 18 | 16 | 49.42 ( 7.99) |
| Week 16 | 9 | 7 | 40.25 (14.62) | 18 | 17 | 47.77 ( 9.13) |
| Week 24 | 9 | 5 | 41.55 (16.03) | 17 | 15 | 52.22 ( 6.16) |
| Week 32 | | | | 16 | 14 | 47.71 ( 9.82) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 51.82 ( 4.38) | 4 | 2 | 42.24 ( 4.92) |
| Week 4 | 4 | 2 | 56.17 ( 0.00) | 4 | 1 | 38.76 ( NA) |
| Week 8 | 4 | 3 | 50.37 (10.05) | 4 | 3 | 50.36 ( 5.32) |
| Week 16 | 4 | 3 | 46.88 ( 8.76) | 4 | 4 | 47.47 ( 8.29) |
| Week 24 | 4 | 1 | 42.24 ( NA) | 3 | 3 | 48.04 ( 8.76) |
| Week 32 | | | | 3 | 3 | 42.24 (12.06) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 45.72 (18.09) | 14 | 12 | 44.85 ( 9.29) |
| Week 4 | 5 | 3 | 41.08 (23.18) | 14 | 14 | 47.96 ( 8.60) |
| Week 8 | 5 | 3 | 43.40 (22.11) | 14 | 13 | 49.21 ( 8.65) |
| Week 16 | 5 | 4 | 35.28 (17.29) | 14 | 13 | 47.87 ( 9.70) |
| Week 24 | 5 | 4 | 41.37 (18.51) | 14 | 12 | 53.27 ( 5.32) |
| Week 32 | | | | 13 | 11 | 49.21 ( 9.21) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 role emotional by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 51.82 ( 4.38) | 9 | 7 | 44.73 ( 8.93) |
| Week 4 | 4 | 2 | 56.17 ( 0.00) | 9 | 6 | 49.21 ( 9.60) |
| Week 8 | 4 | 3 | 50.37 (10.05) | 9 | 7 | 51.19 ( 6.92) |
| Week 16 | 4 | 3 | 46.88 ( 8.76) | 9 | 9 | 50.37 ( 7.98) |
| Week 24 | 4 | 1 | 42.24 ( NA) | 8 | 7 | 52.69 ( 6.67) |
| Week 32 | | | | 8 | 7 | 47.22 (11.17) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 45.72 (18.09) | 9 | 7 | 44.23 ( 9.18) |
| Week 4 | 5 | 3 | 41.08 (23.18) | 9 | 9 | 46.11 ( 8.25) |
| Week 8 | 5 | 3 | 43.40 (22.11) | 9 | 9 | 48.04 ( 8.88) |
| Week 16 | 5 | 4 | 35.28 (17.29) | 9 | 8 | 44.85 ( 9.98) |
| Week 24 | 5 | 4 | 41.37 (18.51) | 9 | 8 | 51.82 ( 6.10) |
| Week 32 | | | | 8 | 7 | 48.21 ( 9.15) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.23 SF-36v2 role physical by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 42.08 (11.79) | 18 | 14 | 41.28 ( 8.14) |
| Week 4 | 9 | 5 | 38.74 (11.27) | 18 | 15 | 46.68 ( 6.72) |
| Week 8 | 9 | 6 | 41.44 (11.36) | 18 | 16 | 48.88 ( 7.85) |
| Week 16 | 9 | 7 | 37.27 (10.40) | 18 | 17 | 48.04 ( 8.31) |
| Week 24 | 9 | 5 | 36.95 ( 8.98) | 17 | 15 | 49.67 ( 7.81) |
| Week 32 | | | | 16 | 14 | 50.42 ( 5.71) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 49.30 ( 5.65) | 4 | 2 | 30.21 ( 6.35) |
| Week 4 | 4 | 2 | 48.17 ( 0.00) | 4 | 1 | 41.44 ( NA) |
| Week 8 | 4 | 3 | 48.92 ( 5.18) | 4 | 3 | 43.68 ( 5.94) |
| Week 16 | 4 | 3 | 45.18 ( 3.43) | 4 | 4 | 40.88 ( 9.59) |
| Week 24 | 4 | 1 | 41.44 ( NA) | 3 | 3 | 47.43 ( 9.08) |
| Week 32 | | | | 3 | 3 | 51.17 ( 5.65) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 32.46 (11.23) | 14 | 12 | 43.12 ( 6.98) |
| Week 4 | 5 | 3 | 32.46 (10.29) | 14 | 14 | 47.05 ( 6.81) |
| Week 8 | 5 | 3 | 33.95 (11.30) | 14 | 13 | 50.07 ( 7.93) |
| Week 16 | 5 | 4 | 31.33 ( 9.96) | 14 | 13 | 50.25 ( 6.83) |
| Week 24 | 5 | 4 | 35.82 ( 9.96) | 14 | 12 | 50.23 ( 7.81) |
| Week 32 | | | | 13 | 11 | 50.21 ( 5.98) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 role physical by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 49.30 ( 5.65) | 9 | 7 | 40.15 ( 9.06) |
| Week 4 | 4 | 2 | 48.17 ( 0.00) | 9 | 6 | 44.06 ( 6.87) |
| Week 8 | 4 | 3 | 48.92 ( 5.18) | 9 | 7 | 47.53 ( 7.86) |
| Week 16 | 4 | 3 | 45.18 ( 3.43) | 9 | 9 | 47.92 ( 9.29) |
| Week 24 | 4 | 1 | 41.44 ( NA) | 8 | 7 | 50.10 ( 8.45) |
| Week 32 | | | | 8 | 7 | 51.70 ( 4.65) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 32.46 (11.23) | 9 | 7 | 42.40 ( 7.65) |
| Week 4 | 5 | 3 | 32.46 (10.29) | 9 | 9 | 48.42 ( 6.40) |
| Week 8 | 5 | 3 | 33.95 (11.30) | 9 | 9 | 49.92 ( 8.16) |
| Week 16 | 5 | 4 | 31.33 ( 9.96) | 9 | 8 | 48.17 ( 7.69) |
| Week 24 | 5 | 4 | 35.82 ( 9.96) | 9 | 8 | 49.30 ( 7.78) |
| Week 32 | | | | 8 | 7 | 49.14 ( 6.72) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.24 SF-36v2 social function by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 47.31 (13.26) | 18 | 14 | 43.37 (10.06) |
| Week 4 | 9 | 5 | 48.32 (14.79) | 18 | 15 | 45.98 ( 9.37) |
| Week 8 | 9 | 6 | 43.14 (13.23) | 18 | 16 | 50.45 ( 6.82) |
| Week 16 | 9 | 7 | 43.02 (10.20) | 18 | 17 | 49.38 ( 7.32) |
| Week 24 | 9 | 5 | 43.30 (15.61) | 17 | 15 | 50.66 ( 8.40) |
| Week 32 | | | | 16 | 14 | 49.82 ( 8.96) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 48.57 ( 8.56) | 4 | 2 | 39.79 (10.63) |
| Week 4 | 4 | 2 | 57.34 ( 0.00) | 4 | 1 | 32.27 ( NA) |
| Week 8 | 4 | 3 | 42.30 ( 8.68) | 4 | 3 | 50.66 ( 7.66) |
| Week 16 | 4 | 3 | 45.64 ( 7.66) | 4 | 4 | 48.56 ( 6.31) |
| Week 24 | 4 | 1 | 47.31 ( NA) | 3 | 3 | 50.66 ( 7.66) |
| Week 32 | | | | 3 | 3 | 45.64 (10.43) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 45.64 (20.26) | 14 | 12 | 43.97 (10.33) |
| Week 4 | 5 | 3 | 42.30 (17.37) | 14 | 14 | 46.95 ( 8.90) |
| Week 8 | 5 | 3 | 43.97 (18.98) | 14 | 13 | 50.40 ( 6.95) |
| Week 16 | 5 | 4 | 41.05 (12.53) | 14 | 13 | 49.63 ( 7.82) |
| Week 24 | 5 | 4 | 42.30 (17.84) | 14 | 12 | 50.66 ( 8.90) |
| Week 32 | | | | 13 | 11 | 50.96 ( 8.71) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 social function by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 48.57 ( 8.56) | 9 | 7 | 40.87 (11.47) |
| Week 4 | 4 | 2 | 57.34 ( 0.00) | 9 | 6 | 44.81 ( 9.38) |
| Week 8 | 4 | 3 | 42.30 ( 8.68) | 9 | 7 | 51.61 ( 5.36) |
| Week 16 | 4 | 3 | 45.64 ( 7.66) | 9 | 9 | 50.10 ( 6.20) |
| Week 24 | 4 | 1 | 47.31 ( NA) | 8 | 7 | 53.04 ( 5.36) |
| Week 32 | | | | 8 | 7 | 50.89 ( 8.54) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 45.64 (20.26) | 9 | 7 | 45.88 ( 8.54) |
| Week 4 | 5 | 3 | 42.30 (17.37) | 9 | 9 | 46.76 ( 9.85) |
| Week 8 | 5 | 3 | 43.97 (18.98) | 9 | 9 | 49.54 ( 7.97) |
| Week 16 | 5 | 4 | 41.05 (12.53) | 9 | 8 | 48.57 ( 8.79) |
| Week 24 | 5 | 4 | 42.30 (17.84) | 9 | 8 | 48.57 (10.29) |
| Week 32 | | | | 8 | 7 | 48.75 ( 9.91) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.25 SF-36v2 vitality by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 53.02 (12.88) | 18 | 14 | 47.72 ( 7.78) |
| Week 4 | 9 | 5 | 52.00 (14.77) | 18 | 15 | 49.83 (10.85) |
| Week 8 | 9 | 6 | 53.09 (12.66) | 18 | 16 | 50.74 (10.89) |
| Week 16 | 9 | 7 | 44.96 (11.74) | 18 | 17 | 51.03 (11.02) |
| Week 24 | 9 | 5 | 47.25 (14.61) | 17 | 15 | 50.62 (10.33) |
| Week 32 | | | | 16 | 14 | 53.66 (11.80) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 54.83 ( 3.74) | 4 | 2 | 52.60 ( 8.40) |
| Week 4 | 4 | 2 | 58.54 ( 0.00) | 4 | 1 | 43.69 ( NA) |
| Week 8 | 4 | 3 | 54.58 ( 9.55) | 4 | 3 | 52.60 (10.71) |
| Week 16 | 4 | 3 | 52.60 ( 7.86) | 4 | 4 | 60.77 ( 5.07) |
| Week 24 | 4 | 1 | 49.63 ( NA) | 3 | 3 | 51.61 ( 8.57) |
| Week 32 | | | | 3 | 3 | 60.52 ( 9.07) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 50.62 (21.49) | 14 | 12 | 46.91 ( 7.75) |
| Week 4 | 5 | 3 | 47.65 (19.10) | 14 | 14 | 50.26 (11.13) |
| Week 8 | 5 | 3 | 51.61 (17.41) | 14 | 13 | 50.31 (11.32) |
| Week 16 | 5 | 4 | 39.23 (11.51) | 14 | 13 | 48.03 (10.69) |
| Week 24 | 5 | 4 | 46.66 (16.81) | 14 | 12 | 50.37 (11.05) |
| Week 32 | | | | 13 | 11 | 51.79 (12.11) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 vitality by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 54.83 ( 3.74) | 9 | 7 | 50.05 ( 9.62) |
| Week 4 | 4 | 2 | 58.54 ( 0.00) | 9 | 6 | 56.07 (10.86) |
| Week 8 | 4 | 3 | 54.58 ( 9.55) | 9 | 7 | 58.54 ( 9.39) |
| Week 16 | 4 | 3 | 52.60 ( 7.86) | 9 | 9 | 58.54 ( 7.12) |
| Week 24 | 4 | 1 | 49.63 ( NA) | 8 | 7 | 55.57 ( 7.67) |
| Week 32 | | | | 8 | 7 | 61.51 ( 7.86) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 50.62 (21.49) | 9 | 7 | 45.39 ( 5.11) |
| Week 4 | 5 | 3 | 47.65 (19.10) | 9 | 9 | 45.67 ( 9.16) |
| Week 8 | 5 | 3 | 51.61 (17.41) | 9 | 9 | 44.68 ( 7.86) |
| Week 16 | 5 | 4 | 39.23 (11.51) | 9 | 8 | 42.57 ( 8.09) |
| Week 24 | 5 | 4 | 46.66 (16.81) | 9 | 8 | 46.29 (10.82) |
| Week 32 | | | | 8 | 7 | 45.81 ( 9.81) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.26 SF-36v2 mental component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 53.27 (15.31) | 18 | 14 | 47.77 ( 9.75) |
| Week 4 | 9 | 5 | 51.21 (18.97) | 18 | 15 | 49.40 (11.27) |
| Week 8 | 9 | 6 | 50.82 (16.32) | 18 | 16 | 50.95 (10.01) |
| Week 16 | 9 | 7 | 44.40 (15.46) | 18 | 17 | 50.45 (11.16) |
| Week 24 | 9 | 5 | 46.50 (18.86) | 17 | 15 | 51.63 ( 9.83) |
| Week 32 | | | | 16 | 14 | 51.00 (11.71) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 53.31 ( 8.15) | 4 | 2 | 50.85 ( 1.94) |
| Week 4 | 4 | 2 | 56.80 ( 4.14) | 4 | 1 | 35.80 ( NA) |
| Week 8 | 4 | 3 | 49.37 ( 8.43) | 4 | 3 | 53.63 ( 9.44) |
| Week 16 | 4 | 3 | 48.58 ( 7.12) | 4 | 4 | 54.25 ( 6.75) |
| Week 24 | 4 | 1 | 45.94 ( NA) | 3 | 3 | 50.45 ( 9.22) |
| Week 32 | | | | 3 | 3 | 48.84 (12.25) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 53.22 (24.56) | 14 | 12 | 47.26 (10.48) |
| Week 4 | 5 | 3 | 47.49 (25.67) | 14 | 14 | 50.37 (11.03) |
| Week 8 | 5 | 3 | 52.27 (24.25) | 14 | 13 | 50.33 (10.40) |
| Week 16 | 5 | 4 | 41.27 (20.35) | 14 | 13 | 49.28 (12.18) |
| Week 24 | 5 | 4 | 46.64 (21.77) | 14 | 12 | 51.92 (10.35) |
| Week 32 | | | | 13 | 11 | 51.59 (12.10) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 mental component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 53.31 ( 8.15) | 9 | 7 | 49.20 ( 9.49) |
| Week 4 | 4 | 2 | 56.80 ( 4.14) | 9 | 6 | 54.45 ( 9.36) |
| Week 8 | 4 | 3 | 49.37 ( 8.43) | 9 | 7 | 57.47 ( 8.10) |
| Week 16 | 4 | 3 | 48.58 ( 7.12) | 9 | 9 | 55.95 ( 6.98) |
| Week 24 | 4 | 1 | 45.94 ( NA) | 8 | 7 | 55.56 ( 7.61) |
| Week 32 | | | | 8 | 7 | 55.84 ( 9.97) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 53.22 (24.56) | 9 | 7 | 46.35 (10.53) |
| Week 4 | 5 | 3 | 47.49 (25.67) | 9 | 9 | 46.03 (11.65) |
| Week 8 | 5 | 3 | 52.27 (24.25) | 9 | 9 | 45.88 ( 8.52) |
| Week 16 | 5 | 4 | 41.27 (20.35) | 9 | 8 | 44.26 (12.09) |
| Week 24 | 5 | 4 | 46.64 (21.77) | 9 | 8 | 48.19 (10.72) |
| Week 32 | | | | 8 | 7 | 46.15 (11.95) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.27 SF-36v2 physical component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 40.68 ( 9.89) | 18 | 14 | 41.19 ( 7.31) |
| Week 4 | 9 | 5 | 39.87 ( 9.08) | 18 | 15 | 43.75 ( 8.33) |
| Week 8 | 9 | 6 | 40.71 (11.35) | 18 | 16 | 45.99 ( 8.59) |
| Week 16 | 9 | 7 | 39.00 ( 8.17) | 18 | 17 | 45.50 ( 8.86) |
| Week 24 | 9 | 5 | 37.65 ( 6.77) | 17 | 15 | 46.40 ( 8.61) |
| Week 32 | | | | 16 | 14 | 48.30 ( 7.66) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 47.83 ( 3.91) | 4 | 2 | 35.98 ( 7.02) |
| Week 4 | 4 | 2 | 49.14 ( 2.45) | 4 | 1 | 46.09 ( NA) |
| Week 8 | 4 | 3 | 50.61 ( 2.41) | 4 | 3 | 45.38 ( 2.43) |
| Week 16 | 4 | 3 | 47.17 ( 4.06) | 4 | 4 | 46.00 (10.60) |
| Week 24 | 4 | 1 | 46.54 ( NA) | 3 | 3 | 49.79 ( 4.84) |
| Week 32 | | | | 3 | 3 | 53.71 ( 6.48) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 31.15 ( 5.67) | 14 | 12 | 42.06 ( 7.27) |
| Week 4 | 5 | 3 | 33.68 ( 4.30) | 14 | 14 | 43.58 ( 8.62) |
| Week 8 | 5 | 3 | 30.82 ( 4.77) | 14 | 13 | 46.13 ( 9.54) |
| Week 16 | 5 | 4 | 32.88 ( 2.39) | 14 | 13 | 45.35 ( 8.74) |
| Week 24 | 5 | 4 | 35.42 ( 5.30) | 14 | 12 | 45.55 ( 9.28) |
| Week 32 | | | | 13 | 11 | 46.82 ( 7.53) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 physical component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 47.83 ( 3.91) | 9 | 7 | 40.79 ( 7.56) |
| Week 4 | 4 | 2 | 49.14 ( 2.45) | 9 | 6 | 42.33 ( 8.36) |
| Week 8 | 4 | 3 | 50.61 ( 2.41) | 9 | 7 | 45.39 ( 7.37) |
| Week 16 | 4 | 3 | 47.17 ( 4.06) | 9 | 9 | 45.93 ( 8.42) |
| Week 24 | 4 | 1 | 46.54 ( NA) | 8 | 7 | 48.44 ( 9.15) |
| Week 32 | | | | 8 | 7 | 49.37 ( 8.27) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 31.15 ( 5.67) | 9 | 7 | 41.60 ( 7.63) |
| Week 4 | 5 | 3 | 33.68 ( 4.30) | 9 | 9 | 44.69 ( 8.67) |
| Week 8 | 5 | 3 | 30.82 ( 4.77) | 9 | 9 | 46.45 ( 9.85) |
| Week 16 | 5 | 4 | 32.88 ( 2.39) | 9 | 8 | 45.01 ( 9.88) |
| Week 24 | 5 | 4 | 35.42 ( 5.30) | 9 | 8 | 44.61 ( 8.28) |
| Week 32 | | | | 8 | 7 | 47.23 ( 7.48) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.28 SF-36v2 bodily pain by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 43.11 ( 6.75) | 18 | 14 | 41.61 ( 8.08) |
| Week 4 | 9 | 5 | 47.08 ( 8.03) | 18 | 15 | 48.40 (10.62) |
| Week 8 | 9 | 6 | 43.18 ( 8.26) | 18 | 16 | 49.27 (10.23) |
| Week 16 | 9 | 7 | 40.74 ( 4.06) | 18 | 17 | 48.50 ( 9.35) |
| Week 24 | 9 | 5 | 40.06 ( 6.63) | 17 | 15 | 47.59 (10.57) |
| Week 32 | | | | 16 | 14 | 48.90 ( 9.76) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 45.67 ( 7.44) | 4 | 2 | 40.62 ( 2.85) |
| Week 4 | 4 | 2 | 53.53 ( 2.86) | 4 | 1 | 46.68 ( NA) |
| Week 8 | 4 | 3 | 49.50 ( 6.74) | 4 | 3 | 50.31 (10.37) |
| Week 16 | 4 | 3 | 42.51 ( 4.04) | 4 | 4 | 49.30 ( 8.77) |
| Week 24 | 4 | 1 | 38.21 ( NA) | 3 | 3 | 51.79 ( 8.85) |
| Week 32 | | | | 3 | 3 | 51.79 ( 8.85) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 39.69 ( 4.77) | 14 | 12 | 41.77 ( 8.73) |
| Week 4 | 5 | 3 | 42.78 ( 7.46) | 14 | 14 | 48.52 (11.01) |
| Week 8 | 5 | 3 | 36.87 ( 2.33) | 14 | 13 | 49.04 (10.61) |
| Week 16 | 5 | 4 | 39.42 ( 4.07) | 14 | 13 | 48.26 ( 9.85) |
| Week 24 | 5 | 4 | 40.53 ( 7.56) | 14 | 12 | 46.54 (11.04) |
| Week 32 | | | | 13 | 11 | 48.11 (10.25) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 bodily pain by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 45.67 ( 7.44) | 9 | 7 | 41.78 ( 9.22) |
| Week 4 | 4 | 2 | 53.53 ( 2.86) | 9 | 6 | 49.50 (11.85) |
| Week 8 | 4 | 3 | 49.50 ( 6.74) | 9 | 7 | 51.98 ( 9.55) |
| Week 16 | 4 | 3 | 42.51 ( 4.04) | 9 | 9 | 51.11 ( 7.59) |
| Week 24 | 4 | 1 | 38.21 ( NA) | 8 | 7 | 53.30 ( 9.55) |
| Week 32 | | | | 8 | 7 | 49.90 ( 9.23) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 39.69 ( 4.77) | 9 | 7 | 41.43 ( 7.51) |
| Week 4 | 5 | 3 | 42.78 ( 7.46) | 9 | 9 | 47.66 (10.40) |
| Week 8 | 5 | 3 | 36.87 ( 2.33) | 9 | 9 | 47.17 (10.79) |
| Week 16 | 5 | 4 | 39.42 ( 4.07) | 9 | 8 | 45.57 (10.74) |
| Week 24 | 5 | 4 | 40.53 ( 7.56) | 9 | 8 | 42.59 ( 9.16) |
| Week 32 | | | | 8 | 7 | 47.89 (10.91) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

## 1.3.2.29 SF-36v2 physical functioning by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| All subjects (Total) | | | | | | |
| total | | | | | | |
| Baseline | 9 | 7 | 41.96 (11.29) | 18 | 14 | 43.87 ( 7.87) |
| Week 4 | 9 | 5 | 40.32 (11.87) | 18 | 15 | 42.49 ( 7.92) |
| Week 8 | 9 | 6 | 44.79 (13.73) | 18 | 16 | 44.74 ( 7.96) |
| Week 16 | 9 | 7 | 38.40 (11.00) | 18 | 17 | 43.47 ( 8.87) |
| Week 24 | 9 | 5 | 39.17 (13.57) | 17 | 15 | 46.31 ( 8.15) |
| Week 32 | | | | 16 | 14 | 47.56 ( 7.36) |
| Age | | | | | | |
| < 18 years | | | | | | |
| Baseline | 4 | 4 | 48.93 ( 3.66) | 4 | 2 | 45.10 ( 9.48) |
| Week 4 | 4 | 2 | 50.84 ( 1.36) | 4 | 1 | 44.15 ( NA) |
| Week 8 | 4 | 3 | 55.63 ( 0.00) | 4 | 3 | 47.33 ( 5.84) |
| Week 16 | 4 | 3 | 49.89 ( 3.31) | 4 | 4 | 45.58 (12.24) |
| Week 24 | 4 | 1 | 55.63 ( NA) | 3 | 3 | 51.16 ( 4.42) |
| Week 32 | | | | 3 | 3 | 51.80 ( 6.90) |
| >= 18 years | | | | | | |
| Baseline | 5 | 3 | 32.66 (11.64) | 14 | 12 | 43.66 ( 8.04) |
| Week 4 | 5 | 3 | 33.30 ( 9.82) | 14 | 14 | 42.37 ( 8.20) |
| Week 8 | 5 | 3 | 33.94 (10.88) | 14 | 13 | 44.14 ( 8.45) |
| Week 16 | 5 | 4 | 29.79 ( 1.91) | 14 | 13 | 42.82 ( 8.10) |
| Week 24 | 5 | 4 | 35.05 (11.52) | 14 | 12 | 45.10 ( 8.54) |
| Week 32 | | | | 13 | 11 | 46.40 ( 7.35) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

SF-36v2 physical functioning by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | |
|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | N | n | Mean (SD) |
| Region | | | | | | |
| Non-OECD country | | | | | | |
| Baseline | 4 | 4 | 48.93 ( 3.66) | 9 | 7 | 43.05 ( 8.76) |
| Week 4 | 4 | 2 | 50.84 ( 1.36) | 9 | 6 | 41.27 ( 7.14) |
| Week 8 | 4 | 3 | 55.63 ( 0.00) | 9 | 7 | 43.87 ( 6.85) |
| Week 16 | 4 | 3 | 49.89 ( 3.31) | 9 | 9 | 42.87 ( 9.13) |
| Week 24 | 4 | 1 | 55.63 ( NA) | 8 | 7 | 46.88 ( 7.23) |
| Week 32 | | | | 8 | 7 | 47.97 ( 6.99) |
| OECD country | | | | | | |
| Baseline | 5 | 3 | 32.66 (11.64) | 9 | 7 | 44.69 ( 7.47) |
| Week 4 | 5 | 3 | 33.30 ( 9.82) | 9 | 9 | 43.29 ( 8.72) |
| Week 8 | 5 | 3 | 33.94 (10.88) | 9 | 9 | 45.42 ( 9.08) |
| Week 16 | 5 | 4 | 29.79 ( 1.91) | 9 | 8 | 44.14 ( 9.15) |
| Week 24 | 5 | 4 | 35.05 (11.52) | 9 | 8 | 45.82 ( 9.35) |
| Week 32 | | | | 8 | 7 | 47.15 ( 8.26) |

HA: Haemophilia A, OTexBR: On-treatment without data before restart, PPX: Prophylaxis, NA: not applicable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. Cut off date for data is 12th July 2022.

# Table of contents

**Page**

## Statistical documentation

### 1.3.3.1 SF-36v2 (standard version) - bodily pain - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:03:48 - f-sf36mean.sas/f-sf36bpfasHA.png

### 1.3.3.2 SF-36v2 (standard version) - physical functioning - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:03:57 - f-sf36mean.sas/f-sf36physfuncfasHA.png

### 1.3.3.3 SF-36v2 (standard version) - role physical - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:02 - f-sf36mean.sas/f-sf36rolephysfasHA.png

### 1.3.3.4 SF-36v2 (standard version) - general health - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:07 - f-sf36mean.sas/f-sf36ghelathfasHA.png

### 1.3.3.5 SF-36v2 (standard version) - vitality - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:12 - f-sf36mean.sas/f-sf36vitalityfasHA.png

### 1.3.3.6 SF-36v2 (standard version) - social functioning - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:16 - f-sf36mean.sas/f-sf36socialfuncfasHA.png

### 1.3.3.7 SF-36v2 (standard version) - role emotional - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:21 - f-sf36mean.sas/f-sf36roleemofasHA.png

### 1.3.3.8 SF-36v2 (standard version) - mental health - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:25 - f-sf36mean.sas/f-sf36mentalhfasHA.png

### 1.3.3.9 SF-36v2 (standard version) - physical component score - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:30 - f-sf36mean.sas/f-sf36physcompfasHA.png

### 1.3.3.10 SF-36v2 (standard version) - mental component score - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:35 - f-sf36mean.sas/f-sf36hecompfasHA.png

### 1.3.3.11 PROMIS Short Form v2.0 – Upper Extremity 7a - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:40 - f-sf36mean.sas/f-prom_upperexfasHA.png

### 1.3.3.12 PROMIS Numeric Rating Scale v.1.0 – Pain Intensity 1a - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:43 - f-sf36mean.sas/f-prom_painfasHA.png

### 1.3.3.13 HAEM-A-QoL - Total score - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:47 - f-sf36mean.sas/f-HAQ_totfasHA.png

### 1.3.3.14 HAEM-A-QoL - Physical Health - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:53 - f-sf36mean.sas/f-HAQ_physfasHA.png

### 1.3.3.15 HAEM-A-QoL - Feeling - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:04:57 - f-sf36mean.sas/f-HAQ_feelfasHA.png

### 1.3.3.16 HAEM-A-QoL - view of yourself - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:02 - f-sf36mean.sas/f-HAQ_viewfasHA.png

### 1.3.3.17 HAEM-A-QoL - sport and leisure - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:06 - f-sf36mean.sas/f-HAQ_sportfasHA.png

### 1.3.3.18 HAEM-A-QoL - work and studies - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:10 - f-sf36mean.sas/f-HAQ_workfasHA.png

### 1.3.3.19 HAEM-A-QoL - dealing with haemophilia - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:14 - f-sf36mean.sas/f-HAQ_dealfasHA.png

### 1.3.3.20 HAEM-A-QoL - treatment - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:18 - f-sf36mean.sas/f-HAQ_treatfasHA.png

### 1.3.3.21 HAEM-A-QoL - future - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:22 - f-sf36mean.sas/f-HAQ_futurefasHA.png

### 1.3.3.22 HAEM-A-QoL - family planning - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:26 - f-sf36mean.sas/f-HAQ_famfasHA.png

### 1.3.3.23 HAEM-A-QoL - partnership and sexuality - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:32 - f-sf36mean.sas/f-HAQ_partfasHA.png

### 1.3.3.24 Hemo-TEM - Total score - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:36 - f-sf36mean.sas/f-HTEM_totalfasHA.png

### 1.3.3.25 Hemo-TEM - Ease of use - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:39 - f-sf36mean.sas/f-HTEM_easefasHA.png

### 1.3.3.26 Hemo-TEM - Physical impact - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:44 - f-sf36mean.sas/f-HTEM_impactfasHA.png

### 1.3.3.27 Hemo-TEM - Interference - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:48 - f-sf36mean.sas/f-HTEM_interfasHA.png

### 1.3.3.28 Hemo-TEM - Treatment burden - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:52 - f-sf36mean.sas/f-HTEM_burdenfasHA.png

### 1.3.3.29 Hemo-TEM - Emotional impact - mean plot - HA - OTexBR - full analysis set




HA: haemophilia A, OTexBR: On-treatment without data before restart.
PPX: Prophylaxis.
Week 0 is defined as the baseline value in this plot (Baseline is defined as the latest measurement before first dose with new regimen or before randomisation for arm 1).
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:05:55 - f-sf36mean.sas/f-HTEM_emoimpfasHA.png

# Table of contents

**Page**

## Statistical documentation

### 1.3.4.1 Return rates of PGI-C on physical functioning by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| Age | | | | | |
| < 18 years | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| >= 18 years | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| OECD membership | | | | | |
| Non-OECD country | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| OECD country | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |

PGI-C: Patient Global Impression of Change, HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not disc ontinue before the nominal week of the visit, n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. There are no baseline results for PGI-C as the questionnaire is defined as "compared to baseline".
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:38 - t-returnrtsumfas.sas/t-returnrtsumfas-pgicHA.txt

## 1.3.4.2 Return rates of PGI-S on physical functioning by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |

PGI-S: Patient Global Impression of Severity, HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not di
scontinue before the nominal week of the visit, n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1)
and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:39 - t-returnrtsumfas.sas/t-returnrtsumfas-pgisHA.txt

### 1.3.4.3 Return rates of Haem-A-QoL dealing with haemophilia domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL dealing with haemophilia domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:39 - t-returnrtsumfas.sas/t-returnrtsumfas-pro1HA.txt

### 1.3.4.4 Return rates of Haem-A-QoL feeling domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL feeling domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:40 - t-returnrtsumfas.sas/t-returnrtsumfas-pro3HA.txt

## 1.3.4.5 Return rates of Haem-A-QoL future domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL future domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:40 - t-returnrtsumfas.sas/t-returnrtsumfas-pro4HA.txt

### 1.3.4.6 Return rates of Haem-A-QoL partnership and sexuality domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 12 (66.7) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 4 (44.4) | 17 | 9 (52.9) |
| | Week 32 | | | 16 | 8 (50.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 10 (71.4) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 4 (80.0) | 14 | 8 (57.1) |
| | Week 32 | | | 13 | 7 (53.8) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 5 (62.5) |
| | Week 32 | | | 8 | 5 (62.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL partnership and sexuality domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 5 (55.6) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:41 - t-returnrtsumfas.sas/t-returnrtsumfas-pro6HA.txt

## 1.3.4.7 Return rates of Haem-A-QoL physical health domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 4 (44.4) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:41 - t-returnrtsumfas.sas/t-returnrtsumfas-pro5HA.txt

Return rates of Haem-A-QoL physical health domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:41 - t-returnrtsumfas.sas/t-returnrtsumfas-pro5HA.txt

### 1.3.4.8 Return rates of Haem-A-QoL sport and leisure domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 13 (72.2) |
| | Week 8 | 9 | 5 (55.6) | 18 | 10 (55.6) |
| | Week 16 | 9 | 5 (55.6) | 18 | 7 (38.9) |
| | Week 24 | 9 | 5 (55.6) | 17 | 7 (41.2) |
| | Week 32 | | | 16 | 5 (31.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 1 (25.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 1 (25.0) |
| >= 18 years | Baseline | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 11 (78.6) |
| | Week 8 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 16 | 5 | 4 (80.0) | 14 | 6 (42.9) |
| | Week 24 | 5 | 5 ( 100) | 14 | 7 (50.0) |
| | Week 32 | | | 13 | 5 (38.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 4 (44.4) |
| | Week 16 | 4 | 1 (25.0) | 9 | 3 (33.3) |
| | Week 24 | | | 8 | 3 (37.5) |
| | Week 32 | | | 8 | 2 (25.0) |
| OECD country | Baseline | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 6 (66.7) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL sport and leisure domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 8 | 5 | 4 (80.0) | 9 | 6 (66.7) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:42 - t-returnrtsumfas.sas/t-returnrtsumfas-pro7HA.txt

## 1.3.4.9 Return rates of Haem-A-QoL total score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL total score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:42 - t-returnrtsumfas.sas/t-returnrtsumfas-pro8HA.txt

## 1.3.4.10 Return rates of Haem-A-QoL treatment domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL treatment domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:42 - t-returnrtsumfas.sas/t-returnrtsumfas-pro9HA.txt

## 1.3.4.11 Return rates of Haem-A-QoL view of yourself domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 16 | 9 | 5 (55.6) | 18 | 11 (61.1) |
| | Week 24 | 9 | 5 (55.6) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 4 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 8 | 5 | 5 ( 100) | 14 | 12 (85.7) |
| | Week 16 | 5 | 4 (80.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 5 ( 100) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL view of yourself domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 5 | 4 (80.0) | 9 | 7 (77.8) |
| | Week 8 | 5 | 5 ( 100) | 9 | 7 (77.8) |
| | Week 16 | 5 | 4 (80.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 5 ( 100) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

### 1.3.4.12 Return rates of Haem-A-QoL work and studies domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 4 (44.4) | 18 | 13 (72.2) |
| | Week 4 | 9 | 4 (44.4) | 18 | 12 (66.7) |
| | Week 8 | 9 | 5 (55.6) | 18 | 12 (66.7) |
| | Week 16 | 9 | 3 (33.3) | 18 | 11 (61.1) |
| | Week 24 | 9 | 3 (33.3) | 17 | 10 (58.8) |
| | Week 32 | | | 16 | 9 (56.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 8 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 16 | 4 | 1 (25.0) | 4 | 2 (50.0) |
| | Week 24 | | | 3 | 1 (33.3) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 11 (78.6) |
| | Week 4 | 5 | 3 (60.0) | 14 | 10 (71.4) |
| | Week 8 | 5 | 4 (80.0) | 14 | 10 (71.4) |
| | Week 16 | 5 | 2 (40.0) | 14 | 9 (64.3) |
| | Week 24 | 5 | 3 (60.0) | 14 | 9 (64.3) |
| | Week 32 | | | 13 | 8 (61.5) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 8 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 1 (25.0) | 9 | 7 (77.8) |
| | Week 24 | | | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL work and studies domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 6 (66.7) |
| | Week 4 | 5 | 3 (60.0) | 9 | 5 (55.6) |
| | Week 8 | 5 | 4 (80.0) | 9 | 5 (55.6) |
| | Week 16 | 5 | 2 (40.0) | 9 | 4 (44.4) |
| | Week 24 | 5 | 3 (60.0) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.4.13 Return rates of Haem-A-QoL family planning domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 3 (33.3) | 18 | 10 (55.6) |
| | Week 4 | 9 | 1 (11.1) | 18 | 8 (44.4) |
| | Week 8 | 9 | 1 (11.1) | 18 | 7 (38.9) |
| | Week 16 | 9 | 2 (22.2) | 18 | 7 (38.9) |
| | Week 24 | 9 | 3 (33.3) | 17 | 7 (41.2) |
| | Week 32 | | | 16 | 6 (37.5) |
| Age | | | | | |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 9 (64.3) |
| | Week 4 | 5 | 1 (20.0) | 14 | 7 (50.0) |
| | Week 8 | 5 | 1 (20.0) | 14 | 6 (42.9) |
| | Week 16 | 5 | 2 (40.0) | 14 | 6 (42.9) |
| | Week 24 | 5 | 3 (60.0) | 14 | 7 (50.0) |
| | Week 32 | | | 13 | 6 (46.2) |
| < 18 years | Baseline | | | 4 | 1 (25.0) |
| | Week 4 | | | 4 | 1 (25.0) |
| | Week 8 | | | 4 | 1 (25.0) |
| | Week 16 | | | 4 | 1 (25.0) |
| OECD membership | | | | | |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 5 (55.6) |
| | Week 4 | 5 | 1 (20.0) | 9 | 4 (44.4) |
| | Week 8 | 5 | 1 (20.0) | 9 | 3 (33.3) |
| | Week 16 | 5 | 2 (40.0) | 9 | 3 (33.3) |
| | Week 24 | 5 | 3 (60.0) | 9 | 4 (44.4) |
| | Week 32 | | | 8 | 3 (37.5) |
| Non-OECD country | Baseline | | | 9 | 5 (55.6) |
| | Week 4 | | | 9 | 4 (44.4) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 1 patient below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Return rates of Haem-A-QoL family planning domain score for subjects older than 16 years by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | |
|---|---|---|---|
| | | Concizumab PPX | |
| | | N | n (%) |
| Non-OECD country | Week 8 | 9 | 4 (44.4) |
| | Week 16 | 9 | 4 (44.4) |
| | Week 24 | 8 | 3 (37.5) |
| | Week 32 | 8 | 3 (37.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32. 1 patient below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:40 - t-returnrtsumfas.sas/t-returnrtsumfas-pro2HA.txt

## 1.3.4.14 Return rates of Hemo-TEM Total Score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 12 (75.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 10 (76.9) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.15 Return rates of Hemo-TEM ease of use by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 12 (75.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 10 (76.9) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:44 - t-returnrtsumfas.sas/t-returnrtsumfas-pro12HA.txt

## 1.3.4.16 Return rates of Hemo-TEM emotional impact by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 12 (75.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 10 (76.9) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.17 Return rates of Hemo-TEM interference by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 12 (75.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 10 (76.9) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:44 - t-returnrtsumfas.sas/t-returnrtsumfas-pro14HA.txt

## 1.3.4.18 Return rates of Hemo-TEM physical impact by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 12 (75.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 10 (76.9) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.19 Return rates of Hemo-TEM treatment burden by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 12 (75.0) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 10 (76.9) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 6 (75.0) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.20 Return rates of PROMIS Numeric Rating Scale v.1.0 Pain Intensity 1a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 6 (66.7) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 14 (77.8) |
| | Week 8 | 9 | 6 (66.7) | 18 | 15 (83.3) |
| | Week 16 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 13 (81.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 2 (66.7) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 8 | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 16 | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 5 (55.6) |
| | Week 8 | 4 | 3 (75.0) | 9 | 6 (66.7) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 6 (75.0) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of PROMIS Numeric Rating Scale v.1.0 Pain Intensity 1a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 3 (60.0) | 9 | 7 (77.8) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:46 - t-returnrtsumfas.sas/t-returnrtsumfas-pro18HA.txt

## 1.3.4.21 Return rates of PROMIS Short Form v2.0 Upper Extremity 7a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 3 (33.3) | 18 | 8 (44.4) |
| | Week 4 | 9 | 2 (22.2) | 18 | 6 (33.3) |
| | Week 8 | 9 | 3 (33.3) | 18 | 7 (38.9) |
| | Week 16 | 9 | 4 (44.4) | 18 | 9 (50.0) |
| | Week 24 | 9 | 2 (22.2) | 17 | 7 (41.2) |
| | Week 32 | | | 16 | 5 (31.3) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 3 (75.0) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 24 | 4 | 1 (25.0) | 3 | 2 (66.7) |
| | Week 32 | | | 3 | 1 (33.3) |
| >= 18 years | Baseline | | | 14 | 6 (42.9) |
| | Week 4 | | | 14 | 5 (35.7) |
| | Week 8 | | | 14 | 4 (28.6) |
| | Week 16 | 5 | 1 (20.0) | 14 | 6 (42.9) |
| | Week 24 | 5 | 1 (20.0) | 14 | 5 (35.7) |
| | Week 32 | | | 13 | 4 (30.8) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 5 (55.6) |
| | Week 8 | 4 | 3 (75.0) | 9 | 6 (66.7) |
| | Week 16 | 4 | 3 (75.0) | 9 | 8 (88.9) |
| | Week 24 | 4 | 1 (25.0) | 8 | 6 (75.0) |
| | Week 32 | | | 8 | 5 (62.5) |
| OECD country | Baseline | | | 9 | 1 (11.1) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of PROMIS Short Form v2.0 Upper Extremity 7a by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | | | 9 | 1 (11.1) |
| | Week 8 | | | 9 | 1 (11.1) |
| | Week 16 | 5 | 1 (20.0) | 9 | 1 (11.1) |
| | Week 24 | 5 | 1 (20.0) | 9 | 1 (11.1) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.22 Return rates of SF-36v2 general health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 general health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.23 Return rates of SF-36v2 mental health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 mental health by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.24 Return rates of SF-36v2 role emotional by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 role emotional by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.25 Return rates of SF-36v2 role physical by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 role physical by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.26 Return rates of SF-36v2 social function by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 social function by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.27 Return rates of SF-36v2 vitality by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 vitality by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.28 Return rates of SF-36v2 mental component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 mental component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.29 Return rates of SF-36v2 physical component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 physical component score by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:06:51 - t-returnrtsumfas.sas/t-returnrtsumfas-pro28HA.txt

## 1.3.4.30 Return rates of SF-36v2 bodily pain by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 bodily pain by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

## 1.3.4.31 Return rates of SF-36v2 physical functioning by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| Total | | | | | |
| All subjects | Baseline | 9 | 7 (77.8) | 18 | 14 (77.8) |
| | Week 4 | 9 | 5 (55.6) | 18 | 15 (83.3) |
| | Week 8 | 9 | 6 (66.7) | 18 | 16 (88.9) |
| | Week 16 | 9 | 7 (77.8) | 18 | 17 (94.4) |
| | Week 24 | 9 | 5 (55.6) | 17 | 15 (88.2) |
| | Week 32 | | | 16 | 14 (87.5) |
| Age | | | | | |
| < 18 years | Baseline | 4 | 4 ( 100) | 4 | 2 (50.0) |
| | Week 4 | 4 | 2 (50.0) | 4 | 1 (25.0) |
| | Week 8 | 4 | 3 (75.0) | 4 | 3 (75.0) |
| | Week 16 | 4 | 3 (75.0) | 4 | 4 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 3 | 3 ( 100) |
| | Week 32 | | | 3 | 3 ( 100) |
| >= 18 years | Baseline | 5 | 3 (60.0) | 14 | 12 (85.7) |
| | Week 4 | 5 | 3 (60.0) | 14 | 14 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 14 | 13 (92.9) |
| | Week 16 | 5 | 4 (80.0) | 14 | 13 (92.9) |
| | Week 24 | 5 | 4 (80.0) | 14 | 12 (85.7) |
| | Week 32 | | | 13 | 11 (84.6) |
| OECD membership | | | | | |
| Non-OECD country | Baseline | 4 | 4 ( 100) | 9 | 7 (77.8) |
| | Week 4 | 4 | 2 (50.0) | 9 | 6 (66.7) |
| | Week 8 | 4 | 3 (75.0) | 9 | 7 (77.8) |
| | Week 16 | 4 | 3 (75.0) | 9 | 9 ( 100) |
| | Week 24 | 4 | 1 (25.0) | 8 | 7 (87.5) |
| | Week 32 | | | 8 | 7 (87.5) |
| OECD country | Baseline | 5 | 3 (60.0) | 9 | 7 (77.8) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2).
Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

Return rates of SF-36v2 physical functioning by treatment week - Explorer 8 - HA - OTexBR - Full analysis set

| | | HA | | | |
|---|---|---|---|---|---|
| | | No PPX | | Concizumab PPX | |
| | | N | n (%) | N | n (%) |
| OECD country | Week 4 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 8 | 5 | 3 (60.0) | 9 | 9 ( 100) |
| | Week 16 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 24 | 5 | 4 (80.0) | 9 | 8 (88.9) |
| | Week 32 | | | 8 | 7 (87.5) |

HA: haemophilia A, PPX: Prophylaxis, N: number of subjects in the analysis set who did not discontinue before the nominal week of the visit , n: number of subjects contributing to analysis. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Patients in arm 1 (No PPX) did not fill out the questionnaire at week 32.
Cut off date for data is 12th July 2022.

# Table of contents

**Page**

# Statistical documentation

## 1.3.1.1 PGI-C on physical functioning responders a week 24 - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 11 (61.1) | 9 | 0 ( 0.0) | 29.13 (1.47, 578.70) | 12.11 (0.79, 184.85) | 61.11 (38.59, 83.63) | 0.0020 |
| Age group | | | | | | | | |
| < 18 years | 4 | 2 (50.0) | 4 | 0 ( 0.0) | | | | |
| >= 18 years | 14 | 9 (64.3) | 5 | 0 ( 0.0) | | | | |
| OECD membership | | | | | | | | |
| OECD country | 9 | 6 (66.7) | 5 | 0 ( 0.0) | | | | |
| Non-OECD country | 9 | 5 (55.6) | 4 | 0 ( 0.0) | | | | |

PGI-C: Patient Global Impression of Change, responder: Subjects with VERY MUCH BETTER or MODERATELY BETTER at week 24, HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with an observed response at week 24, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). Missing values are counted as 'non responder'. P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. All randomized patients were included in the analysis of PGI-C, whether or not week 24 data was available. Patients without week 24 data were considered non-responders. Cut off date for data is 12th July 2022.

## 1.3.1.2 PGI-S on physical functioning responders a week 24 - Explorer 8 - HA - OTexBR - Full analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 6 (33.3) | 9 | 0 ( 0.0) | 9.88 (0.49, 197.97) | 6.84 (0.43, 109.48) | 33.33 (11.56, 55.11) | 0.0626 |

PGI-S: Patient Global Impression of Severity, responder: Subjects who improve at least one level from baseline to week 24, HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with an observed response at week 24, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). Missing values are counted as "non responder". P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. All randomized patients were included in the analysis of PGI-S, whether or not week 24 data was available. Patients without week 24 data were considered non-responders. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:45 - chef-safety-output.R/PGI_S_HA_saf_e8.txt

## 1.3.1.3 Change from baseline to week 24 in Haem-A-QoL dealing with haemophilia domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 22.22 (19.48) | | 18 | 14 | 27.38 (20.00) | | | | | |
| Week 24 | 9 | 5 | 20.00 (18.26) | | 17 | 10 | 17.50 (22.72) | | | | | |
| Change from baseline to week 24 | 9 | 5 | -5.00 ( 7.45) | -3.21 ( 6.36) | 17 | 10 | -10.00 (23.17) | -7.65 ( 4.37) | -4.44 [-20.22; 11.34] | 0.5709 | -0.26 [-1.22; 0.70] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 8.33 ( NA) | | 4 | 2 | 4.17 ( 5.89) | | | | | |
| Week 24 | | | | | 3 | 1 | 25.00 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | 25.00 ( NA) | 23.24 (13.16) | NE [NE; NE] | NE | NE [NE; NE] | 0.0350 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 25.00 (20.41) | | 14 | 12 | 31.25 (18.84) | | | | | |
| Week 24 | 5 | 5 | 20.00 (18.26) | | 14 | 9 | 16.67 (23.94) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -5.00 ( 7.45) | -3.65 ( 5.72) | 14 | 9 | -13.89 (20.83) | -12.34 ( 4.21) | -8.69 [-23.50; 6.12] | 0.2381 | -0.58 [-1.65; 0.48] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL dealing with haemophilia domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 8.33 ( NA) | | 9 | 7 | 26.19 (27.40) | | | | | |
| Week 24 | | | | | 8 | 6 | 19.44 (29.19) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -9.72 (29.07) | -5.83 ( 5.96) | NE [NE; NE] | NE | NE [NE; NE] | 0.3994 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 25.00 (20.41) | | 9 | 7 | 28.57 (10.60) | | | | | |
| Week 24 | 5 | 5 | 20.00 (18.26) | | 9 | 4 | 14.58 (10.49) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -5.00 ( 7.45) | -4.52 ( 6.62) | 9 | 4 | -10.42 (14.23) | -10.01 ( 7.02) | -5.50 [-25.76; 14.77] | 0.5815 | -0.30 [-1.45; 0.86] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.1.4 Change from baseline to week 24 in Haem-A-QoL feeling domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 48.96 (39.21) | | 18 | 14 | 44.64 (22.45) | | | | | |
| Week 24 | 9 | 5 | 53.75 (32.66) | | 17 | 10 | 26.25 (24.62) | | | | | |
| Change from baseline to week 24 | 9 | 5 | -2.50 (12.96) | -1.27 ( 8.30) | 17 | 10 | -20.62 (23.94) | -20.49 ( 5.64) | -19.21 [-39.66; 1.23] | 0.0645 | -0.88 [-1.88; 0.11] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 12.50 ( NA) | | 4 | 2 | 31.25 (26.52) | | | | | |
| Week 24 | | | | | 3 | 1 | 0.00 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | -12.50 ( NA) | -25.96 (19.29) | NE [NE; NE] | NE | NE [NE; NE] | 0.9505 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 56.25 (39.03) | | 14 | 12 | 46.88 (22.22) | | | | | |
| Week 24 | 5 | 5 | 53.75 (32.66) | | 14 | 9 | 29.17 (24.21) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -2.50 (12.96) | -0.25 ( 8.93) | 14 | 9 | -21.53 (25.22) | -19.78 ( 6.32) | -19.53 [-41.92; 2.86] | 0.0845 | -0.87 [-1.95; 0.22] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:17:41 - t-prostats-output.R/HAQ_feeling_HA_e8.txt

Change from baseline to week 24 in Haem-A-QoL feeling domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 12.50 ( NA) | | 9 | 7 | 49.11 (23.23) | | | | | |
| Week 24 | | | | | 8 | 6 | 20.83 (21.53) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -28.12 (22.62) | -29.84 ( 7.02) | NE [NE; NE] | NE | NE [NE; NE] | 0.1337 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 56.25 (39.03) | | 9 | 7 | 40.18 (22.49) | | | | | |
| Week 24 | 5 | 5 | 53.75 (32.66) | | 9 | 4 | 34.38 (29.97) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -2.50 (12.96) | -1.15 ( 7.84) | 9 | 4 | -9.38 (24.21) | -8.59 ( 8.38) | -7.44 [-31.53; 16.65] | 0.5304 | -0.34 [-1.49; 0.82] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:17:41 - t-prostats-output.R/HAQ_feeling_HA_e8.txt

## 1.3.1.5 Change from baseline to week 24 in Haem-A-QoL future domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 46.67 (35.87) | | 18 | 14 | 42.86 (16.72) | | | | | |
| Week 24 | 9 | 5 | 52.00 (29.71) | | 17 | 10 | 32.00 (18.44) | | | | | |
| Change from baseline to week 24 | 9 | 5 | -1.00 (12.94) | 0.24 ( 4.80) | 17 | 10 | -10.00 (10.00) | -10.61 ( 3.23) | -10.85 [-22.72; 1.03] | 0.0719 | -0.87 [-1.86; 0.13] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 15.00 ( NA) | | 4 | 2 | 30.00 (14.14) | | | | | |
| Week 24 | | | | | 3 | 1 | 25.00 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | -15.00 ( NA) | -11.80 ( 9.93) | NE [NE; NE] | NE | NE [NE; NE] | 0.3736 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 53.00 (36.16) | | 14 | 12 | 45.00 (16.65) | | | | | |
| Week 24 | 5 | 5 | 52.00 (29.71) | | 14 | 9 | 32.78 (19.38) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -1.00 (12.94) | 0.35 ( 5.32) | 14 | 9 | -9.44 (10.44) | -10.72 ( 3.60) | -11.06 [-24.38; 2.26] | 0.0997 | -0.85 [-1.93; 0.23] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL future domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 15.00 ( NA) | | 9 | 7 | 31.43 ( 9.45) | | | | | |
| Week 24 | | | | | 8 | 6 | 22.50 (12.94) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -10.83 (10.68) | -14.49 ( 4.86) | NE [NE; NE] | NE | NE [NE; NE] | 0.3365 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 53.00 (36.16) | | 9 | 7 | 54.29 (14.56) | | | | | |
| Week 24 | 5 | 5 | 52.00 (29.71) | | 9 | 4 | 46.25 (17.02) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -1.00 (12.94) | 0.58 ( 5.01) | 9 | 4 | -8.75 (10.31) | -6.95 ( 5.36) | -7.53 [-22.40; 7.34] | 0.3070 | -0.53 [-1.70; 0.64] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:17:43 - t-prostats-output.R/HAQ_future_HA_e8.txt

## 1.3.1.6 Change from baseline to week 24 in Haem-A-QoL partnership and sexuality domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) / CSE (SE) | N | n | Mean (SD) / CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| **All subjects (Total)** | | | | | | | | | | |
| total | | | | | | | | | | |
| Baseline | 9 | 6 | 47.22 (44.93) | 18 | 14 | 39.88 (32.88) | | | | |
| Week 24 | 9 | 4 | 50.00 (41.39) | 17 | 9 | 22.22 (37.27) | | | | |
| Change from baseline to week 24 | 9 | 4 | 4.17 ( 8.33) / -3.66 (11.21) | 17 | 9 | -9.26 (22.61) / -12.13 ( 7.50) | -8.47 [-36.17; 19.23] | 0.5362 | -0.29 [-1.25; 0.67] | |
| **Age** | | | | | | | | | | |
| < 18 years | | | | | | | | | | |
| Baseline | 4 | 1 | 100.00 ( NA) | 4 | 2 | 58.33 (11.79) | | | | |
| Week 24 | | | | 3 | 1 | 0.00 ( NA) | | | | |
| Change from baseline to week 24 | | | | 3 | 1 | -66.67 ( NA) / -57.10 (11.19) | NE [NE; NE] | NE | NE [NE; NE] | < 0.0001 |
| >= 18 years | | | | | | | | | | |
| Baseline | 5 | 5 | 36.67 (41.08) | 14 | 12 | 36.81 (34.53) | | | | |
| Week 24 | 5 | 4 | 50.00 (41.39) | 14 | 8 | 25.00 (38.83) | | | | |
| Change from baseline to week 24 | 5 | 4 | 4.17 ( 8.33) / 3.84 ( 6.35) | 14 | 8 | -2.08 ( 7.39) / -3.91 ( 4.37) | -7.75 [-23.89; 8.39] | 0.3293 | -0.49 [-1.55; 0.56] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL partnership and sexuality domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 100.00 ( NA) | | 9 | 7 | 48.81 (40.38) | | | | | |
| Week 24 | | | | | 8 | 5 | 26.67 (43.46) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 5 | -13.33 (29.81) | -12.49 ( 8.26) | NE [NE; NE] | NE | NE [NE; NE] | < 0.0001 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 36.67 (41.08) | | 9 | 7 | 30.95 (22.93) | | | | | |
| Week 24 | 5 | 4 | 50.00 (41.39) | | 9 | 4 | 16.67 (33.33) | | | | | |
| Change from baseline to week 24 | 5 | 4 | 4.17 ( 8.33) | 4.41 ( 9.54) | 9 | 4 | -4.17 (10.76) | -11.81 ( 8.86) | -16.22 [-43.76; 11.31] | 0.2340 | -0.66 [-1.84; 0.52] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.1.7 Change from baseline to week 24 in Haem-A-QoL physical health domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 60.00 (18.71) | | 18 | 14 | 47.86 (18.99) | | | | | |
| Week 24 | 9 | 5 | 62.00 (21.68) | | 17 | 10 | 34.50 (18.92) | | | | | |
| Change from baseline to week 24 | 9 | 5 | -3.00 (14.83) | 1.20 ( 8.55) | 17 | 10 | -13.50 (19.44) | -15.09 ( 5.58) | -16.29 [-37.68; 5.10] | 0.1305 | -0.75 [-1.73; 0.24] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | | 4 | 2 | 62.50 ( 3.54) | | | | | |
| Week 24 | | | | | 3 | 1 | 25.00 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | -35.00 ( NA) | -34.61 (16.25) | NE [NE; NE] | NE | NE [NE; NE] | 0.3384 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 65.00 (15.81) | | 14 | 12 | 45.42 (19.48) | | | | | |
| Week 24 | 5 | 5 | 62.00 (21.68) | | 14 | 9 | 35.56 (19.76) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -3.00 (14.83) | 1.41 ( 8.99) | 14 | 9 | -11.11 (19.00) | -12.09 ( 5.98) | -13.50 [-36.81; 9.81] | 0.2436 | -0.62 [-1.69; 0.44] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL physical health domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | | 9 | 7 | 57.86 (10.75) | | | | | |
| Week 24 | | | | | 8 | 6 | 35.00 (19.49) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -21.67 (19.66) | -21.97 ( 7.60) | NE [NE; NE] | NE | NE [NE; NE] | 0.8178 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 65.00 (15.81) | | 9 | 7 | 37.86 (20.79) | | | | | |
| Week 24 | 5 | 5 | 62.00 (21.68) | | 9 | 4 | 33.75 (20.97) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -3.00 (14.83) | 0.31 ( 9.24) | 9 | 4 | -1.25 (12.50) | -6.87 ( 9.74) | -7.18 [-37.61; 23.26] | 0.6308 | -0.28 [-1.43; 0.88] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.1.8 Change from baseline to week 24 in Haem-A-QoL sport and leisure domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 5 | 81.50 (13.39) | | 18 | 14 | 71.85 (25.51) | | | | | |
| Week 24 | 9 | 5 | 83.00 (17.18) | | 17 | 7 | 45.54 (26.85) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -5.63 ( 6.81) | -4.49 ( 6.89) | 17 | 7 | -22.80 (20.83) | -26.41 ( 5.09) | -21.92 [-40.04; -3.80] | 0.0201 | -1.18 [-2.28; -0.08] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 70.00 ( NA) | | 4 | 2 | 71.25 (22.98) | | | | | |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 4 | 84.38 (13.56) | | 14 | 12 | 71.94 (26.85) | | | | | |
| Week 24 | 5 | 5 | 83.00 (17.18) | | 14 | 7 | 45.54 (26.85) | | | | | |
| Change from baseline to week 24 | 5 | 4 | -5.63 ( 6.81) | -2.62 ( 6.66) | 14 | 7 | -22.80 (20.83) | -27.13 ( 4.81) | -24.51 [-42.33; -6.69] | 0.0103 | -1.50 [-2.76; -0.23] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL sport and leisure domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 70.00 ( NA) | | 9 | 7 | 83.93 (16.82) | | | | | |
| Week 24 | | | | | 8 | 3 | 52.92 (10.92) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 3 | -38.75 (21.32) | -40.95 ( 7.25) | NE [NE; NE] | NE | NE [NE; NE] | 0.0309 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 4 | 84.38 (13.56) | | 9 | 7 | 59.76 (28.04) | | | | | |
| Week 24 | 5 | 5 | 83.00 (17.18) | | 9 | 4 | 40.00 (35.59) | | | | | |
| Change from baseline to week 24 | 5 | 4 | -5.63 ( 6.81) | -4.11 ( 6.67) | 9 | 4 | -10.83 (10.93) | -16.23 ( 7.26) | -12.12 [-34.72; 10.48] | 0.2694 | -0.67 [-1.97; 0.63] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:17:50 - t-prostats-output.R/HAQ_sport_HA_e8.txt

## 1.3.1.9 Change from baseline to week 24 in Haem-A-QoL total score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 51.84 (21.12) | | 18 | 14 | 45.18 (14.39) | | | | | |
| Week 24 | 9 | 5 | 57.41 (21.73) | | 17 | 10 | 28.80 (15.38) | | | | | |
| Change from baseline to week 24 | 9 | 5 | 2.46 ( 2.56) | 3.38 ( 4.33) | 17 | 10 | -16.94 (14.07) | -17.47 ( 2.89) | -20.85 [-31.55; -10.15] | 0.0004 | -1.86 [-2.97; -0.74] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 36.31 ( NA) | | 4 | 2 | 41.79 ( 2.99) | | | | | |
| Week 24 | | | | | 3 | 1 | 16.67 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | -27.24 ( NA) | -23.28 ( 8.99) | NE [NE; NE] | NE | NE [NE; NE] | 0.8084 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 54.95 (22.03) | | 14 | 12 | 45.75 (15.54) | | | | | |
| Week 24 | 5 | 5 | 57.41 (21.73) | | 14 | 9 | 30.15 (15.68) | | | | | |
| Change from baseline to week 24 | 5 | 5 | 2.46 ( 2.56) | 4.53 ( 4.81) | 14 | 9 | -15.80 (14.42) | -16.65 ( 3.23) | -21.18 [-33.20; -9.17] | 0.0013 | -1.82 [-3.03; -0.61] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL total score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 36.31 ( NA) | | 9 | 7 | 46.31 (13.52) | | | | | |
| Week 24 | | | | | 8 | 6 | 24.00 ( 8.76) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -23.42 (15.11) | -22.95 ( 3.81) | NE [NE; NE] | NE | NE [NE; NE] | 0.3388 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 54.95 (22.03) | | 9 | 7 | 44.05 (16.21) | | | | | |
| Week 24 | 5 | 5 | 57.41 (21.73) | | 9 | 4 | 36.01 (21.61) | | | | | |
| Change from baseline to week 24 | 5 | 5 | 2.46 ( 2.56) | 4.26 ( 4.31) | 9 | 4 | -7.21 ( 1.78) | -10.73 ( 4.28) | -14.99 [-27.71; -2.28] | 0.0227 | -1.30 [-2.55; -0.04] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.1.10 Change from baseline to week 24 in Haem-A-QoL treatment domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 53.12 (22.10) | | 18 | 14 | 45.54 (21.15) | | | | | |
| Week 24 | 9 | 5 | 64.38 (16.03) | | 17 | 10 | 24.42 (24.38) | | | | | |
| Change from baseline to week 24 | 9 | 5 | 7.50 ( 9.27) | 13.07 ( 8.24) | 17 | 10 | -21.83 (22.60) | -24.11 ( 5.44) | -37.19 [-57.46; -16.91] | 0.0007 | -1.75 [-2.85; -0.65] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 34.38 ( NA) | | 4 | 2 | 46.88 ( 8.84) | | | | | |
| Week 24 | | | | | 3 | 1 | 3.57 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | -37.05 ( NA) | -27.75 (16.64) | NE [NE; NE] | NE | NE [NE; NE] | 0.9533 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 56.88 (22.47) | | 14 | 12 | 45.31 (22.83) | | | | | |
| Week 24 | 5 | 5 | 64.38 (16.03) | | 14 | 9 | 26.74 (24.66) | | | | | |
| Change from baseline to week 24 | 5 | 5 | 7.50 ( 9.27) | 11.77 ( 9.43) | 14 | 9 | -20.14 (23.29) | -23.10 ( 6.22) | -34.87 [-58.32; -11.42] | 0.0052 | -1.55 [-2.71; -0.38] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL treatment domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 34.38 ( NA) | | 9 | 7 | 41.96 (16.02) | | | | | |
| Week 24 | | | | | 8 | 6 | 11.53 (13.00) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -28.57 (25.47) | -29.96 ( 9.08) | NE [NE; NE] | NE | NE [NE; NE] | 0.9703 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 56.88 (22.47) | | 9 | 7 | 49.11 (26.13) | | | | | |
| Week 24 | 5 | 5 | 64.38 (16.03) | | 9 | 4 | 43.75 (25.90) | | | | | |
| Change from baseline to week 24 | 5 | 5 | 7.50 ( 9.27) | 12.20 ( 9.27) | 9 | 4 | -11.72 (14.96) | -17.74 ( 9.55) | -29.95 [-56.86; -3.04] | 0.0306 | -1.17 [-2.41; 0.07] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:17:55 - t-prostats-output.R/HAQ_treatment_HA_e8.txt

## 1.3.1.11 Change from baseline to week 24 in Haem-A-QoL view of yourself domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 60.00 (25.88) | | 18 | 14 | 50.71 (18.80) | | | | | |
| Week 24 | 9 | 5 | 63.00 (27.29) | | 17 | 10 | 41.00 (17.92) | | | | | |
| Change from baseline to week 24 | 9 | 5 | -2.00 ( 5.70) | -1.15 ( 7.04) | 17 | 10 | -11.50 (17.00) | -11.12 ( 4.65) | -9.97 [-27.31; 7.37] | 0.2501 | -0.55 [-1.52; 0.42] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | | 4 | 2 | 40.00 (21.21) | | | | | |
| Week 24 | | | | | 3 | 1 | 30.00 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | -25.00 ( NA) | -9.51 (14.58) | NE [NE; NE] | NE | NE [NE; NE] | 0.4292 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 5 | 65.00 (25.50) | | 14 | 12 | 52.50 (18.77) | | | | | |
| Week 24 | 5 | 5 | 63.00 (27.29) | | 14 | 9 | 42.22 (18.56) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -2.00 ( 5.70) | 1.18 ( 7.48) | 14 | 9 | -10.00 (17.32) | -11.54 ( 5.03) | -12.72 [-31.43; 5.99] | 0.1736 | -0.70 [-1.77; 0.37] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL view of yourself domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 35.00 ( NA) | | 9 | 7 | 48.57 (20.76) | | | | | |
| Week 24 | | | | | 8 | 6 | 32.50 (15.08) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -20.00 (17.32) | -18.22 ( 6.34) | NE [NE; NE] | NE | NE [NE; NE] | 0.5397 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 5 | 65.00 (25.50) | | 9 | 7 | 52.86 (17.99) | | | | | |
| Week 24 | 5 | 5 | 63.00 (27.29) | | 9 | 4 | 53.75 (14.93) | | | | | |
| Change from baseline to week 24 | 5 | 5 | -2.00 ( 5.70) | 1.42 ( 7.06) | 9 | 4 | 1.25 ( 2.50) | -2.47 ( 7.31) | -3.89 [-24.77; 16.99] | 0.7041 | -0.20 [-1.35; 0.95] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:17:57 - t-prostats-output.R/HAQ_view_HA_e8.txt

## 1.3.1.12 Change from baseline to week 24 in Haem-A-QoL work and studies domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 4 | 40.62 (16.54) | | 18 | 13 | 35.10 (24.41) | | | | | |
| Week 24 | 9 | 3 | 52.08 (23.66) | | 17 | 10 | 22.50 (18.45) | | | | | |
| Change from baseline to week 24 | 9 | 2 | 18.75 (17.68) | 20.29 (11.38) | 17 | 10 | -13.12 (28.33) | -13.39 ( 5.40) | -33.68 [-59.82; -7.55] | 0.0138 | -1.62 [-2.88; -0.36] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 1 | 25.00 ( NA) | | 4 | 2 | 25.00 ( 0.00) | | | | | |
| Week 24 | | | | | 3 | 1 | 25.00 ( NA) | | | | | |
| Change from baseline to week 24 | | | | | 3 | 1 | 0.00 ( NA) | -20.40 (15.34) | NE [NE; NE] | NE | NE [NE; NE] | 0.1214 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 45.83 (15.73) | | 14 | 11 | 36.93 (26.29) | | | | | |
| Week 24 | 5 | 3 | 52.08 (23.66) | | 14 | 9 | 22.22 (19.54) | | | | | |
| Change from baseline to week 24 | 5 | 2 | 18.75 (17.68) | 26.52 (11.51) | 14 | 9 | -14.58 (29.65) | -13.72 ( 5.53) | -40.24 [-67.43; -13.05] | 0.0064 | -2.09 [-3.60; -0.57] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Haem-A-QoL work and studies domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 1 | 25.00 ( NA) | | 9 | 7 | 35.71 (27.41) | | | | | |
| Week 24 | | | | | 8 | 6 | 19.79 (17.86) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 6 | -17.71 (37.17) | -18.50 ( 6.57) | NE [NE; NE] | NE | NE [NE; NE] | 0.2055 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 45.83 (15.73) | | 9 | 6 | 34.38 (22.96) | | | | | |
| Week 24 | 5 | 3 | 52.08 (23.66) | | 9 | 4 | 26.56 (21.27) | | | | | |
| Change from baseline to week 24 | 5 | 2 | 18.75 (17.68) | 25.97 (11.20) | 9 | 4 | -6.25 ( 0.00) | -7.28 ( 8.04) | -33.26 [-63.41; -3.10] | 0.0327 | -1.57 [-3.19; 0.06] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 2 patients below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

## 1.3.1.13 Change from baseline to week 24 in Haem-A-QoL family planning domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 3 | 12.50 (21.65) | | 18 | 10 | 24.38 (22.91) | | | | | |
| Week 24 | 9 | 3 | 8.33 (14.43) | | 17 | 7 | 17.56 (29.19) | | | | | |
| Change from baseline to week 24 | 9 | 3 | -4.17 ( 7.22) | -4.26 ( 5.67) | 17 | 6 | -1.39 ( 7.65) | -3.18 ( 3.76) | 1.08 [-14.64; 16.80] | 0.8785 | 0.10 [-1.26; 1.45] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | | | | | 4 | 1 | 25.00 ( NA) | | | | | |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 12.50 (21.65) | | 14 | 9 | 24.31 (24.30) | | | | | |
| Week 24 | 5 | 3 | 8.33 (14.43) | | 14 | 7 | 17.56 (29.19) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -4.17 ( 7.22) | -4.22 ( 4.94) | 14 | 6 | -1.39 ( 7.65) | -1.39 ( 3.41) | 2.83 [-12.62; 18.27] | 0.6577 | 0.30 [-1.09; 1.69] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 1 patient below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:18:02 - t-prostats-output.R/HAQ_family_HA_e8.txt

Change from baseline to week 24 in Haem-A-QoL family planning domain score for subjects older than 16 years - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | | | | | 9 | 5 | 20.00 (20.92) | | | | | |
| Week 24 | | | | | 8 | 3 | 7.64 ( 8.42) | | | | | |
| Change from baseline to week 24 | | | | | 8 | 3 | -0.69 ( 7.32) | -5.18 ( 5.92) | NE [NE; NE] | NE | NE [NE; NE] | 0.8065 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 12.50 (21.65) | | 9 | 5 | 28.75 (26.37) | | | | | |
| Week 24 | 5 | 3 | 8.33 (14.43) | | 9 | 4 | 25.00 (38.53) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -4.17 ( 7.22) | -4.55 ( 6.25) | 9 | 3 | -2.08 ( 9.55) | -1.45 ( 6.49) | 3.10 [-22.99; 29.20] | 0.7580 | 0.22 [-1.38; 1.83] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. 1 patient below the age of 17 filled out the questionnaire at baseline and post baseline. These data are included. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:18:02 - t-prostats-output.R/HAQ_family_HA_e8.txt

## 1.3.1.14 Change from baseline to week 24 in Hemo-TEM Total Score - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 28.63 (27.67) | | 18 | 14 | 27.82 (15.59) | | | | | |
| Week 24 | 9 | 5 | 41.12 (27.69) | | 17 | 15 | 13.43 (13.32) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 4.87 (12.66) | 13.21 ( 8.74) | 17 | 12 | -11.03 (19.69) | -12.33 ( 4.67) | -25.54 [-47.49; -3.59] | 0.0262 | -1.47 [-2.71; -0.23] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 3 | 17.72 (17.07) | | 4 | 2 | 22.02 ( 1.00) | | | | | |
| Week 24 | 4 | 1 | 20.06 ( NA) | | 3 | 3 | 12.00 (13.25) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -13.99 ( NA) | -7.26 (16.22) | 3 | 2 | -4.99 (13.14) | -10.31 (11.48) | -3.05 [-48.07; 41.96] | 0.8829 | 0.00 [-2.40; 2.40] | 0.3634 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 39.54 (35.57) | | 14 | 12 | 28.79 (16.73) | | | | | |
| Week 24 | 5 | 4 | 46.38 (28.94) | | 14 | 12 | 13.79 (13.90) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 11.15 ( 1.82) | 20.11 ( 9.87) | 14 | 10 | -12.23 (21.10) | -12.76 ( 5.05) | -32.87 [-57.68; -8.05] | 0.0145 | -1.89 [-3.37; -0.41] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Hemo-TEM Total Score - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 17.72 (17.07) | | 9 | 7 | 28.62 (14.66) | | | | | |
| Week 24 | 4 | 1 | 20.06 ( NA) | | 8 | 7 | 7.41 ( 9.36) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -13.99 ( NA) | -7.15 (14.52) | 8 | 6 | -17.49 (17.28) | -18.90 ( 5.84) | -11.75 [-46.78; 23.27] | 0.4719 | -0.69 [-2.84; 1.46] | 0.1207 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 39.54 (35.57) | | 9 | 7 | 27.02 (17.61) | | | | | |
| Week 24 | 5 | 4 | 46.38 (28.94) | | 9 | 8 | 18.71 (14.56) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 11.15 ( 1.82) | 20.24 ( 8.82) | 9 | 6 | -4.56 (21.32) | -5.84 ( 5.84) | -26.09 [-49.95; -2.22] | 0.0351 | -1.59 [-3.16; -0.02] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.15 Change from baseline to week 24 in Hemo-TEM ease of use - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] p-value interact. |
| All subjects (Total) | | | | | | | | | | | |
| total | | | | | | | | | | | |
| Baseline | 9 | 6 | 25.00 (22.97) | | 18 | 14 | 28.57 (20.34) | | | | |
| Week 24 | 9 | 5 | 35.00 (34.05) | | 17 | 15 | 10.56 (12.39) | | | | |
| Change from baseline to week 24 | 9 | 4 | 8.33 (15.21) | 17.33 ( 9.86) | 17 | 12 | -13.19 (25.24) | -15.25 ( 5.37) | -32.58 [-57.33; -7.82] | 0.0142 | -1.63 [-2.90; -0.37] |
| Age | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | |
| Baseline | 4 | 3 | 16.67 (16.67) | | 4 | 2 | 16.67 ( 0.00) | | | | |
| Week 24 | 4 | 1 | 25.00 ( NA) | | 3 | 3 | 19.44 (20.97) | | | | |
| Change from baseline to week 24 | 4 | 1 | -8.33 ( NA) | -0.28 (17.43) | 3 | 2 | 12.50 (17.68) | 3.53 (12.45) | 3.80 [-44.73; 52.34] | 0.8649 | 0.00 [-2.40; 2.40] 0.1880 |
| >= 18 years | | | | | | | | | | | |
| Baseline | 5 | 3 | 33.33 (28.87) | | 14 | 12 | 30.56 (21.42) | | | | |
| Week 24 | 5 | 4 | 37.50 (38.79) | | 14 | 12 | 8.33 ( 9.40) | | | | |
| Change from baseline to week 24 | 5 | 3 | 13.89 (12.73) | 21.95 (10.40) | 14 | 10 | -18.33 (23.83) | -18.77 ( 5.42) | -40.71 [-66.87; -14.56] | 0.0060 | -2.19 [-3.73; -0.65] |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Hemo-TEM ease of use - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 16.67 (16.67) | | 9 | 7 | 30.95 (20.81) | | | | | |
| Week 24 | 4 | 1 | 25.00 ( NA) | | 8 | 7 | 10.71 (15.75) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -8.33 ( NA) | 0.66 (19.63) | 8 | 6 | -15.28 (27.60) | -15.75 ( 7.89) | -16.41 [-63.68; 30.86] | 0.4571 | -0.72 [-2.87; 1.43] | 0.6201 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 33.33 (28.87) | | 9 | 7 | 26.19 (21.21) | | | | | |
| Week 24 | 5 | 4 | 37.50 (38.79) | | 9 | 8 | 10.42 ( 9.71) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 13.89 (12.73) | 22.88 (11.70) | 9 | 6 | -11.11 (25.09) | -14.73 ( 7.99) | -37.61 [-69.51; -5.71] | 0.0253 | -1.69 [-3.28; -0.10] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.16 Change from baseline to week 24 in Hemo-TEM emotional impact - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 37.50 (34.86) | | 18 | 14 | 30.12 (20.55) | | | | | |
| Week 24 | 9 | 5 | 42.50 (37.55) | | 17 | 15 | 16.94 (22.07) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -6.25 (24.18) | 2.51 (14.45) | 17 | 12 | -9.10 (26.86) | -10.65 ( 7.60) | -13.15 [-49.51; 23.21] | 0.4459 | -0.46 [-1.61; 0.68] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 3 | 30.56 (31.27) | | 4 | 2 | 21.25 (12.37) | | | | | |
| Week 24 | 4 | 1 | 20.83 ( NA) | | 3 | 3 | 8.33 (14.43) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -41.67 ( NA) | -29.45 (27.78) | 3 | 2 | -8.75 ( 5.30) | -14.15 (18.99) | 15.30 [-62.15; 92.74] | 0.6692 | 0.00 [-2.40; 2.40] | 0.4168 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 44.44 (43.77) | | 14 | 12 | 31.60 (21.65) | | | | | |
| Week 24 | 5 | 4 | 47.92 (41.04) | | 14 | 12 | 19.10 (23.60) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 5.56 ( 6.36) | 12.29 (16.13) | 14 | 10 | -9.17 (29.65) | -9.75 ( 8.29) | -22.04 [-62.64; 18.57] | 0.2544 | -0.77 [-2.10; 0.55] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Hemo-TEM emotional impact - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 30.56 (31.27) | | 9 | 7 | 31.07 (21.35) | | | | | |
| Week 24 | 4 | 1 | 20.83 ( NA) | | 8 | 7 | 5.95 (10.45) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -41.67 ( NA) | -29.34 (23.94) | 8 | 6 | -20.97 (24.18) | -22.68 ( 9.28) | 6.67 [-51.29; 64.62] | 0.8029 | 0.25 [-1.87; 2.37] | 0.0955 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 44.44 (43.77) | | 9 | 7 | 29.17 (21.38) | | | | | |
| Week 24 | 5 | 4 | 47.92 (41.04) | | 9 | 8 | 26.56 (25.58) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 5.56 ( 6.36) | 12.22 (13.89) | 9 | 6 | 2.78 (25.78) | 1.68 ( 9.25) | -10.53 [-48.14; 27.07] | 0.5465 | -0.41 [-1.80; 0.99] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.17 Change from baseline to week 24 in Hemo-TEM interference - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] p-value interact. |
| All subjects (Total) | | | | | | | | | | | |
| total | | | | | | | | | | | |
| Baseline | 9 | 6 | 29.17 (30.53) | | 18 | 14 | 28.72 (23.29) | | | | |
| Week 24 | 9 | 5 | 46.67 (32.23) | | 17 | 15 | 7.08 (12.24) | | | | |
| Change from baseline to week 24 | 9 | 4 | 4.69 (17.95) | 17.38 ( 9.31) | 17 | 12 | -22.57 (28.62) | -23.33 ( 5.04) | -40.71 [-63.99; -17.42] | 0.0025 | -2.17 [-3.53; -0.81] |
| Age | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | |
| Baseline | 4 | 3 | 14.58 (13.01) | | 4 | 2 | 21.88 (13.26) | | | | |
| Week 24 | 4 | 1 | 6.25 ( NA) | | 3 | 3 | 10.42 (13.01) | | | | |
| Change from baseline to week 24 | 4 | 1 | -18.75 ( NA) | -15.24 (15.13) | 3 | 2 | -9.38 ( 4.42) | -17.96 (10.63) | -2.72 [-44.44; 39.00] | 0.8873 | 0.00 [-2.40; 2.40] 0.0786 |
| >= 18 years | | | | | | | | | | | |
| Baseline | 5 | 3 | 43.75 (39.03) | | 14 | 12 | 29.86 (24.80) | | | | |
| Week 24 | 5 | 4 | 56.77 (26.54) | | 14 | 12 | 6.25 (12.50) | | | | |
| Change from baseline to week 24 | 5 | 3 | 12.50 (10.83) | 28.28 ( 9.09) | 14 | 10 | -25.21 (30.86) | -24.32 ( 4.68) | -52.60 [-75.32; -29.89] | 0.0004 | -3.27 [-5.07; -1.47] |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Hemo-TEM interference - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 14.58 (13.01) | | 9 | 7 | 34.82 (24.70) | | | | | |
| Week 24 | 4 | 1 | 6.25 ( NA) | | 8 | 7 | 4.46 ( 9.35) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -18.75 ( NA) | -14.66 (14.52) | 8 | 6 | -31.25 (29.58) | -27.90 ( 5.91) | -13.24 [-48.51; 22.02] | 0.4223 | -0.77 [-2.93; 1.38] | 0.0521 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 43.75 (39.03) | | 9 | 7 | 22.62 (21.86) | | | | | |
| Week 24 | 5 | 4 | 56.77 (26.54) | | 9 | 8 | 9.38 (14.56) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 12.50 (10.83) | 28.21 ( 8.71) | 9 | 6 | -13.89 (27.31) | -18.72 ( 5.88) | -46.92 [-70.77; -23.08] | 0.0014 | -2.86 [-4.77; -0.94] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.18 Change from baseline to week 24 in Hemo-TEM physical impact - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 18.75 (18.59) | | 18 | 14 | 22.62 (17.12) | | | | | |
| Week 24 | 9 | 5 | 35.00 (22.36) | | 17 | 15 | 16.39 (13.50) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 16.67 ( 5.89) | 18.96 ( 6.50) | 17 | 12 | -1.04 (14.34) | -1.87 ( 3.54) | -20.83 [-37.11; -4.54] | 0.0164 | -1.58 [-2.84; -0.33] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 3 | 12.50 (11.02) | | 4 | 2 | 27.08 ( 2.95) | | | | | |
| Week 24 | 4 | 1 | 37.50 ( NA) | | 3 | 3 | 11.11 (15.77) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 16.67 ( NA) | 18.46 (13.01) | 3 | 2 | -10.42 (20.62) | -10.14 ( 9.31) | -28.60 [-64.93; 7.74] | 0.1100 | 0.00 [-2.40; 2.40] | 0.6359 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 25.00 (25.00) | | 14 | 12 | 21.88 (18.47) | | | | | |
| Week 24 | 5 | 4 | 34.38 (25.77) | | 14 | 12 | 17.71 (13.31) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 16.67 ( 7.22) | 19.63 ( 7.74) | 14 | 10 | 0.83 (13.44) | -0.17 ( 4.11) | -19.80 [-39.35; -0.25] | 0.0476 | -1.41 [-2.81; -0.01] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Hemo-TEM physical impact - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 12.50 (11.02) | | 9 | 7 | 23.81 (14.77) | | | | | |
| Week 24 | 4 | 1 | 37.50 ( NA) | | 8 | 7 | 11.31 (10.12) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 16.67 ( NA) | 17.93 (12.29) | 8 | 6 | -6.25 (14.13) | -7.08 ( 4.95) | -25.01 [-54.58; 4.57] | 0.0890 | -1.74 [-4.04; 0.57] | 0.3635 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 25.00 (25.00) | | 9 | 7 | 21.43 (20.33) | | | | | |
| Week 24 | 5 | 4 | 34.38 (25.77) | | 9 | 8 | 20.83 (15.11) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 16.67 ( 7.22) | 19.30 ( 7.32) | 9 | 6 | 4.17 (13.69) | 3.34 ( 4.95) | -15.96 [-35.79; 3.87] | 0.1031 | -1.16 [-2.64; 0.33] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.19 Change from baseline to week 24 in Hemo-TEM treatment burden - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 6 | 32.74 (35.89) | | 18 | 14 | 29.08 (23.39) | | | | | |
| Week 24 | 9 | 5 | 46.43 (29.12) | | 17 | 15 | 16.19 (21.38) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 0.89 (17.83) | 10.29 (10.28) | 17 | 12 | -9.23 (21.07) | -10.55 ( 5.37) | -20.85 [-46.61; 4.92] | 0.1034 | -1.04 [-2.22; 0.15] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 3 | 14.29 (14.29) | | 4 | 2 | 23.21 (17.68) | | | | | |
| Week 24 | 4 | 1 | 10.71 ( NA) | | 3 | 3 | 10.71 ( 6.19) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -17.86 ( NA) | -14.33 (18.23) | 3 | 2 | -8.93 (17.68) | -14.60 (12.94) | -0.27 [-50.81; 50.28] | 0.9908 | 0.00 [-2.40; 2.40] | 0.2962 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 51.19 (44.65) | | 14 | 12 | 30.06 (24.72) | | | | | |
| Week 24 | 5 | 4 | 55.36 (24.48) | | 14 | 12 | 17.56 (23.76) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 7.14 (15.57) | 20.03 (11.57) | 14 | 10 | -9.29 (22.54) | -9.95 ( 5.67) | -29.98 [-58.88; -1.07] | 0.0435 | -1.52 [-2.94; -0.10] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in Hemo-TEM treatment burden - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 14.29 (14.29) | | 9 | 7 | 22.45 (18.64) | | | | | |
| Week 24 | 4 | 1 | 10.71 ( NA) | | 8 | 7 | 4.59 ( 6.75) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -17.86 ( NA) | -14.51 (15.57) | 8 | 6 | -13.69 (16.81) | -20.06 ( 6.53) | -5.55 [-43.28; 32.18] | 0.7500 | -0.29 [-2.41; 1.83] | 0.0616 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 51.19 (44.65) | | 9 | 7 | 35.71 (27.12) | | | | | |
| Week 24 | 5 | 4 | 55.36 (24.48) | | 9 | 8 | 26.34 (24.96) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 7.14 (15.57) | 21.88 ( 9.92) | 9 | 6 | -4.76 (25.42) | -1.84 ( 6.34) | -23.72 [-49.44; 2.01] | 0.0670 | -1.32 [-2.83; 0.20] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.20 Change from baseline to week 24 in PROMIS Numeric Rating Scale v.1.0 Pain Intensity 1a - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N n | Mean (SD) | CSE (SE) | N n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] p-value interact. |
| All subjects (Total) | | | | | | | | | |
| total | | | | | | | | | |
| Baseline | 9 6 | 2.50 ( 1.05) | | 18 14 | 4.71 ( 2.27) | | | | |
| Week 24 | 9 5 | 2.80 ( 1.48) | | 17 15 | 2.80 ( 2.04) | | | | |
| Change from baseline to week 24 | 9 4 | 0.75 ( 0.96) | -1.07 ( 1.10) | 17 12 | -1.33 ( 2.19) | -1.07 ( 0.54) | 0.00 [ -2.63; 2.64] | 0.9992 | 0.00 [-0.96; 0.96] |
| Age | | | | | | | | | |
| < 18 years | | | | | | | | | |
| Baseline | 4 3 | 3.00 ( 1.00) | | 4 2 | 5.00 ( 2.83) | | | | |
| Week 24 | 4 1 | 5.00 ( NA) | | 3 3 | 1.67 ( 1.53) | | | | |
| Change from baseline to week 24 | 4 1 | 2.00 ( NA) | 0.45 ( 1.86) | 3 2 | -2.50 ( 2.12) | -1.60 ( 1.44) | -2.05 [ -7.07; 2.97] | 0.4084 | -0.52 [-2.34; 1.30] 0.8798 |
| >= 18 years | | | | | | | | | |
| Baseline | 5 3 | 2.00 ( 1.00) | | 14 12 | 4.67 ( 2.31) | | | | |
| Week 24 | 5 4 | 2.25 ( 0.96) | | 14 12 | 3.08 ( 2.11) | | | | |
| Change from baseline to week 24 | 5 3 | 0.33 ( 0.58) | -1.43 ( 1.38) | 14 10 | -1.10 ( 2.23) | -0.97 ( 0.61) | 0.46 [ -2.76; 3.68] | 0.7710 | 0.20 [-1.07; 1.47] |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in PROMIS Numeric Rating Scale v.1.0 Pain Intensity 1a - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 3.00 ( 1.00) | | 9 | 7 | 4.71 ( 2.69) | | | | | |
| Week 24 | 4 | 1 | 5.00 ( NA) | | 8 | 7 | 2.00 ( 1.53) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 2.00 ( NA) | 0.35 ( 1.65) | 8 | 6 | -2.17 ( 2.32) | -2.13 ( 0.73) | -2.48 [ -6.26; 1.29] | 0.1873 | -1.02 [-2.45; 0.40] | 0.0706 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 2.00 ( 1.00) | | 9 | 7 | 4.71 ( 1.98) | | | | | |
| Week 24 | 5 | 4 | 2.25 ( 0.96) | | 9 | 8 | 3.50 ( 2.27) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 0.33 ( 0.58) | -1.52 ( 1.27) | 9 | 6 | -0.50 ( 1.87) | -0.02 ( 0.73) | 1.50 [ -1.66; 4.66] | 0.3362 | 0.68 [-0.71; 2.06] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.21 Change from baseline to week 24 in PROMIS Short Form v2.0 Upper Extremity 7a - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) / CSE (SE) | N | n | Mean (SD) / CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | |
| total | | | | | | | | | | |
| Baseline | 9 | 3 | 54.55 ( 6.31) | 18 | 8 | 44.41 (10.87) | | | | |
| Week 24 | 9 | 2 | 46.53 ( 0.09) | 17 | 7 | 47.00 ( 8.90) | | | | |
| Change from baseline to week 24 | 9 | 1 | -11.72 ( NA) -5.85 ( 4.32) | 17 | 7 | 0.74 ( 3.72) 0.84 ( 1.77) | 6.69 [ -4.00; 17.38] | 0.1906 | 1.08 [-0.32; 2.49] | |
| Age | | | | | | | | | | |
| < 18 years | | | | | | | | | | |
| Baseline | 4 | 3 | 54.55 ( 6.31) | 4 | 2 | 44.19 ( 2.62) | | | | |
| Week 24 | 4 | 1 | 46.47 ( NA) | 3 | 2 | 42.85 ( 2.54) | | | | |
| Change from baseline to week 24 | 4 | 1 | -11.72 ( NA) -6.67 ( 4.66) | 3 | 2 | -1.34 ( 5.15) -2.21 ( 3.32) | 4.46 [-11.11; 20.03] | 0.4944 | 0.46 [-1.36; 2.27] | 0.6723 |
| >= 18 years | | | | | | | | | | |
| Baseline | | | | 14 | 6 | 44.48 (12.81) | | | | |
| Week 24 | 5 | 1 | 46.60 ( NA) | 14 | 5 | 48.66 (10.26) | | | | |
| Change from baseline to week 24 | 5 | 0 | NA ( NA) NE (NE) | 14 | 5 | 1.58 ( 3.33) 1.91 ( 2.07) | NE [NE; NE] | NE | NE [NE; NE] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in PROMIS Short Form v2.0 Upper Extremity 7a - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 3 | 54.55 ( 6.31) | | 9 | 7 | 42.44 (10.09) | | | | | |
| Week 24 | 4 | 1 | 46.47 ( NA) | | 8 | 6 | 45.13 ( 8.12) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -11.72 ( NA) | 0.09 ( 4.12) | 8 | 6 | 0.87 ( 4.06) | -0.01 ( 2.16) | -0.10 [-12.90; 12.69] | 0.9841 | -0.02 [-1.37; 1.34] | 0.0403 |
| OECD country | | | | | | | | | | | | |
| Baseline | | | | | 9 | 1 | 58.19 ( NA) | | | | | |
| Week 24 | 5 | 1 | 46.60 ( NA) | | 9 | 1 | 58.19 ( NA) | | | | | |
| Change from baseline to week 24 | 5 | 0 | NA ( NA) | NE (NE) | 9 | 1 | 0.00 ( NA) | 7.38 ( 6.21) | NE [NE; NE] | NE | NE [NE; NE] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.22 Change from baseline to week 24 in SF-36v2 general health - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 45.31 (12.20) | | 18 | 14 | 42.18 ( 9.43) | | | | | |
| Week 24 | 9 | 5 | 38.73 (11.92) | | 17 | 15 | 45.48 ( 9.44) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -2.14 ( 8.91) | 2.44 ( 3.07) | 17 | 12 | 2.22 ( 6.88) | 2.07 ( 1.85) | -0.37 [ -7.71; 6.97] | 0.9199 | -0.05 [-0.96; 0.86] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 52.35 ( 7.90) | | 4 | 2 | 38.44 ( 0.67) | | | | | |
| Week 24 | 4 | 1 | 46.05 ( NA) | | 3 | 3 | 48.43 ( 4.12) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -11.89 ( NA) | 2.35 ( 5.94) | 3 | 2 | 7.60 ( 0.67) | 5.86 ( 4.85) | 3.51 [-12.94; 19.96] | 0.6652 | 0.26 [-1.44; 1.96] | 0.6058 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 35.91 (11.01) | | 14 | 12 | 42.80 (10.10) | | | | | |
| Week 24 | 5 | 4 | 36.90 (12.93) | | 14 | 12 | 44.75 (10.36) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 1.11 ( 7.46) | 1.22 ( 4.14) | 14 | 10 | 1.14 ( 7.07) | 1.42 ( 2.01) | 0.20 [ -9.30; 9.69] | 0.9661 | 0.03 [-1.24; 1.29] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 general health - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 52.35 ( 7.90) | | 9 | 7 | 45.31 ( 8.98) | | | | | |
| Week 24 | 4 | 1 | 46.05 ( NA) | | 8 | 7 | 49.65 ( 9.74) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -11.89 ( NA) | 3.00 ( 5.95) | 8 | 6 | 2.69 ( 5.52) | 2.59 ( 2.71) | -0.41 [-13.45; 12.63] | 0.9492 | -0.04 [-1.27; 1.19] | 0.6047 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 35.91 (11.01) | | 9 | 7 | 39.06 ( 9.44) | | | | | |
| Week 24 | 5 | 4 | 36.90 (12.93) | | 9 | 8 | 41.83 ( 8.01) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 1.11 ( 7.46) | 1.12 ( 4.26) | 9 | 6 | 1.74 ( 8.54) | 1.22 ( 2.74) | 0.10 [-10.00; 10.20] | 0.9842 | 0.01 [-1.34; 1.36] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.23 Change from baseline to week 24 in SF-36v2 mental health - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 50.12 (14.06) | | 18 | 14 | 48.07 ( 9.32) | | | | | |
| Week 24 | 9 | 5 | 44.59 (15.21) | | 17 | 15 | 48.25 (11.27) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 0.00 ( 7.08) | -0.37 ( 4.10) | 17 | 12 | 0.65 (12.43) | 1.48 ( 2.52) | 1.86 [ -7.99; 11.70] | 0.7038 | 0.18 [-0.73; 1.09] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 52.18 (11.00) | | 4 | 2 | 53.48 ( 3.70) | | | | | |
| Week 24 | 4 | 1 | 48.25 ( NA) | | 3 | 3 | 51.74 ( 9.19) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 10.46 ( NA) | 6.02 ( 7.07) | 3 | 2 | -6.54 ( 9.25) | -4.55 ( 6.41) | -10.56 [-30.27; 9.14] | 0.2810 | -0.65 [-2.38; 1.09] | 0.5690 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 47.38 (19.81) | | 14 | 12 | 47.16 ( 9.75) | | | | | |
| Week 24 | 5 | 4 | 43.67 (17.40) | | 14 | 12 | 47.38 (11.93) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -3.49 ( 1.51) | -4.20 ( 5.35) | 14 | 10 | 2.09 (12.86) | 2.53 ( 2.70) | 6.73 [ -5.58; 19.04] | 0.2718 | 0.68 [-0.61; 1.97] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 mental health - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 52.18 (11.00) | | 9 | 7 | 50.50 ( 9.12) | | | | | |
| Week 24 | 4 | 1 | 48.25 ( NA) | | 8 | 7 | 53.86 ( 7.46) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 10.46 ( NA) | 6.54 ( 7.25) | 8 | 6 | 0.00 (12.60) | 3.08 ( 3.72) | -3.46 [-20.39; 13.48] | 0.6786 | -0.27 [-1.51; 0.96] | 0.7759 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 47.38 (19.81) | | 9 | 7 | 45.64 ( 9.55) | | | | | |
| Week 24 | 5 | 4 | 43.67 (17.40) | | 9 | 8 | 43.35 (12.14) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -3.49 ( 1.51) | -4.32 ( 5.62) | 9 | 6 | 1.31 (13.42) | -0.02 ( 3.78) | 4.30 [ -9.79; 18.39] | 0.5362 | 0.39 [-0.97; 1.75] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.24 Change from baseline to week 24 in SF-36v2 role emotional - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 49.21 (11.37) | | 18 | 14 | 44.48 ( 8.70) | | | | | |
| Week 24 | 9 | 5 | 41.55 (16.03) | | 17 | 15 | 52.22 ( 6.16) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -2.61 ( 3.33) | -3.91 ( 3.45) | 17 | 12 | 6.96 ( 8.66) | 7.30 ( 1.93) | 11.21 [ 3.02; 19.40] | 0.0087 | 1.37 [ 0.37; 2.36] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 51.82 ( 4.38) | | 4 | 2 | 42.24 ( 4.92) | | | | | |
| Week 24 | 4 | 1 | 42.24 ( NA) | | 3 | 3 | 48.04 ( 8.76) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -3.48 ( NA) | -3.07 ( 6.40) | 3 | 2 | 1.74 ( 2.46) | 2.48 ( 4.98) | 5.55 [-11.43; 22.53] | 0.5082 | 0.38 [-1.33; 2.09] | 0.4235 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 45.72 (18.09) | | 14 | 12 | 44.85 ( 9.29) | | | | | |
| Week 24 | 5 | 4 | 41.37 (18.51) | | 14 | 12 | 53.27 ( 5.32) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -2.32 ( 4.02) | -4.49 ( 4.09) | 14 | 10 | 8.01 ( 9.15) | 8.17 ( 2.10) | 12.66 [ 3.18; 22.15] | 0.0108 | 1.64 [ 0.25; 3.04] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 role emotional - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 51.82 ( 4.38) | | 9 | 7 | 44.73 ( 8.93) | | | | | |
| Week 24 | 4 | 1 | 42.24 ( NA) | | 8 | 7 | 52.69 ( 6.67) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -3.48 ( NA) | -3.55 ( 6.36) | 8 | 6 | 5.80 ( 8.43) | 6.70 ( 2.70) | 10.26 [ -3.98; 24.49] | 0.1510 | 1.00 [-0.30; 2.30] | 0.3755 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 45.72 (18.09) | | 9 | 7 | 44.23 ( 9.18) | | | | | |
| Week 24 | 5 | 4 | 41.37 (18.51) | | 9 | 8 | 51.82 ( 6.10) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -2.32 ( 4.02) | -4.83 ( 4.04) | 9 | 6 | 8.12 ( 9.51) | 7.89 ( 2.73) | 12.72 [ 2.54; 22.89] | 0.0162 | 1.60 [ 0.08; 3.12] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.25 Change from baseline to week 24 in SF-36v2 role physical - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 42.08 (11.79) | | 18 | 14 | 41.28 ( 8.14) | | | | | |
| Week 24 | 9 | 5 | 36.95 ( 8.98) | | 17 | 15 | 49.67 ( 7.81) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 1.12 ( 3.88) | -2.24 ( 3.31) | 17 | 12 | 7.67 ( 8.69) | 8.03 ( 1.82) | 10.27 [ 2.54; 18.00] | 0.0107 | 1.32 [ 0.33; 2.31] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 49.30 ( 5.65) | | 4 | 2 | 30.21 ( 6.35) | | | | | |
| Week 24 | 4 | 1 | 41.44 ( NA) | | 3 | 3 | 47.43 ( 9.08) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -2.24 ( NA) | -2.32 ( 6.37) | 3 | 2 | 12.35 ( 1.58) | 7.26 ( 5.94) | 9.58 [ -9.44; 28.60] | 0.3106 | 0.65 [-1.09; 2.39] | 0.9090 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 32.46 (11.23) | | 14 | 12 | 43.12 ( 6.98) | | | | | |
| Week 24 | 5 | 4 | 35.82 ( 9.96) | | 14 | 12 | 50.23 ( 7.81) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 2.24 ( 3.89) | -2.86 ( 4.40) | 14 | 10 | 6.74 ( 9.29) | 8.17 ( 2.16) | 11.03 [ 0.54; 21.53] | 0.0401 | 1.39 [ 0.03; 2.75] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 role physical - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 49.30 ( 5.65) | | 9 | 7 | 40.15 ( 9.06) | | | | | |
| Week 24 | 4 | 1 | 41.44 ( NA) | | 8 | 7 | 50.10 ( 8.45) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -2.24 ( NA) | -2.78 ( 6.12) | 8 | 6 | 8.61 ( 9.14) | 8.52 ( 2.66) | 11.30 [ -2.52; 25.12] | 0.1050 | 1.13 [-0.18; 2.45] | 0.6078 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 32.46 (11.23) | | 9 | 7 | 42.40 ( 7.65) | | | | | |
| Week 24 | 5 | 4 | 35.82 ( 9.96) | | 9 | 8 | 49.30 ( 7.78) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 2.24 ( 3.89) | -2.70 ( 4.23) | 9 | 6 | 6.74 ( 8.98) | 7.54 ( 2.65) | 10.24 [ -0.21; 20.68] | 0.0545 | 1.30 [-0.16; 2.77] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.26 Change from baseline to week 24 in SF-36v2 social function - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 47.31 (13.26) | | 18 | 14 | 43.37 (10.06) | | | | | |
| Week 24 | 9 | 5 | 43.30 (15.61) | | 17 | 15 | 50.66 ( 8.40) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -1.25 ( 2.51) | 0.18 ( 3.81) | 17 | 12 | 6.27 (11.73) | 5.45 ( 2.16) | 5.27 [ -3.83; 14.36] | 0.2475 | 0.58 [-0.35; 1.50] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 48.57 ( 8.56) | | 4 | 2 | 39.79 (10.63) | | | | | |
| Week 24 | 4 | 1 | 47.31 ( NA) | | 3 | 3 | 50.66 ( 7.66) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -5.02 ( NA) | -3.51 ( 6.82) | 3 | 2 | 7.52 ( 3.54) | 4.82 ( 5.69) | 8.32 [-10.46; 27.11] | 0.3712 | 0.53 [-1.19; 2.26] | 0.3382 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 45.64 (20.26) | | 14 | 12 | 43.97 (10.33) | | | | | |
| Week 24 | 5 | 4 | 42.30 (17.84) | | 14 | 12 | 50.66 ( 8.90) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 0.00 ( 0.00) | 0.82 ( 4.69) | 14 | 10 | 6.02 (12.90) | 5.58 ( 2.37) | 4.76 [ -6.04; 15.57] | 0.3737 | 0.55 [-0.73; 1.83] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 social function - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 48.57 ( 8.56) | | 9 | 7 | 40.87 (11.47) | | | | | |
| Week 24 | 4 | 1 | 47.31 ( NA) | | 8 | 7 | 53.04 ( 5.36) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -5.02 ( NA) | -3.51 ( 6.67) | 8 | 6 | 10.86 (12.04) | 9.33 ( 3.10) | 12.84 [ -2.54; 28.23] | 0.0982 | 1.15 [-0.17; 2.47] | 0.2110 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 45.64 (20.26) | | 9 | 7 | 45.88 ( 8.54) | | | | | |
| Week 24 | 5 | 4 | 42.30 (17.84) | | 9 | 8 | 48.57 (10.29) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 0.00 ( 0.00) | 0.65 ( 4.61) | 9 | 6 | 1.67 (10.35) | 1.79 ( 3.02) | 1.13 [-10.22; 12.49] | 0.8391 | 0.13 [-1.23; 1.48] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.27 Change from baseline to week 24 in SF-36v2 vitality - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 53.02 (12.88) | | 18 | 14 | 47.72 ( 7.78) | | | | | |
| Week 24 | 9 | 5 | 47.25 (14.61) | | 17 | 15 | 50.62 (10.33) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -2.97 ( 2.42) | 0.06 ( 4.00) | 17 | 12 | 3.96 (11.70) | 3.54 ( 2.45) | 3.48 [ -6.24; 13.19] | 0.4721 | 0.35 [-0.57; 1.26] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 54.83 ( 3.74) | | 4 | 2 | 52.60 ( 8.40) | | | | | |
| Week 24 | 4 | 1 | 49.63 ( NA) | | 3 | 3 | 51.61 ( 8.57) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 0.00 ( NA) | 5.27 ( 6.27) | 3 | 2 | -5.94 ( 8.40) | -4.90 ( 6.09) | -10.17 [-28.01; 7.68] | 0.2525 | -0.70 [-2.44; 1.05] | 0.0489 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 50.62 (21.49) | | 14 | 12 | 46.91 ( 7.75) | | | | | |
| Week 24 | 5 | 4 | 46.66 (16.81) | | 14 | 12 | 50.37 (11.05) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -3.96 ( 1.71) | -3.80 ( 5.10) | 14 | 10 | 5.94 (11.55) | 5.15 ( 2.59) | 8.96 [ -2.86; 20.77] | 0.1314 | 0.94 [-0.37; 2.25] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 vitality - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 54.83 ( 3.74) | | 9 | 7 | 50.05 ( 9.62) | | | | | |
| Week 24 | 4 | 1 | 49.63 ( NA) | | 8 | 7 | 55.57 ( 7.67) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 0.00 ( NA) | 5.49 ( 6.44) | 8 | 6 | 3.96 (12.97) | 3.90 ( 3.33) | -1.59 [-16.48; 13.30] | 0.8285 | -0.14 [-1.37; 1.09] | 0.1406 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 50.62 (21.49) | | 9 | 7 | 45.39 ( 5.11) | | | | | |
| Week 24 | 5 | 4 | 46.66 (16.81) | | 9 | 8 | 46.29 (10.82) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -3.96 ( 1.71) | -4.03 ( 5.12) | 9 | 6 | 3.96 (11.53) | 3.14 ( 3.47) | 7.17 [ -5.76; 20.10] | 0.2655 | 0.71 [-0.68; 2.10] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.28 Change from baseline to week 24 in SF-36v2 mental component score - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 53.27 (15.31) | | 18 | 14 | 47.77 ( 9.75) | | | | | |
| Week 24 | 9 | 5 | 46.50 (18.86) | | 17 | 15 | 51.63 ( 9.83) | | | | | |
| Change from baseline to week 24 | 9 | 4 | -2.63 ( 3.74) | -1.95 ( 3.76) | 17 | 12 | 4.08 (11.21) | 4.45 ( 2.29) | 6.40 [ -2.71; 15.51] | 0.1625 | 0.68 [-0.25; 1.61] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 53.31 ( 8.15) | | 4 | 2 | 50.85 ( 1.94) | | | | | |
| Week 24 | 4 | 1 | 45.94 ( NA) | | 3 | 3 | 50.45 ( 9.22) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 2.63 ( NA) | 1.88 ( 5.82) | 3 | 2 | -5.13 ( 4.03) | -3.97 ( 5.64) | -5.84 [-22.46; 10.78] | 0.4769 | -0.43 [-2.15; 1.28] | 0.0622 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 53.22 (24.56) | | 14 | 12 | 47.26 (10.48) | | | | | |
| Week 24 | 5 | 4 | 46.64 (21.77) | | 14 | 12 | 51.92 (10.35) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -4.38 ( 1.58) | -4.68 ( 4.84) | 14 | 10 | 5.92 (11.36) | 6.02 ( 2.38) | 10.70 [ -0.50; 21.89] | 0.0604 | 1.22 [-0.12; 2.56] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 mental component score - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 53.31 ( 8.15) | | 9 | 7 | 49.20 ( 9.49) | | | | | |
| Week 24 | 4 | 1 | 45.94 ( NA) | | 8 | 7 | 55.56 ( 7.61) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 2.63 ( NA) | 2.36 ( 5.99) | 8 | 6 | 3.54 (10.40) | 5.10 ( 3.20) | 2.75 [-11.23; 16.72] | 0.6900 | 0.26 [-0.98; 1.49] | 0.1177 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 53.22 (24.56) | | 9 | 7 | 46.35 (10.53) | | | | | |
| Week 24 | 5 | 4 | 46.64 (21.77) | | 9 | 8 | 48.19 (10.72) | | | | | |
| Change from baseline to week 24 | 5 | 3 | -4.38 ( 1.58) | -4.99 ( 5.05) | 9 | 6 | 4.62 (12.94) | 3.98 ( 3.28) | 8.97 [ -3.72; 21.67] | 0.1584 | 0.93 [-0.48; 2.35] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.29 Change from baseline to week 24 in SF-36v2 physical component score - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 40.68 ( 9.89) | | 18 | 14 | 41.19 ( 7.31) | | | | | |
| Week 24 | 9 | 5 | 37.65 ( 6.77) | | 17 | 15 | 46.40 ( 8.61) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 0.81 ( 5.12) | 0.70 ( 2.44) | 17 | 12 | 4.08 ( 7.12) | 4.11 ( 1.40) | 3.41 [ -2.37; 9.19] | 0.2394 | 0.58 [-0.34; 1.50] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 47.83 ( 3.91) | | 4 | 2 | 35.98 ( 7.02) | | | | | |
| Week 24 | 4 | 1 | 46.54 ( NA) | | 3 | 3 | 49.79 ( 4.84) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -6.42 ( NA) | -0.95 ( 5.02) | 3 | 2 | 11.06 ( 5.75) | 9.12 ( 3.72) | 10.07 [ -3.72; 23.87] | 0.1457 | 0.89 [-0.88; 2.66] | 0.6349 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 31.15 ( 5.67) | | 14 | 12 | 42.06 ( 7.27) | | | | | |
| Week 24 | 5 | 4 | 35.42 ( 5.30) | | 14 | 12 | 45.55 ( 9.28) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 3.22 ( 2.12) | 0.69 ( 3.46) | 14 | 10 | 2.68 ( 6.73) | 3.17 ( 1.55) | 2.48 [ -5.61; 10.57] | 0.5352 | 0.43 [-0.85; 1.70] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 physical component score - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 47.83 ( 3.91) | | 9 | 7 | 40.79 ( 7.56) | | | | | |
| Week 24 | 4 | 1 | 46.54 ( NA) | | 8 | 7 | 48.44 ( 9.15) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -6.42 ( NA) | -1.09 ( 4.75) | 8 | 6 | 7.11 ( 8.59) | 6.59 ( 1.98) | 7.68 [ -3.03; 18.39] | 0.1528 | 1.01 [-0.29; 2.31] | 0.3168 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 31.15 ( 5.67) | | 9 | 7 | 41.60 ( 7.63) | | | | | |
| Week 24 | 5 | 4 | 35.42 ( 5.30) | | 9 | 8 | 44.61 ( 8.28) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 3.22 ( 2.12) | 0.70 ( 3.46) | 9 | 6 | 1.05 ( 3.97) | 1.44 ( 2.00) | 0.74 [ -7.76; 9.24] | 0.8593 | 0.12 [-1.23; 1.48] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.30 Change from baseline to week 24 in SF-36v2 bodily pain - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | Concizumab PPX (arm 2) | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | |
|---|---|---|---|---|---|---|---|---|---|
| | N n | Mean (SD) | CSE (SE) | N n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] p-value interact. |
| All subjects (Total) | | | | | | | | | |
| total | | | | | | | | | |
| Baseline | 9 7 | 43.11 ( 6.75) | | 18 14 | 41.61 ( 8.08) | | | | |
| Week 24 | 9 5 | 40.06 ( 6.63) | | 17 15 | 47.59 (10.57) | | | | |
| Change from baseline to week 24 | 9 4 | -0.91 ( 7.62) | 0.26 ( 4.03) | 17 12 | 4.30 ( 9.33) | 4.53 ( 2.33) | 4.28 [ -5.29; 13.84] | 0.3701 | 0.44 [-0.48; 1.36] |
| Age | | | | | | | | | |
| < 18 years | | | | | | | | | |
| Baseline | 4 4 | 45.67 ( 7.44) | | 4 2 | 40.62 ( 2.85) | | | | |
| Week 24 | 4 1 | 38.21 ( NA) | | 3 3 | 51.79 ( 8.85) | | | | |
| Change from baseline to week 24 | 4 1 | -8.47 ( NA) | -6.70 ( 7.70) | 3 2 | 6.06 ( 2.85) | 5.53 ( 6.22) | 12.23 [ -8.67; 33.12] | 0.2403 | 0.70 [-1.05; 2.44] 0.7603 |
| >= 18 years | | | | | | | | | |
| Baseline | 5 3 | 39.69 ( 4.77) | | 14 12 | 41.77 ( 8.73) | | | | |
| Week 24 | 5 4 | 40.53 ( 7.56) | | 14 12 | 46.54 (11.04) | | | | |
| Change from baseline to week 24 | 5 3 | 1.61 ( 6.99) | 0.86 ( 5.13) | 14 10 | 3.95 (10.23) | 4.35 ( 2.61) | 3.49 [ -8.31; 15.29] | 0.5491 | 0.36 [-0.91; 1.64] |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 bodily pain - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 45.67 ( 7.44) | | 9 | 7 | 41.78 ( 9.22) | | | | | |
| Week 24 | 4 | 1 | 38.21 ( NA) | | 8 | 7 | 53.30 ( 9.55) | | | | | |
| Change from baseline to week 24 | 4 | 1 | -8.47 ( NA) | -6.23 ( 7.16) | 8 | 6 | 9.48 (10.47) | 10.68 ( 3.19) | 16.90 [ 0.73; 33.07] | 0.0411 | 1.44 [ 0.07; 2.80] | 0.1902 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 39.69 ( 4.77) | | 9 | 7 | 41.43 ( 7.51) | | | | | |
| Week 24 | 5 | 4 | 40.53 ( 7.56) | | 9 | 8 | 42.59 ( 9.16) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 1.61 ( 6.99) | 0.94 ( 4.81) | 9 | 6 | -0.87 ( 4.18) | -1.60 ( 3.20) | -2.53 [-14.46; 9.40] | 0.6665 | -0.27 [-1.63; 1.09] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

## 1.3.1.31 Change from baseline to week 24 in SF-36v2 physical functioning - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| All subjects (Total) | | | | | | | | | | | | |
| total | | | | | | | | | | | | |
| Baseline | 9 | 7 | 41.96 (11.29) | | 18 | 14 | 43.87 ( 7.87) | | | | | |
| Week 24 | 9 | 5 | 39.17 (13.57) | | 17 | 15 | 46.31 ( 8.15) | | | | | |
| Change from baseline to week 24 | 9 | 4 | 1.91 ( 2.21) | 1.16 ( 2.28) | 17 | 12 | 2.07 ( 7.89) | 1.83 ( 1.36) | 0.67 [ -4.78; 6.12] | 0.8042 | 0.12 [-0.79; 1.03] | |
| Age | | | | | | | | | | | | |
| < 18 years | | | | | | | | | | | | |
| Baseline | 4 | 4 | 48.93 ( 3.66) | | 4 | 2 | 45.10 ( 9.48) | | | | | |
| Week 24 | 4 | 1 | 55.63 ( NA) | | 3 | 3 | 51.16 ( 4.42) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 3.83 ( NA) | 6.55 ( 4.04) | 3 | 2 | 4.79 ( 4.07) | 5.36 ( 3.48) | -1.19 [-12.09; 9.71] | 0.8240 | -0.13 [-1.83; 1.57] | 0.6037 |
| >= 18 years | | | | | | | | | | | | |
| Baseline | 5 | 3 | 32.66 (11.64) | | 14 | 12 | 43.66 ( 8.04) | | | | | |
| Week 24 | 5 | 4 | 35.05 (11.52) | | 14 | 12 | 45.10 ( 8.54) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 1.27 ( 2.21) | -2.83 ( 3.25) | 14 | 10 | 1.53 ( 8.50) | 1.31 ( 1.47) | 4.14 [ -3.24; 11.52] | 0.2601 | 0.75 [-0.54; 2.05] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

Change from baseline to week 24 in SF-36v2 physical functioning - Explorer 8 - HA - OTexBR - Full analysis set

| | No PPX (arm 1) | | | | Concizumab PPX (arm 2) | | | | Concizumab PPX (arm 2) vs. No PPX (arm 1) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | N | n | Mean (SD) | CSE (SE) | N | n | Mean (SD) | CSE (SE) | DE [95% CI] | p-value | Hedges' g [95% CI] | p-value interact. |
| Region | | | | | | | | | | | | |
| Non-OECD country | | | | | | | | | | | | |
| Baseline | 4 | 4 | 48.93 ( 3.66) | | 9 | 7 | 43.05 ( 8.76) | | | | | |
| Week 24 | 4 | 1 | 55.63 ( NA) | | 8 | 7 | 46.88 ( 7.23) | | | | | |
| Change from baseline to week 24 | 4 | 1 | 3.83 ( NA) | 6.37 ( 4.06) | 8 | 6 | 3.51 ( 9.17) | 2.24 ( 1.96) | -4.13 [-13.47; 5.21] | 0.3720 | -0.60 [-1.85; 0.66] | 0.5946 |
| OECD country | | | | | | | | | | | | |
| Baseline | 5 | 3 | 32.66 (11.64) | | 9 | 7 | 44.69 ( 7.47) | | | | | |
| Week 24 | 5 | 4 | 35.05 (11.52) | | 9 | 8 | 45.82 ( 9.35) | | | | | |
| Change from baseline to week 24 | 5 | 3 | 1.27 ( 2.21) | -2.55 ( 3.35) | 9 | 6 | 0.64 ( 6.92) | 1.44 ( 1.99) | 3.98 [ -4.30; 12.26] | 0.3323 | 0.67 [-0.72; 2.05] | |

HA: Haemophilia A, OTexBR: On-treatment excluding data before restart, PPX: Prophylaxis, NA: not applicable, NE: not estimable, N: number of subjects in the analysis set, n: number of subjects contributing to analysis, SD: Standard deviation, SE: Standard error, CI: confidence interval,p-value: unadjusted two-sided p-value for test of no difference from X (t-test), p-value int.: unadjusted two-sided p-value for test of no treatment by subgroup interaction (F-test), CSE: Change score estimate, DE: Difference estimate. Change from baseline values have been analysed using a mixed model for repeated measurements (MMRM), with treatment and bleeding frequency prior to screening as factors, and baseline value as a covariate, all nested within week (week 4, 8, 16 and 24). For subgroup analyses the subgroup variable is added as a factor, in addition to the interaction with treatment. A compound symmetry covariance matrix is used to describe the variability for the repeated measurements for a subject. Baseline is visit 2/2a for no PPX (arm 1) and visit 2a for concizumab PPX (arms 2). Only patients with available data for week 24 were included. Cut off date for data is 12th July 2022.

# Table of contents

**Page**

# Statistical documentation

## 1.4.1.1 Any adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 7 (38.9) | 9 | 3 (33.3) | 1.27 (0.24, 6.82) | 1.17 (0.39, 3.47) | 5.56 (-32.60, 43.71) | 0.8653 |
| Age group | | | | | | | | |
| < 18 years | 4 | 1 (25.0) | 4 | 1 (25.0) | | | | |
| >= 18 years | 14 | 6 (42.9) | 5 | 2 (40.0) | | | | |
| OECD membership | | | | | | | | |
| OECD country | 9 | 5 (55.6) | 5 | 2 (40.0) | | | | |
| Non-OECD country | 9 | 2 (22.2) | 4 | 1 (25.0) | | | | |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:06 - chef-safety-output.R/AnyAE_HA_24saf_e8.txt

## 1.4.1.2 Severe adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:09 - chef-safety-output.R/SevAE_HA_24saf_e8.txt

### 1.4.1.3 Moderate adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 0 ( 0.0) | 1.63 (0.06, 44.01) | 1.58 (0.07, 35.32) | 5.56 (-5.03, 16.14) | 0.5904 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:11 - chef-safety-output.R/ModAE_HA_24saf_e8.txt

### 1.4.1.4 Mild adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 6 (33.3) | 9 | 3 (33.3) | 1.00 (0.18, 5.46) | 1.00 (0.32, 3.10) | 0.00 (-37.72, 37.72) | 1.0000 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:13 - chef-safety-output.R/MilAE_HA_24saf_e8.txt

### 1.4.1.5 Serious adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:16 - chef-safety-output.R/SerAE_HA_24saf_e8.txt

### 1.4.1.6 Adverse events leading to premature treatment discontinuation - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:18 - chef-safety-output.R/DisAE_HA_24saf_e8.txt

### 1.4.1.7 Any adverse events of special interest - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:20 - chef-safety-output.R/AnyAESI_HA_24saf_e8.txt

### 1.4.1.8 Overall Mortality - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:22 - chef-safety-output.R/MORT_HA_24saf_e8.txt

### 1.4.1.9 Any adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 9 (50.0) | 9 | 3 (33.3) | 2.00 (0.38, 10.58) | 1.50 (0.53, 4.21) | 16.67 (-21.83, 55.16) | 0.4816 |
| Age group | | | | | | | | |
| < 18 years | 4 | 2 (50.0) | 4 | 1 (25.0) | | | | |
| >= 18 years | 14 | 7 (50.0) | 5 | 2 (40.0) | | | | |
| OECD membership | | | | | | | | |
| OECD country | 9 | 6 (66.7) | 5 | 2 (40.0) | | | | |
| Non-OECD country | 9 | 3 (33.3) | 4 | 1 (25.0) | | | | |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:24 - chef-safety-output.R/AnyAE_HA_saf_e8.txt

### 1.4.1.10 Severe adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:27 - chef-safety-output.R/SevAE_HA_saf_e8.txt

## 1.4.1.11 Moderate adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 0 ( 0.0) | 1.63 (0.06, 44.01) | 1.58 (0.07, 35.32) | 5.56 (-5.03, 16.14) | 0.5904 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

### 1.4.1.12 Mild adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| All subjects (total) | 18 | 8 (44.4) | 9 | 3 (33.3) | 1.60 (0.30, 8.49) | 1.33 (0.46, 3.84) | 11.11 (-27.30, 49.52) | 0.6506 |
| Age group | | | | | | | | |
| < 18 years | 4 | 1 (25.0) | 4 | 1 (25.0) | | | | |
| >= 18 years | 14 | 7 (50.0) | 5 | 2 (40.0) | | | | |
| OECD membership | | | | | | | | |
| OECD country | 9 | 6 (66.7) | 5 | 2 (40.0) | | | | |
| Non-OECD country | 9 | 2 (22.2) | 4 | 1 (25.0) | | | | |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:31 - chef-safety-output.R/MilAE_HA_saf_e8.txt

### 1.4.1.13 Serious adverse events - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:34 - chef-safety-output.R/SerAE_HA_saf_e8.txt

### 1.4.1.14 Adverse events leading to premature treatment discontinuation - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:36 - chef-safety-output.R/DisAE_HA_saf_e8.txt

### 1.4.1.15 Any adverse events of special interest - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:38 - chef-safety-output.R/AnyAESI_HA_saf_e8.txt

### 1.4.1.16 Overall Mortality - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:40 - chef-safety-output.R/MORT_HA_saf_e8.txt

# Table of contents

**Page**

# Statistical documentation

## 1.4.2.1 Any adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Upper respiratory tract infection | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 1 (11.1) | 1.00 (0.08, 12.76) | 1.00 (0.10, 9.61) | 0.00 (-25.15, 25.15) | 1.0000 |
| Hypoaesthesia | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Acne | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Hypertension | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Rhinitis | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

## 1.4.2.2 Any adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Infections and infestations | | | | | | | | |
| All subjects (total) | 18 | 3 (16.7) | 9 | 1 (11.1) | 1.60 (0.14, 18.00) | 1.50 (0.18, 12.46) | 5.56 (-21.24, 32.35) | 0.7861 |
| Gastrointestinal disorders | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 0 ( 0.0) | 2.88 (0.12, 66.48) | 2.63 (0.14, 49.69) | 11.11 (-3.41, 25.63) | 0.3922 |
| Nervous system disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Skin and subcutaneous tissue disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Vascular disorders | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

### 1.4.2.3 Severe adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:55 - chef-safety-output.R/SevAEPT_HA_24saf_e8.txt

### 1.4.2.4 Severe adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:57 - chef-safety-output.R/SevAESOC_HA_24saf_e8.txt

### 1.4.2.5 Moderate adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:35:59 - chef-safety-output.R/ModAEPT_HA_24saf_e8.txt

### 1.4.2.6 Moderate adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

## 1.4.2.7 Mild adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Upper respiratory tract infection | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 1 (11.1) | 1.00 (0.08, 12.76) | 1.00 (0.10, 9.61) | 0.00 (-25.15, 25.15) | 1.0000 |
| Hypoaesthesia | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Acne | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Hypertension | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Rhinitis | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

## 1.4.2.8 Mild adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Infections and infestations | | | | | | | | |
| All subjects (total) | 18 | 3 (16.7) | 9 | 1 (11.1) | 1.60 (0.14, 18.00) | 1.50 (0.18, 12.46) | 5.56 (-21.24, 32.35) | 0.7861 |
| Gastrointestinal disorders | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 0 ( 0.0) | 2.88 (0.12, 66.48) | 2.63 (0.14, 49.69) | 11.11 (-3.41, 25.63) | 0.3922 |
| Nervous system disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Skin and subcutaneous tissue disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Vascular disorders | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

### 1.4.2.9 Serious adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:08 - chef-safety-output.R/SerAEPT_HA_24saf_e8.txt

### 1.4.2.10 Serious adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:10 - chef-safety-output.R/SerAESOC_HA_24saf_e8.txt

### 1.4.2.11 Adverse events leading to premature treatment discontinuation by preferred term- Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:12 - chef-safety-output.R/DisAEPT_HA_24saf_e8.txt

### 1.4.2.12 Adverse events leading to premature treatment discontinuation by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 24 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

## 1.4.2.13 Any adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Upper respiratory tract infection | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 1 (11.1) | 1.00 (0.08, 12.76) | 1.00 (0.10, 9.61) | 0.00 (-25.15, 25.15) | 1.0000 |
| Hypoaesthesia | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Acne | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Hypertension | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Rhinitis | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

## 1.4.2.14 Any adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Infections and infestations | | | | | | | | |
| All subjects (total) | 18 | 5 (27.8) | 9 | 1 (11.1) | 3.08 (0.30, 31.33) | 2.50 (0.34, 18.33) | 16.67 (-12.48, 45.82) | 0.4011 |
| Gastrointestinal disorders | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 0 ( 0.0) | 2.88 (0.12, 66.48) | 2.63 (0.14, 49.69) | 11.11 (-3.41, 25.63) | 0.3922 |
| Nervous system disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Skin and subcutaneous tissue disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Vascular disorders | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

### 1.4.2.15 Severe adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:21 - chef-safety-output.R/SevAEPT_HA_saf_e8.txt

### 1.4.2.16 Severe adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:23 - chef-safety-output.R/SevAESOC_HA_saf_e8.txt

### 1.4.2.17 Moderate adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:26 - chef-safety-output.R/ModAEPT_HA_saf_e8.txt

### 1.4.2.18 Moderate adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

```
There is no data for this output
```

## 1.4.2.19 Mild adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Upper respiratory tract infection | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 1 (11.1) | 1.00 (0.08, 12.76) | 1.00 (0.10, 9.61) | 0.00 (-25.15, 25.15) | 1.0000 |
| Hypoaesthesia | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Acne | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Hypertension | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |
| Rhinitis | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

## 1.4.2.20 Mild adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

| | Concizumab PPX | | No PPX | | Concizumab PPX vs. No PPX | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) | N | n (%) | OR (95% CI) | RR (95% CI) | RD (95% CI) | p-value |
| Infections and infestations | | | | | | | | |
| All subjects (total) | 18 | 5 (27.8) | 9 | 1 (11.1) | 3.08 (0.30, 31.33) | 2.50 (0.34, 18.33) | 16.67 (-12.48, 45.82) | 0.4011 |
| Gastrointestinal disorders | | | | | | | | |
| All subjects (total) | 18 | 2 (11.1) | 9 | 0 ( 0.0) | 2.88 (0.12, 66.48) | 2.63 (0.14, 49.69) | 11.11 (-3.41, 25.63) | 0.3922 |
| Nervous system disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Skin and subcutaneous tissue disorders | | | | | | | | |
| All subjects (total) | 18 | 1 ( 5.6) | 9 | 1 (11.1) | 0.47 (0.03, 8.52) | 0.50 (0.04, 7.10) | -5.56 (-28.65, 17.54) | 0.7334 |
| Vascular disorders | | | | | | | | |
| All subjects (total) | 18 | 0 ( 0.0) | 9 | 1 (11.1) | 0.15 (0.01, 4.16) | 0.18 (0.01, 3.92) | -11.11 (-31.64, 9.42) | 0.1620 |

HA: Haemophilia A, PPX: Prophylaxis, N: number of subjects, n: number of subjects with at least one event, OR: Odds Ratio, RR: Relative Risk, RD: Risk Difference, CI: Confidence Interval. The relative risk, odds ratio, risk difference estimates and confidence limits were derived based on a non-parametric analysis (2x2 contingency tables) of the binary response (had an event in the in-trial observation period or not). To calculate odds ratios and relative risks in the event of zero cells, the correction value of 0.5 was added to each cell frequency of the corresponding fourfold table. P-values (two-sided) are based on Barnard's unconditional exact test if the minimum of the four cell counts in the 2x2 contingency table is <= 5 or the sum of the four cell counts is <= 200. Otherwise, Fisher's exact test is applied (*: Barnard's unconditional exact test, **: Fisher's exact test). P-value (two-sided) for the interaction of subgroups is calculated using the Q-test for homogeneity across 2x2xk contingency tables for k levels of each subgroup. Cut off date for data is 12th July 2022.

### 1.4.2.21 Serious adverse events by preferred term - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:35 - chef-safety-output.R/SerAEPT_HA_saf_e8.txt

### 1.4.2.22 Serious adverse events by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:37 - chef-safety-output.R/SerAESOC_HA_saf_e8.txt

### 1.4.2.23 Adverse events leading to premature treatment discontinuation by preferred term- Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:39 - chef-safety-output.R/DisAEPT_HA_saf_e8.txt

### 1.4.2.24 Adverse events leading to premature treatment discontinuation by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:41 - chef-safety-output.R/DisAESOC_HA_saf_e8.txt

### 1.4.2.25 Any adverse events of special interest by preferred term- Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:43 - chef-safety-output.R/AnyAESIPT_HA_saf_e8.txt

### 1.4.2.26 Any adverse events of special interest by system organ class - Explorer 8 - HA - on-treatment excluding data before restart - 32 weeks (Concizumab PPX) vs 24 weeks (No PPX) - safety analysis set

There is no data for this output

nn7415/nn7415-summary/amnog_8_20250520_er
21MAY2025:14:36:46 - chef-safety-output.R/AnyAESISOC_HA_saf_e8.txt